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General introduction
Chronic Fatigue Syndrome is deﬁned as ‘an unexplained persistent or relapsing chronic fatigue 
that is not the result of ongoing exertion, is not substantially alleviated by rest, and results 
in a substantial reduction in previous levels of occupational, educational, social, or personal 
activities’1. Since 1990 the Nijmegen Fatigue Research Group (NFRG), a collaboration of the 
Departments of General Internal Medicine, Medical Microbiology and Medical Psychology of 
the University Medical Centre Nijmegen St Radboud (UMCN), has been involved in research 
on the chronic fatigue syndrome. The studies presented in this thesis are all related to the de-
velopment of the treatment manual ‘Cognitive Behaviour Therapy (CBT) for Chronic Fatigue 
Syndrome (CFS)’. Included are studies on prevalence, perpetuating factors and the effect of 
CBT for CFS. 
Chronic fatigue syndrome in general practice
Fatigue is a major problem in general practice. Studies show that 9% to 25% of the patients con-
sulting their general practitioner (GP) complain of fatigue2-9. Most of this fatigue resolves within 
weeks. In CFS however the unexplained fatigue remains for at least 6 months. The prevalence of 
CFS in the Netherlands was unknown. Prevalence data are however important to assess disease 
burden and give directions for health policy. We investigated the prevalence of CFS in general 
practice, using questionnaire reports of GPs. Besides estimating the prevalence, our aim was 
to inform all GPs in the Netherlands about CFS. To prevent patients with Primary Fibromyalgia 
Syndrome (PFS) to be reported as CFS patients, the prevalence of PFS in general practice was 
studied at the same time. The results of this study are presented in chapter 2. 
Why do CFS patients remain so tired?
In early studies on CFS conducted by the NFRG, several hypotheses on microbiological and 
immunological causes were tested, but none proved to be an explanation for CFS10-17. Other 
hypotheses about physical and psychological causes of CFS had been formulated and studied, 
but no single cause of CFS could be detected18. Gradually, we became aware that research on 
pathogenesis might be more fruitful if facilitating, initiating and perpetuating factors for CFS 
were distinguished. Little is known about facilitating factors. The initiating factors are most 
likely heterogeneous: infection, anaesthesia, operation and psycho trauma are likely to play a 
role. However, most is known about the perpetuating factors. In a study by Vercoulen and col-
leagues a model of perpetuating factors in CFS was developed and tested19. It turned out that 
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a strong focus on bodily symptoms, low levels of physical activity and a low self-efﬁcacy con-
tributed to an increase in the severity of fatigue and functional impairment. Strong somatic at-
tributions had only an indirect inﬂuence on fatigue, via lower levels of physical activity. These 
cognitive and behavioural perpetuating factors discovered by our group, were found in other 
studies as well20-21.
Clinical observations suggested that at least some CFS patients also fulﬁlled criteria for 
Hyperventilation Syndrome (HVS). Because of a similarity in symptoms between CFS and HVS, 
it is conceivable that the physiological process held responsible for HVS, also plays an important 
role in CFS. For example, physiological hyperventilation may aggravate fatigue, which in turn may 
aggravate hyperventilation. If that is the case, this might have important consequences for CFS 
treatment. In chapter 3 we addressed the question whether hyperventilation plays a role in CFS.
In 1989, Wessely and colleagues had formulated the hypothesis that CFS patients, experiencing 
a worsening of complaints after activity, learn to avoid activity in order to prevent an increase 
of complaints22. Consequently, inactivity might result in a decrease of physical ﬁtness, and a 
worse physical ﬁtness, in turn, might cause complaints to occur at increasingly lower levels of 
physical activity. In this way a perpetuating circle might be established. In chapter 4 we investi-
gated the question to what extent physical deconditioning occurs in CFS and how it relates to 
fatigue, impairment and physical activity. 
Vercoulen and colleagues had found that cognitive factors, such as the expectancy that activ-
ity is harmful, were involved in producing low levels of activity in CFS23. Activities that patients 
expected to result in higher levels of fatigue were less frequently performed. Many CFS patients 
complain that after physical exercise their symptoms increase and that their level of activity de-
creases. Although CFS patients seem to have the belief that exercise is harmful, the actual effect 
of exercise on symptoms and activity in CFS was unclear. Therefore we studied the impact of 
exercise on symptoms and activity in CFS. Results of this study are presented in chapter 5. 
How to relieve fatigue in CFS? The effect of cognitive behaviour therapy
Several studies revealed that cognitions and behaviour are important perpetuating factors in 
CFS, suggesting a promising role for CBT in CFS. After some individual try-outs, the ﬁrst publi-
cation of the NFRG on CBT for CFS, aiming at changing these perpetuating factors, appeared in 
199424. After successful preliminary individual treatments of CFS patients25, controlled studies 
on the effect of CBT were set up. Our ﬁrst study addressed the effect of cognitive behaviour 
group therapy (CBGT) for CFS. The main advantage of group therapy lies in the fact that several 
patients can be treated simultaneously. Modelling processes by seeing other members of the 
group might facilitate behaviour change. Aim of our controlled study on CBGT for CFS was to 
investigate the effect of CBGT for CFS on fatigue and impairment. Additionally pre-treatment 
characteristics of CFS patients who improve after CBGT were explored to investigate whether 
CBGT for CFS was only suitable for a subgroup of patients. This study, ‘CBGT for CFS: a wait 
list controlled study’, is presented in chapter 6
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Subsequently, the effect of individual CBT for CFS was studied in a large multi-centre ran-
domised controlled trial. In earlier randomised controlled trials on the effect of individual CBT 
for CFS only a few highly skilled therapists or even a single therapist administered CBT in spe-
cialist centres. In our study CBT was administered in three different centres. Experts taught 
the treatment protocol to many therapists with no previous experience in CBT for CFS. CBT 
was compared with guided support groups and the natural course. Guided support groups 
should control for the absence of speciﬁc cognitive-behavioural interventions and the presence 
of therapist’s attention and treatment expectations. Our hypothesis was that fatigue severity 
and functional impairment should decrease signiﬁcantly more in the group of patients assigned 
CBT than in patients in the control groups. The study is presented in chapter 7.
Besides examining the effect of CB(G)T for CFS, we wanted to know to what extent therapists 
adhered to the treatment manual and which perceptions they had of the treatment manual. 
Two questions were relevant. First, did the therapists, who were extensively trained and super-
vised, comply with the various aspects of the treatment manual during the actual sessions? 
Second, what is their judgment as to the treatments suitability for transfer? For this purpose, 
the therapists of the individual CBT study audio taped their sessions and ﬁlled in a question-
naire after completion of the study. Our aim was not only to have an integrity check, but also 
to use this information to further reﬁne our treatment manual. In chapter 8 the results of this 
study are presented.
Based on our knowledge gained from aforementioned studies, the treatment manual was ad-
justed. Treatment manuals used at the different stages of our studies have appeared in several 
publications26-31. The last version is presented in chapter 9.
Finally, chapter 10 covers a general discussion of the studies in this thesis. The role of activity 
in CFS is re-examined, ingredients of CBT for CFS are discussed, and the suitability of the treat-
ment manual in various circumstances and settings is reviewed. Future directions are given. 
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Abstract
Background. Prevalence studies on Chronic Fatigue Syndrome (CFS) are rare. Because of the 
similarity in symptoms, the prevalence of Primary Fibromyalgia Syndrome (PFS) was investi-
gated at the same time.
Objectives. To determine the prevalence of CFS and PFS as recognized by GPs in The Netherlands 
and to inform them of the existence of CFS.
Methods. A postal questionnaire was sent to all GPs.
Results. The questionnaire was returned by 60% of the GPs. Seventy-three per cent reported 
one or more CFS patients and 83% one or more PFS patients in their practice.
Conclusion. The estimated prevalence of CFS as recognized by GPs of 112 (PFS 157) patients per 
100 000 is a minimum estimate.
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Introduction
Chronic Fatigue Syndrome (CFS) is described as severe fatigue which has persisted for more 
than six months, is not relieved by bed rest and leads to severe disability in daily life. A physi-
cal explanation for this condition has not yet been found. Various other complaints can accom-
pany the fatigue, such as muscular pain, headache, memory and concentration problems, and 
depression. Despite extensive research, the cause of CFS is still unknown and the diagnosis is 
established by means of exclusion. For this reason, some physicians do not accept CFS as a dis-
ease. However, CFS has since been recognized as a disease by the World Health Organisation 
and has been included in the International Classiﬁcation of Diseases (ICD 10).
Many of the symptoms of CFS are also characteristic of the Primary Fibromyalgia Syndrome 
(PFS). To prevent confusion, one has to inquire for both syndromes. In this article, the results of 
a study carried out among Dutch GPs are described. There were two major aims. The ﬁrst was 
to gain insight into the number of CFS and PFS cases as recognized by GPs in the Netherlands. 
The second aim was to confront all GPs in The Netherlands with the existence of CFS and to 
give them information about this disease.
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Method
All 6657 GPs in The Netherlands received a mailed questionnaire. A Dutch institute for health 
research (NIVEL) provided their names and addresses. In the questionnaire the GPs were asked 
to report the size of their practice, the number of CFS and PFS patients in their practice and 
the distribution of these patients according to age and sex. A text with a deﬁnition of CFS and 
PFS was included in the questionnaire. For CFS a complaint duration of one year was used. If a 
response was not received within six weeks, a reminder was sent.
c
h
a
p
ter 2   |   c
h
r
o
n
ic fatig
u
e syn
d
r
o
m
e a
n
d
 pr
im
a
r
y fibr
o
m
ya
lg
ia syn
d
r
o
m
e a
s r
ec
o
g
n
ized
 by G
P
s
21
Results
Response
In total, 4027 questionnaires were returned (60.5%). Of the 4027 questionnaires 3881 (58.3%) were 
suitable for analysis. A reason for not completing or not ﬁlling in the questionnaire was given by 397 of 
these 3881 GPs. Twenty-seven of the responders (0.7%) said they “never make this diagnosis, ﬁnd the 
diagnosis too difﬁcult, or ﬁnd the diagnosis insufﬁcient”, and 37 GPs (1.0%) said they “refuse to make 
this diagnosis or do not believe in this disease”. Other reasons given for not completing the question-
naire were “I do not have my own patient database”, “this is not a scientiﬁc study”, “I do not partici-
pate in surveys”, “I do not yet have insight”, or “I will not review my patient data for this purpose”.
Number of CFS and PFS patients as recognized by GPs
The frequency distribution of CFS and PFS patients in their practice, as reported by GPs, is 
shown in ﬁgure 1. Seventy-three per cent of the GPs stated that they had one or more CFS pa-
tients in their practice. Eighty-three per cent of the GPs reported that they had one or more PFS 
patients in their practice.
Figure 1
FREQUENCY DISTRIBUTION OF THE NUMBER OF CFS AND PFS PATIENTS IN THE GP’S PRACTICE
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Since the size of the average practice, as indicated by the GPs, was 2486 patients, the number 
of CFS patients as recognized by GPs in The Netherlands is 112 per 100 000 inhabitants; for 
PFS, it is 157 per 100 000 inhabitants. Overall, 81% of the CFS patients and 87% of the PFS 
patients were female. Among CFS patients, 55% were between 25 and 44 years old versus 48% 
of the PFS patients.
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Discussion
In this survey, GPs reported to recognize 112 CFS patients and 157 PFS patients per 100 000 
inhabitants. This means that there are at least 17 000 CFS patients and 24 000 PFS patients in 
the Netherlands, in a total population of about 15 million inhabitants. The data obtained from 
this study were validated by comparing the age and sex of the CFS patients of this survey with 
those of a population of 298 CFS patients who were previously studied in detail by our research 
group1. In that cohort, 75% were female and 62% were between 25 and 44 years of age. The 
respective values for this study are 81 % and 55 %.
The prevalence rate based on recognitions by GPs in our study is considerably lower than those 
found in population-based studies, in which prevalence rates of up to 0.56 and 2.6%, respectively, 
were found2-3. Such differences may be due to a number of causes. Although a response rate of 
60% can be considered high, the question is whether it can be considered representative for 
all GPs and whether the data can be generalized. It is likely that there were more GPs that did 
not accept this condition among the 40% non-responders than among the 60% responders. 
However, if a GP never establishes the diagnosis CFS, this does not mean that there are no 
patients with CFS in his practice. In addition, the GPs who did ﬁll in the questionnaire may have 
been conservative in making the diagnosis. The fact that CFS was relatively unknown among 
GPs also played a role. It is quite likely that only those patients with an obvious diagnosis were 
included in this survey. If such a survey were to be repeated in the future, then one might ex-
pect that a higher number of CFS patients will be recognized by GPs because the presentation 
of information leads to better recognition. Furthermore, in the present study a fairly conserva-
tive deﬁnition of CFS was used as far as the duration of the complaints: a fatigue persisting for 
at least one year. This was applied because we had the impression that a number of patients 
recover within six months to a year. If the label CFS is attached to these complaints at an early 
stage, this may have the effect of perpetuating the complaints. However, in the current agree-
ment on the CDC criteria, in which our group also participated, duration of the complaints is 
six months. This is another reason why the number of CFS patients found in our study will be 
a low estimate of the number of CFS patients in the Netherlands.
If we take into consideration the fact that 1% of the GPs refuse to establish this diagnosis or do 
not believe in the disease and that 0.7% do not make the diagnosis or ﬁnd the condition too dif-
ﬁcult to diagnose, then acceptance of the diagnosis CFS is not as poor as is so often suggested. 
This was also concluded by Denz and Murdoch, who found that the clinical validity of chronic 
fatigue syndrome was accepted by 90% of the GPs in Otago, New Zealand4. Fitzgibbon and 
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colleagues found that CFS as a distinct clinical entity was accepted by 58% of the GPs in Ireland, 
and that 82% would consider a diagnosis of CFS in their own patients with chronic debilitating 
fatigue5. In view of the 60% response rate and the generally positive reactions in our study, it 
can be said that the aim of confronting and informing all Dutch GPs about the existence of CFS 
was achieved. Nevertheless, there are still more GPs that diagnose PFS (83%) than diagnose 
CFS (73%). It is of interest that 27% of the GPs who do not diagnose CFS 65 % still diagnose 
PFS. Of the 17% of the GPs that do report not to have PFS patients in their practice, only 46% 
diagnose CFS. Because CFS and PFS are rather similar diagnoses, this may indicate that PFS is 
more accepted than CFS.
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Abstract
 
Chronic fatigue syndrome (CFS) is characterized by severe fatigue, lasting for at least six months, 
for which no somatic explanation can be found. Because hyperventilation can produce substan-
tial fatigue, it seems worthwhile to investigate the relationship between it and CFS. It might 
be hypothesized that hyperventilation plays a causal or perpetuating role in CFS. CFS patients, 
non-CFS patients known to experience hyperventilation, and healthy controls were compared on 
complaints of fatigue and hyperventilation. CFS patients and non-CFS patients known to experi-
ence hyperventilation offered substantial complaints of fatigue and hyperventilation, both to a 
similar degree. Physiological evidence of hyperventilation was found signiﬁcantly more often in 
CFS patients than in healthy controls. However, no signiﬁcant differences between CFS patients 
with and CFS patients without hyperventilation were found on severity of fatigue, impairment, 
number of complaints, activity level, psychopathology, and depression. It is concluded that hy-
perventilation in CFS should probably be regarded as an epiphenomenon. 
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Introduction
Chronic fatigue Syndrome (CFS) is deﬁned as severe fatigue, lasting for at least six months, 
for which no somatic explanation can be offered. The pathogenesis of CFS is still unknown1. 
Because hyperventilation can produce substantial fatigue, and because fatigue is one of the 
main complaints in hyperventilation, it seems worthwhile to investigate their relationship. 
Grossman and de Swart2 showed that 64% of the patients with hyperventilation syndrome 
complained of tiredness. In addition, the fatigue in hyperventilation3 as well as in CFS4-6 seems 
to be of a central type.
One might hypothesize that CFS is caused by hyperventilation. It is possible that stress causes 
hyperventilation, which in turn might lead to chronic fatigue. Another possibility is that hyper-
ventilation plays a perpetuating role in CFS. Patients with CFS might develop hyperventilation 
due to their fatigue, and hyperventilation might in turn lead to an aggravation of fatigue.
Only a few studies have dealt with the relationship between CFS and hyperventilation. Rosen 
and colleagues7 demonstrated hyperventilation in 38 of 40 patients suffering from CFS and 
claimed that hyperventilation plays an important role in the pathogenesis. Riley and colleagues4, 
however, found no differences in the mean end-tidal PCO2 both before and after exercise be-
tween 13 patients with CFS and 13 healthy controls. Saisch and colleagues8 found evidence for 
hyperventilation in 9 of 31 CFS patients (29%). They did not ﬁnd a relationship between the 
severity of hyperventilation and the degree of functional impairment, which was to be expected 
when hyperventilation would play a perpetuating role in CFS.
The ﬁrst purpose of the present study is to determine whether there is any evidence for subjec-
tive complaints of hyperventilation in CFS, and whether there is evidence of fatigue in patients 
with hyperventilation. CFS patients and patients with known hyperventilation are compared to 
healthy controls to see whether these complaints are not only common but also speciﬁc for 
CFS and hyperventilation. The aim of the second part of the study is to determine whether 
there is any physiological evidence for hyperventilation in CFS and whether CFS patients show 
physiological evidence for hyperventilation more frequently than healthy controls. In the third 
part of the study, CFS patients with physiological evidence for hyperventilation (CFS HV) are 
compared to CFS patients without hyperventilation (CFS non-HV) on severity of fatigue, impair-
ment, number of complaints, activity level, psychopathology, and depression, to determine the 
role of hyperventilation in CFS.
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Method
Subjects
For the ﬁrst part of this study, 39 patients with CFS and 32 healthy controls (all from a 
sample described elsewhere)9 completed the questionnaires. The healthy controls were matched 
and recruited by a regional newspaper advertisement. Furthermore, 17 non-CFS patients with 
established hyperventilation (non-CFS HV) participated, all from the out-patient clinic of the 
Department of Pulmonology, Dekkerswald, University of Nijmegen. For the second and third 
part of the study 27 CFS patients and the 32 healthy controls from the ﬁrst part of the study 
participated. The experimental groups are not of an equal size because the study was linked to 
an already ongoing study.
All CFS patients were diagnosed at the General Internal Medicine out-patient clinic of the 
University Hospital Nijmegen. CFS is deﬁned as severe fatigue, lasting for at least six months, 
for which no somatic explanation can be offered. Patients were diagnosed with CFS if they ful-
ﬁlled the Sharpe criteria10. According to these criteria, patients with a current diagnosis of major 
depression with melancholic or psychotic features, bipolar affective disorder, schizophrenia of 
any subtype, delusional disorders of any subtype, manic depressive illness, substance abuse, 
eating disorder, or proven organic brain disease (dementias of any subtype) were excluded.
Patients and healthy controls were diagnosed as having hyperventilation when they fulﬁlled 
three of the following criteria11:
• low PaCO2 in rest (<4.5 kPa)
• High breathing frequency, irregular breathing, or frequent sighing in rest.
• Decreasing PaCO2 in control condition on a spirometer.
• Inverted ventilators response to CO2.
• Adding CO2 results in a regulation of breathing.
• One of the following criteria during or after the provocation test:
- no step change in PetCO2 when stopping voluntary hyperventilation;
- no step change in respiratory frequency when stopping voluntary hyperventilation;
- PaCO2 three minutes after the end of the provocation <90% of the starting level.
Instruments
Subjective fatigue was measured with the subscale of subjective fatigue of the Checklist of 
Individual Strength (CIS)12. On this scale, the minimum score is 1 and the maximum score is 7.
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Level of impairment was assessed with the Sickness Impact Proﬁle (SIP)13. This questionnaire 
measures the inﬂuence of complaints in different areas of daily functioning. For this study, eight 
subscales were used (alertness behaviour, sleep, homemaking, leisure activities, work, mobility, 
social interactions, ambulation).
Level of physical activity was assessed using an actometer. This apparatus is worn around the 
ankle for two weeks, recording the amount of movements every ﬁve minutes. This information 
is stored to an internal memory, and can be read by use of a personal computer14.
Subjective complaints of hyperventilation were assessed by the Nijmegen Hyperventilation 
Questionnaire (NHQ)15. The cut-off score for hyperventilation is 23.
Psychopathology was measured with the Symptom Checklist (SCL-90), an indicator of psycho-
logical disturbances, and the Beck Depression Inventory (BDI)16,17, a standardized self-report 
questionnaire for measuring depression.
Respiratory measurements were performed using a hyperventilation test in which the patient was 
connected to a closed spirometer circuit by a mouthpiece. A sampling capnograph measured 
PCO2 in the respiratory air. Resting respiratory parameters were measured during ﬁve minutes: 
minute ventilators, PetCO2, breathing frequency, irregularity of breathing, and the time course of 
PetCO2 during the ﬁrst ﬁve minutes of the test. Next, some CO2 was given in the inspiratory 
air, to raise PetCO2 by 1.0±0.2 kPa. The response of the ventilation to the increase in PetCO2 
was measured during another ﬁve minutes. Subsequently, the patient was disconnected from 
the spirometer, and only PetCO2 was monitored during a one-minute period of voluntary hy-
perventilation, and during the three minutes thereafter. The patients were asked whether they 
recognized their daily symptoms, during the hyperventilation. Finally, an arterialised capillary 
blood gas sample was taken to assess a possible metabolic acidosis, compensating for chronic 
hyperventilation.
Statistical analysis
The analysis of differences between groups on dichotomous variables was carried out with 
the chi-square test. Bonferroni correction was applied for the comparison of three experimen-
tal groups. Assuming a signiﬁcant level of 0.05, a difference was considered signiﬁcant if the 
p<0.017. The analysis of differences between two groups on ratio variables was carried out with 
the t-test, with the signiﬁcance level set at p=0.05. The analysis of differences between more 
than two groups on ratio variables was performed by analysis of variance. Multiple comparisons 
were made by Duncan’s multiple range tests, with p<0.05.
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Results
First part
The mean age of the CFS patients was 36.5 (sd=8.8), of the non-CFS patients with known hy-
perventilation (non-CFS HV) 44.0 (sd=12.6), and of the healthy controls 37.0 (sd=12.8). Only 
the non-CFS HV patients differed signiﬁcantly in age from the other two groups. There were 
no signiﬁcant differences in gender: 80% of the CFS patients were female, as were 59% of the 
non-CFS HV patients and 84% of the healthy controls.
Data concerning subjective complaints of hyperventilation and subjective complaints of fatigue 
are presented in table 1. On the NHQ, 59% of the CFS patients scored above the cut-off score 
for hyperventilation. This is signiﬁcantly different from healthy controls (3%), but not from non-
CFS HV patients (65%). Non-CFS HV patients had a mean CIS score for subjective fatigue of 
5.2. This is signiﬁcantly different from healthy controls (2.0), but not from CFS patients (5.9).
Table 1
MEAN SCORES (SD) ON SUBJECTIVE COMPLAINTS OF HYPERVENTILATION (NHQ), % ABOVE THE CUT-OFF SCORE FOR 
HYPERVENTILATION (NHQ>23), AND MEAN SCORE (SD) OF SUBJECTIVE FATIGUE (CIS), OF 39 CFS PATIENTS COMPARED TO 17 NON-
CFS PATIENTS KNOWN WITH HYPERVENTILATION (NON-CFS HV), AND 32 HEALTHY CONTROLS
CFS non-CFS HV Healthy
NHQ* 25.1 (9.8) 31.4 (11.6) 10.4 (6.3)
NHQ % > 23** 59% 65% 3%
CIS-subjective fatigue*** 5.9 (1.1) 5.2 (2.2) 2.0 (1.1)
* One-way ANOVA, with Duncan multiple range test (p<0.05); CFS signiﬁcantly different from non-CFS HV and healthy 
controls; non-CFS HV signiﬁcantly different from healthy controls
** Chi-square (p<0.001); CFS signiﬁcantly different from healthy controls (p<0.001); non-CFS HV signiﬁcantly different 
from healthy controls (p<0.001); non-CFS HV not signiﬁcantly different from CFS
*** One-way ANOVA, with Duncan multiple range test (p<0.05); CFS signiﬁcantly different from healthy controls; non-
CFS HV signiﬁcantly different from healthy controls; non-CFS HV not signiﬁcantly different from CFS
Second part
The CFS patients and the healthy controls who underwent respiratory measurements did not dif-
fer signiﬁcantly on age and gender. Mean age of the CFS patients was 36.6 (sd=8.0), and of the 
healthy controls 37.0 (sd=12.8). Seventy-eight percent of the CFS patients were female, compared 
c
h
a
p
ter 3   |   th
e c
h
r
o
n
ic fatig
u
e syn
d
r
o
m
e a
n
d
 h
yper
ven
tilatio
n
33
to 85% of the healthy controls. Between CFS patients and healthy controls signiﬁcant differences 
were found on fatigue, impairment, number of complaints, level of activity, subjective complaints 
of hyperventilation, and psychopathology, as expected9 (table 2). Table 3 shows the results of the 
respiratory measurements in CFS and healthy controls. Signiﬁcantly more CFS patients showed 
hyperventilation (59%) than did healthy controls (22%). CFS patients differed from healthy 
controls on PetCO2 and recognition of complaints, but not on the other respiratory parameters.
Table 2
MEAN SCORES (SD) OF 27 CFS PATIENTS AND 32 HEALTHY CONTROLS RECRUITED FOR RESPIRATORY MEASUREMENTS, ON 
SUBJECTIVE FATIGUE (CIS), IMPAIRMENT (SIP), NUMBER OF COMPLAINTS, ACTIVITY LEVEL (ACTOMETER), SUBJECTIVE COMPLAINTS 
OF HYPERVENTILATION (NHQ), PSYCHOPATHOLOGY (SCL-90) AND DEPRESSION (BDI) 
CFS Healthy p - value*
CIS-subjective fatigue  5.9 (1.0)  2.0 (1.1) <0.001
SIP  17.1 (6.3)  1.2 (0.3) <0.001
Number of complaints  7.4 (3.7)  0.0 (0.0) <0.001
Actometer  25.1 (12.3)  36.4 (12.2) <0.001
NHQ  25.6 (11.3)  10.4 (6.3) <0.001
SCL-90  155.4 (27.2)  106.9 (22.0) <0.001
BDI  10.6 (5.3)  2.7 (4.0) <0.001
*  Using the t-test
Third part
The 16 CFS patients with hyperventilation (CFS HV) and the 11 CFS patients without hyper-
ventilation (CFS non-HV) were compared on subjective fatigue (CIS), impairment (SIP), num-
ber of complaints, activity level (actometer), subjective complaints speciﬁc for hyperventilation 
(NHQ score), psychopathology (SCL-90) and depression (BDI). No signiﬁcant differences be-
tween groups were found (table 4). CFS HV patients as well as CFS non-HV patients were both 
extremely fatigued and impaired. There was neither a signiﬁcant difference in the number of 
complaints, nor the level of activity or subjective complaints of hyperventilation. Finally, CFS HV 
patients and CFS non-HV patients did not differ on psychopathology and depression.
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Table 3
MEAN SCORES (SD) OR % ON RESPIRATORY MEASUREMENTS IN 27 CFS PATIENTS AND 32 HEALTHY CONTROLS
CFS Healthy p - value
PetCO2 (kPa)*  4.5 (0.66)  4.9 (0.40) <0.005
PetCO2 < 4.5** 52% 22% <0.05
PaCO2 *  4.75 (0.69)  4.83 (0.57) ns
Breathing frequency*  13.1 (3.7)  15.1 (3.7) ns
Tidal volume*  0.604 (0.20)  0.560 (0.18) ns
Decreasing PetCO2** 36% 22% ns
Irregular breathing** 30% 16% ns
Delayed recovery after provocation** 56% 38% ns
Recognition** <0.01
 none 41% 81%
 partly 37% 13%
 completely 22% 6%
Hyperventilation, according to 
physiological criteria**
59% 22% <0.005
* Using the t-test
** Using chi-square
Table 4
MEAN SCORES (SD) OF 16 CFS PATIENTS WITH HYPERVENTILATION (CFS HV) AND 11 CFS PATIENTS WITHOUT HYPERVENTILATION 
(CFS NON-HV) ON SUBJECTIVE FATIGUE (CIS), IMPAIRMENT (SIP), NUMBER OF COMPLAINTS, ACTIVITY LEVEL (ACTOMETER), 
SUBJECTIVE COMPLAINTS OF HYPERVENTILATION (NHQ), PSYCHOPATHOLOGY (SCL-90) AND DEPRESSION (BDI)
CFS HV CFS non-HV p - value*
CIS-subjective fatigue  5.8 (1.0)  6.0 (0.9) ns
SIP-score  18.2 (6.1)  16.4 (6.5) ns
Number of complaints  8.1 (3.6)  6.5 (3.7) ns
Actometer  24.1 (10.2)  26.6 (15.2) ns
NHQ  25.6 (8.2)  25.5 (15.4) ns
SCL-90  153.9 (28.1)  157.9 (27.1) ns
BDI  10.1 (4.0)  11.4 (6.9) ns
*  Using the t-test
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Discussion
Patients with CFS endorsed subjective complaints of hyperventilation, similar to non-CFS pa-
tients with known hyperventilation. The latter showed substantial fatigue, of similar severity as 
CFS patients. Physiological evidence for hyperventilation was found signiﬁcantly more often in 
CFS patients (59%) than in healthy controls (22%), with a signiﬁcant difference in the mean 
resting PetCO2. Rosen and colleagues7 found hyperventilation in 93% of the CFS patients and 
55% of the healthy controls, whereas Saisch and colleagues8 found evidence for hyperventila-
tion in 29% of the CFS patients, and Riley and colleagues4 found no differences in the mean 
PetCO2 between CFS patients and healthy controls. These conﬂicting ﬁndings can he explained 
by the differences in the criteria used in diagnosing hyperventilation. In the study by Rosen and 
colleagues7, less stringent criteria were used. Patients were also diagnosed with hyperventila-
tion if they had a positive ‘think test’: three minutes after the hyperventilation provocation test, 
patients were requested to close their eyes and think about the circumstances of an attack and 
the feelings and sensations experienced. A fall of end-tidal PaCO2 of 1.3 kPa or more was taken 
as a positive response18. However, the resting PetCO2 in that study did not differ between CFS 
patients and healthy controls, as in the study of Riley and colleagues4. In the study by Saisch 
and colleagues8, the criteria were more strict than in our study. Patients were diagnosed with 
hyperventilation only if the PetCO2 was less than 4.0 kPa at rest, during or after exercise, or at 
ﬁve minutes after the end of voluntary overbreathing. Using the criterion of a PetCO2 of less 
than 4.0 kPa, in our study, 19% of the CFS patients and none of the healthy controls were diag-
nosed with hyperventilation. This is closer to the ﬁnding of 29% hyperventilating CFS patients 
found in the study by Saisch and colleagues8.
If hyperventilation plays an important role in the pathogenesis or perpetuation of CFS, one 
would assume that hyperventilation is common in CFS, and one would expect higher scores of 
fatigue and impairment in the CFS patients with hyperventilation, compared to the CFS patients 
without hyperventilation. Like Saisch and colleagues8, we found physiological evidence for hy-
perventilation in some of the CFS patients, the exact percentage depending on the criteria used. 
In addition, we could show that the high percentage of 93% found in the study by Rosen and 
colleagues7 could be explained by the less strict criteria used: hyperventilation in CFS is not as 
common as they suggest. Comparing CFS patients with hyperventilation to CFS patients with-
out hyperventilation, no differences on fatigue and impairment were found, as in the study by 
Saisch and colleagues8. There were also no differences found on variables such as the number 
of complaints, level of activity, psychopathology, and depression. If hyperventilation plays a role 
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in CFS, one would at least expect some differences. Using the strict criteria of a 4.0 kPa PaCO2 
at rest, ﬁve of our CFS patients showed hyperventilation. However, even then, no differences 
are found between CFS patients with and CFS patients without hyperventilation. Therefore, it is 
unlikely that hyperventilation plays a role in the pathogenesis or perpetuation of CFS.
Depending on the criteria one uses, it can be said that signs of hyperventilation were found 
in a substantial number of the CFS patients. Furthermore, non-CFS hyperventilating patients 
had signiﬁcantly more complaints of fatigue than healthy controls. However, we did not ﬁnd 
more complaints of fatigue in hyperventilating CFS patients than in non-hyperventilating CFS 
patients. Therefore, hyperventilation is probably an epiphenomenon in CFS, and does not play 
a substantial causal or perpetuating role.
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Is physical deconditioning  
a perpetuating factor in  
chronic fatigue syndrome? 
a controlled study on maximal exercise performance and 
relations with fatigue, impairment and physical activity
Psychological Medicine 2001;31:107-114
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Abstract
Background. Chronic fatigue syndrome (CFS) patients often complain that physical exertion 
produces an increase of complaints, leading to a greater need for rest and more time spent in 
bed. It has been suggested that this is due to a bad physical ﬁtness and that physical decon-
ditioning is a perpetuating factor in CFS. Until now, studies on physical deconditioning in CFS 
have shown inconsistent results.
Methods. Twenty CFS patients and 20 matched neighbourhood controls performed a maxi-
mal exercise test with incremental load. Heart rate, blood pressure, respiratory tidal volume, 
O2 saturation, O2 consumption, CO2 production, and blood-gas values of arterialized capillary 
blood were measured. Physical ﬁtness was quantiﬁed as the difference between the actual and 
predicted ratios of maximal workload versus increase of heart rate. Fatigue, impairment and 
physical activity were assessed to study its relationship with physical ﬁtness. 
Results. There were no statistically signiﬁcant differences in physical ﬁtness between CFS pa-
tients and their controls. Nine CFS patients had a better ﬁtness than their control. A negative 
relationship between physical ﬁtness and fatigue was found in both groups. For CFS patients 
a negative correlation between ﬁtness and impairment and a positive correlation between ﬁt-
ness and physical activity was found as well. Finally, it was found that more CFS patients than 
controls did not achieve a physiological limitation at maximal exercise. 
Conclusion. Physical deconditioning does not seem a perpetuating factor in CFS.
c
h
a
p
ter 4   |   is ph
ysic
a
l d
ec
o
n
d
itio
n
in
g
 a per
petu
atin
g
 fa
c
to
r in
 c
h
r
o
n
ic fatig
u
e syn
d
r
o
m
e?
41
Introduction
Chronic fatigue syndrome (CFS) is deﬁned as a severe fatigue lasting for at least 6 months, for 
which no somatic explanation can be offered and which leads to severe disability in daily life. 
CFS patients often complain that physical exertion produces an increase in complaints, leading 
to a greater need for rest and more time spent in bed. In some CFS studies it has been argued 
that muscle deﬁcits might cause this fatigue after activity1-3. More recent studies on physical 
exercise in CFS showed that the neuromuscular mechanism is intact4-9. Wessely and colleagues10 
hypothesized that physical deconditioning might play an important role in CFS. The rationale 
was that because CFS patients experience a worsening of complaints after activity, they learn 
to avoid activity in order to prevent an increase of complaints. Being inactive, however, results 
in a decrease of physical ﬁtness. This means that over time complaints get worse at an increasingly 
lower level of physical activity. In this way a vicious and perpetuating circle might be established, 
resulting in a decreasing physical ﬁtness. Based on this hypothesis, the role of (avoidance of) physical 
activity in CFS has been emphasized more and more11. In cognitive behavioural therapy12,13 as well as 
in graded exercise therapy14 a gradually increasing activity programme is of main importance. One 
might wonder, however, whether improving physical ﬁtness is an essential factor in CFS, or whether 
other factors determine treatment effects. If physical ﬁtness is an important and perpetuating factor 
in CFS, one would not only expect CFS patients to have a worse physical ﬁtness, but one would also 
expect a negative relationship between physical ﬁtness and fatigue and impairment and a positive 
relationship between physical ﬁtness and physical activity.
Studies on aerobic or cardiocirculatory deconditioning in CFS have shown contradictory results15-20. 
These differences might be due to differences in tests, sample sizes and patient and control selec-
tion. Differences in tests used make it difﬁcult to compare results. However, the most important 
reason for the inconsistencies found seems to be the use of an inappropriate control group in most 
studies. Physical ﬁtness in CFS should not be compared with selected healthy and rather active 
controls. To deal with this problem, Sisto and colleagues18 used sedentary controls. In our study, 
well-matched neighbourhood controls are used. Although inconsistencies exist in the ﬁndings 
concerning physical ﬁtness, most studies are consistent in their ﬁndings that at least part of the 
CFS patient sample does not attain a physiological limitation on a maximal exercise test. The 
aims of the present study are to determine whether CFS patients have a worse physical ﬁtness 
as compared to matched neighbourhood controls, and whether there is a negative relationship 
between physical ﬁtness and fatigue and impairment and a positive relationship between physi-
cal ﬁtness and physical activity. We also investigated whether CFS patients attain a physiological 
maximum on a maximal exercise test.
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Method
Subjects
Patients diagnosed at the General Internal Medicine out-patient clinic of the University 
Hospital Nijmegen, who already agreed to participate in scientiﬁc studies, were asked to par-
ticipate. Patients were diagnosed as having CFS if they fulﬁlled the Fukuda criteria21. In ad-
dition, CFS patients were only included if they had a CIS fatigue severity score of ≥40 and a 
total score on the eight SIP subscales used of >800, to guarantee severe fatigue and disability 
(see instruments)22. Patients invited for the current study were further selected on whether 
they lived in the surroundings of our hospital, because a heart rate monitor was brought to 
the patients’ and controls’ home a day before the exercise test and was picked up again one 
day after the test. None of the patients refused. All patients were asked to invite a neighbour 
of the same gender and about the same age as a control person. Twenty of 26 CFS patients 
fulﬁlled our additional criteria of the CIS and the SIP and found a neighbourhood control of 
about the same age and the same sex. So 20 CFS patients and 20 matched neighbourhood 
controls participated.
Instruments
Fatigue 
Fatigue was measured by the subscale fatigue severity of the fatigue questionnaire Checklist 
Individual Strength (CIS)22. This scale consists of eight items concerning fatigue during the last 
two weeks. Each item is scored on a 7-point Likert scale, so the range is 8 - 56.
Functional impairment
The Sickness Impact Proﬁle (SIP)23,24 was used to assess functional impairment. This question-
naire measures the inﬂuence of complaints in different areas of daily functioning. Eight sub-
scales were used (alertness behaviour, sleep, homemaking, leisure activities, work, mobility, 
social interactions and ambulation).
Physical activity
This was measured using the actometer25. The actometer is an apparatus worn around the ankle 
for two weeks, recording the amount of movements every ﬁve minutes. The actometer consists 
of a piezoelectric sensor. Acceleration of the sensor results in an output signal. This informa-
tion is stored to an internal memory, and can be read by use of a personal computer. The mean 
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actometer score for the days that the actometer was worn before the exercise test was used to 
assess the level of physical activity.
Exercise test
A bicycle ergometer test with incremental load was used as an exercise test. The workload was 
increased every minute in steps of 10% of estimated maximal workload, in order to complete the 
maximal exercise test in approximately 10 minutes26. The steps varied from 10 to 30 watt/minute. 
Subjects were instructed to go on until they could no longer continue. They were verbally encour-
aged to perform maximally. During this test, heart rate, blood pressure, respiratory tidal volume, O2 
saturation, O2 consumption, CO2 production, and bloodgas values of arterialized capillary blood 
(before and after exercise, at minute three, six, and nine of the exercise and at maximal workload) 
were measured. Every three minutes and at maximal workload, the modiﬁed Borgscale was used to 
assess the rate of perceived exertion27. On a scale from 1 to 10, patients were asked to indicate how 
difﬁcult it was to perform the pedalling exercise. The intensity of anaerobic workload was measured 
from the difference in base excess at rest and three minutes after maximal workload, which repre-
sents the produced lactate within the cells of the leg muscles. Achieved maximal workload (W) was 
compared with the predicted value. The predicted maximal workload was calculated from28: 
 Wmax_pred =    
VO2max_pred – VO2rest_pred  
                                 10.29
In this formula, predicted maximal ventilatory O2 uptake (VO2max_pred) is related to height 
(H/cm), age (A/year) and sex (S/m=0, f=1)29 :
 VO2max_pred (l/minute)=0.046H – 0.021A – 0.62S – 4.31 
and30
 VO2rest_pred=0.25 l/minute.
Maximal heart rate (HR) was compared with the predicted maximal heart rate, depending on 
age (A/year)28:
 HRmax_pred (beats/minute) = 220 – A.
Fitness was deﬁned as the differences in slope of the relationships between heart rate and ex-
ternal workload of the individual subject versus a normalized slope. Fit subjects have relatively 
low heart rates at a certain workload and vice versa31. In formula: 
 
      Wmax    
       –        
       Wmax_pred             
    = Watt per beat.
 HRmax – HRrest        HRmax_pred – HRrest
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A negative outcome indicates a ﬁtness that is worse than would be expected; a positive outcome 
indicates a better ﬁtness than expected. 
Subjects were considered attaining a physiological limitation if one of the following criteria was 
met: 1) attainment of predicted maximal heart rate; 2) increase of base excess at three minutes 
after maximal workload compared with base excess at rest (lactate production) of more than 
10 mmol/minute; 3) increase of CO2 pressure in blood at maximal workload compared with 
the value at rest.
The 24 hours heart rate
This was assessed using a Polar sport tester. The Polar sport tester consists of a belt around 
the chest, containing ECG electrodes, ampliﬁer and transmitter, and a watch. The ECG signals 
are sent to the watch, recording the R-tops in an internal memory every 60 seconds, during 24 
hours. For the analysis in this study mean scores of every half an hour were used. The Polar 
sport tester was brought to the patients’ and controls’ home to wear during the 12 hours pre-
ceding the start of the ergometer test. After the ergometer test the Polar sport tester was worn 
for another 12 hours. Then the sport tester was collected from the subjects’ homes.
For six controls and four CFS patients almost all data of the Polar sport testers were missing, 
probably because of pressing the buttons accidentally during sleep. Also, 10 subjects (one CFS 
patient and nine controls) had incidental missing data. In these cases (1.7% of all sport tester 
data) missing values were replaced by the mean value of the half hour scores before and after 
the missing value of the particular subject.
Statistical analysis
Differences between groups were tested using one-way analysis of variance (ANOVA) or re-
peated measures ANOVA for ratio variables. The Mann-Whitney U test was used in case of 
skewed variables, chi-square was used for dichotomous variables. Fisher’s Exact Test was used 
when >20% of the cells had an expected count <5. Before Pearson correlation coefﬁcients were 
computed, skewed variables were transformed. To test whether the correlations obtained for 
CFS and for controls were signiﬁcantly different, both correlations were converted to Fisher’s z 
and the difference between them was divided by the standard error of the difference to yield a 
normal curve deviate (z)32. For all tests, the signiﬁcance level was set at p<0.05.
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Results
Patient and control characteristics
Demographic data, height, weight, fatigue severity, functional impairment and physical activity 
are displayed in table 1. There were no signiﬁcant differences in gender, age, height and weight. 
On fatigue severity, functional impairment and physical activity differences were found as ex-
pected. Mean duration of complaints in CFS was 3.2 years (±2.5).
Table 1
CHARACTERISTICS (% OR MEAN (SD)) OF CFS PATIENTS (N=20) AND CONTROLS (N=20)
CFS Controls p - value
Female (%) 60 60  1.00
Age (yrs)  34.1 (8.3)  32.8 (7.2)  0.59
Height (cm)  175.7 (9.4)  174.8 (9.5)  0.78
Weight (kg)  72.0 (16.4)  71.5 (14.2)  0.91
Fatigue (CIS; range 8-56)  51.7 (5.1)  13.4 (5.1)  <0.001*
Functional impairment (SIP-8) 1743 (1249-2058) 0 (0-0)  <0.001*
Physical activity (actometer)a  58.2 (27.2)  99.5 (25.0)  <0.001*
Chi-square for % female; Mann-Whitney U test for SIP, medians (25th and 75th percentile) presented; one-way ANOVA 
for other variables
a Deviating N because of failing actometers, N=15 for CFS and N=18 for controls
* p<0.05
Fitness
CFS patients had a mean ﬁtness of –0.32 ± 0.50 watts/beat and their controls had a mean ﬁt-
ness of –0.22 ± 0.82 watts/beat (non-signiﬁcant: Mann-Whitney U test, p=0.25). Nine of the 
20 CFS patients had a better ﬁtness than their own control. In Figure 1 a boxplot of ﬁtness in 
CFS and controls is displayed.
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Figure 1
BOXPLOT OF FITNESS FOR CFS AND CONTROLS
Figure 2 
HEART RATE 12 HOURS BEFORE UP TO 12 HOURS AFTER THE MAXIMAL EXERCISE TEST, CFS PATIENTS COMPARED TO CONTROLS 
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Repeated measures ANOVA: within 
subjects, p<0.001 (F=9.66; df=47); 
interaction effect, p=0.75 (F=0.85; df=47)
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Heart rate
Heart rates from 12 hours before the test up to 12 hours after the test for CFS and their controls 
are displayed in ﬁgure 2. No signiﬁcant interaction effect was found.
Table 2
OXYGEN CONSUMPTION AND CO2 PRODUCTION (SD) IN REST AND AT MAXIMAL WORKLOAD FOR CFS (N=20) AND CONTROLS (N=20)
Rest
Maximal 
workload
Within subjects
p-value
Interaction effect
p-value
O2 consumption (l/minute)
CFS
Controls
0.30 (0.08)
0.29 (0.08)
2.01 (0.74)
2.27 (0.68)
<0.001*
(F=288.95; df=1)
0.22
(F=1.58; df=1)
CO2 production (l/minute)
CFS
Controls 
0.27 (0.09)
0.28 (0.09)
2.37 (0.90)
2.75 (0.90)
<0.001*
(F=270.96; df=1)
0.20
(F=1.72; df=1)
O2 pressure in blood (kPa) 
CFS 
Controls
9.07 (1.05)
8.87 (0.92)
11.29 (1.34)
10.25 (1.01)
<0.001*
(F=50.19; df=1)
0.10
(F=2.84; df=1)
CO2 pressure in blood (kPa)
CFS
Controls
5.19 (0.51)
5.36 (0.46)
4.65 (0.57)
5.22 (0.59)
<0.001*
(F=14.42; df=1)
0.03*
(F=4.89; df=1)
Repeated measures ANOVA
* p<0.05
Oxygen consumption and CO2 production
Table 2 shows the O2 and CO2 uptake and production. CO2 pressure in the blood declined more 
for CFS than for controls (p=0.03). There were no other signiﬁcant interaction effects for the 
respiratory exchange variables.
Fitness and relations with fatigue, impairment and physical activity 
For CFS as well as for controls a signiﬁcant correlation of –0.45 was found between ﬁtness and 
fatigue (p=0.049 and 0.044 respectively). In CFS signiﬁcant correlations between ﬁtness and 
functional impairment (r=0.49, p=0.027) and ﬁtness and physical activity (r=0.54, p=0.039; 
N=15 because of failing actometers) were found as well. Because 85% of the controls had a 
functional impairment score of zero, a correlation between functional impairment and ﬁtness 
could not be computed. The correlation between ﬁtness and physical activity in controls was non-
signiﬁcant (r=0.28, p=0.260; N=18 because of failing actometers). The difference in the correla-
tions between ﬁtness and physical activity in CFS and in controls (0.54 and 0.28 respectively) were 
statistically non-signiﬁcant (p=0.414).
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Exercise capacity
Neither the duration of the maximal bicycle ergometer test nor achieved workloads were sig-
niﬁcantly different for CFS and controls (table 3). However, there was a statistically signiﬁcant 
difference for the percentage of the predicted workload reached, being lower in CFS. On average, 
CFS patients reached 70% of their predicted workload, whereas the controls reached 83% of their 
predicted value. For heart rate scores during exercise, no statistically signiﬁcant differences were 
found.
Attaining a physiological limitation
Of the CFS patients 55% performed up to a physiological limitation, compared with 80% of the 
controls (this difference was not signiﬁcant, table 4).
Perceived exertion
Not all subjects performed the maximal exercise test for six minutes or more. Therefore, Borgscale 
scores were compared three minutes after starting the test and at maximal workload only. 
Scores on the Borgscale three minutes after starting the test were 3.82±0.88 for CFS (N=17) and 
2.44±0.86 for controls (N=18). At maximal workload Borgscale scores were 8.76±1.68 for CFS 
and 7.33±2.11 for controls. There was a signiﬁcant within subjects’ effect (p<0.001; F=210.06; 
df=1). No signiﬁcant interaction effect was found (p=0.94; F=0.01; df=1).
c
h
a
p
ter 4   |   is ph
ysic
a
l d
ec
o
n
d
itio
n
in
g
 a per
petu
atin
g
 fa
c
to
r in
 c
h
r
o
n
ic fatig
u
e syn
d
r
o
m
e?
49
Table 3
EXERCISE CAPACITY (MEAN AND (SD)) FOR CFS PATIENTS (N=20) AND CONTROLS (N=20)
CFS Controls p-value
Time (minutes)   8.0 (2.3)  9.2 (1.9) 0.07
Workload (watt)
predicted value  241 (51.5) 245 (50.1) 0.81
 value reached  172 (68.3) 204 (64.1) 0.14
 % of the predicted 
value reached a
   70 (17)   83 (18) 0.02*
Heart rate (bmp)
 predicted value  186 (8.3) 187 (7.2) 0.59
 value reached  165 (16.2) 173 (13.4) 0.08
 % of the predicted 
value reached a
   89 (8)   92 (7) 0.11
One-way ANOVA
a Value reached / predicted value x 100
* p<0.05
Table 4
PERCENTAGE (N) OF CFS PATIENTS (N=20) AND CONTROLS (N=20) ATTAINING A PHYSIOLOGICAL LIMITATION AT MAXIMAL 
EXERCISE
CFS Controls p-value
ΔHR >0 a  5 (1)  15 (3) 0.61
ΔBE >10 b  35 (7)  55 (11) 0.20
ΔPaCO2 >0 c  30 (6)  40 (8) 0.51
Attaining one of these criteria  55 (11)  80 (16) 0.09
Fisher’s  exact test for ΔHR; chi-square for other variables
a ΔHR, heart rate at maximal workload - predicted heart rate
b  ΔBE, base excess at maximal workload - base excess 3 minutes after test
c  ΔPaCO2, CO2 pressure in blood at maximal workload - CO2 pressure in blood at rest
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Discussion
In the present study CFS patients did not have a worse physical ﬁtness compared with their con-
trols. Both groups had a lower physical ﬁtness than would be expected according to height, age 
and sex. This particularly emphasizes the importance of a well-matched control group. In our 
study, the ﬁtness score of one of the controls was an extreme. When this extreme is excluded 
from the analysis, the difference remains statistically non-signiﬁcant. One might suggest that 
not ﬁnding a signiﬁcant difference in ﬁtness is due to a power problem, because of sample sizes. 
However, almost half of the CFS patients had a better ﬁtness than their own control. This result 
underlines the conclusion that there is no difference in ﬁtness between CFS patients and their 
controls. Our ﬁnding agrees with that of Sisto and colleagues18, who found that CFS patients 
had a low but normal ﬁtness, comparable to sedentary controls. Another objection might be 
that in spite of substantial and expected differences in fatigue, functional impairment and level 
of activity, only a selected group of patients was included. Bedridden patients, in particular, are 
unlikely to participate in these scientiﬁc studies. Van der Werf and colleagues33 recently found 
that passive patients can be distinguished from the relatively active patients based on the ac-
tometer. In the present study three passive CFS patients participated. These patients resemble 
bedridden patients. 
Concerning respiratory variables it was found that the CO2 pressure in the blood of CFS patients 
decreased more than in the controls. This might indicate that CFS patients tend to hyperventi-
late during exercise. In other studies34-35 it was found that hyperventilation, although prevalent 
in a substantial part of the cases, does not seem to play an essential role in CFS. However, no 
other signiﬁcant differences were found concerning oxygen consumption and carbon dioxide 
production. In addition, according to Wasserman and colleagues28 oxygen consumption should 
be 10.29 (±1) ml per minute per watt for normal subjects. If we compute millilitre oxygen 
consumption per minute per watt for the subjects in our study (O2 consumption at maximal 
workload minus O2 consumption at rest multiplied by 1000 and divided by maximal workload 
reached) this is 9.94 (±1.31) for CFS patients and 9.71 (±1.41) for controls. These values are both 
very similar to the normal value of Wasserman and colleagues28. Very unﬁt subjects usually need 
more O2 per watt. Consequently, this ﬁnding adds to the conclusion that the ﬁtness of the CFS 
patients is not substantially impaired.
The maximal workload reached during an incremental bicycle ergometer test did not differ 
between CFS patients and controls, neither did the heart rate at maximal workload. However, 
the average percentage of the predicted maximal workload reached was lower for CFS than for 
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controls. In spite of the absence of signiﬁcant differences in physical ﬁtness, CFS patients are 
not performing until they are limited by physiological mechanisms. It might be supposed that 
achieved workload is a parallel test for physical activity. Indeed, post hoc analysis revealed that 
the average percentage of the predicted maximal workload reached is highly correlated with 
physical activity in CFS (r=0.78, p<0.001), but not in controls (r=0.16, p=0.55). These correla-
tions are signiﬁcantly different (p=0.03). 
Because there was no signiﬁcant difference in ﬁtness between CFS and controls, it is not like-
ly that physical ﬁtness should be considered a perpetuating factor in CFS. The relationship 
between physical ﬁtness and fatigue is of less importance now. Nevertheless, the fact that 
the relationship between physical ﬁtness and fatigue is of the same strength for both groups, 
indicates that a worse physical ﬁtness goes with more fatigue for all subjects, for which CFS 
patients are no exception. The ﬁnding that in CFS a worse ﬁtness goes together with a lower 
level of physical activity (and higher level of impairment), is of interest. For controls no rela-
tionship between ﬁtness and physical activity was found. Apparently, CFS patients with a lower 
physical ﬁtness are less active, whereas controls are not. It is conceivable that CFS patients 
with a lower physical ﬁtness adjust to this by being less active, while controls do not. However, 
although the correlations between ﬁtness and the level of activity are different in CFS and in 
controls this difference is not statistically signiﬁcant. Besides, the sample sizes were small. 
Therefore, this ﬁnding has to be interpreted with caution. Wagenmakers11, reviewing some of the 
literature on physical ﬁtness and CFS, concludes that deconditioning might be a perpetuating 
factor. In this article it is supposed that CFS patients show a metabolic adaptation to a low level 
of physical activity. Wagenmakers11 suggests that the abnormal physiology found in CFS may 
well be a consequence of the lack of exercise in CFS patients. For this reason he suggests that 
exercise programmes have to be brought into practice. However, this explanation does not 
seem plausible: in our study the controls also had a lower physical ﬁtness than predicted while 
they were not less active or fatigued. Considering the above mentioned correlations as well, 
it seems more likely that low levels of activity are an adaptation to a lower physical ﬁtness of 
some CFS patients but not for controls, rather than that low levels of activity lead to a worse 
physical ﬁtness. Besides, Fulcher & White14 showed that there was no relationship between 
improvement in CFS after an exercise treatment programme and increase of peak aerobic 
capacity produced by exercise after this programme. This ﬁnding adds to the hypothesis that 
factors other than physical ﬁtness determine a lower level of activity, fatigue and impair-
ment in CFS. Possibly cognitions are responsible for a lower exercise tolerance in some CFS 
patients. Vercoulen and colleagues25 found that low levels of physical activity are in part 
caused by attributing complaints to a physical cause. Petrie and colleagues36 found that CFS 
patients who expected that activity would have negative consequences for their complaints, 
were also more impaired. However, based on the results of our study, it must be concluded 
that a worse physical ﬁtness does not seem to be a perpetuating factor in CFS.
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Abstract
Objective. This study examined the effects of exercise on symptoms and activity in CFS.
Methods. Twenty CFS patients and 20 neighbourhood controls performed an incremental ex-
ercise test until exhaustion. Fatigue, muscle pain, minutes spent resting and the level of physi-
cal activity were assessed with a self-observation list. Physical activity was assessed with an 
actometer as well. Data were obtained three days before the maximal exercise test up to ﬁve 
days thereafter.
Results. For CFS patients daily observed fatigue was increased up to two days after the exercise 
test. For controls self-observed fatigue returned to baseline after two hours. Both CFS patients 
and controls spent more minutes resting on the day before and on the day after the maximal 
exercise test. For CFS patients self-observed minutes resting was increased on the day of the 
exercise test also. For neither group a decrease of actometer recorded or self-observed physical 
activity after exercise was found.
Conclusion. Fatigue in CFS patients increased after exercise but the level of actual physical ac-
tivity remained unchanged.
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Introduction
Chronic Fatigue Syndrome (CFS) is characterized by a severe, disabling and unexplained fa-
tigue, lasting for at least six months. CFS patients often report that even minimal exercise 
aggravates symptoms and leads to a decrease of physical activity1. Nevertheless, in several 
studies gradually increasing activity programs have proven to be important in the treatment 
of CFS2-7. Although CFS patients seem to have the belief that activity is harmful, the effect of 
exercise on symptoms and activity in CFS patients is not known. 
Until now only a few studies examined exacerbation of symptoms and decrease of physical ac-
tivity after exercise. Most of these studies mainly concern physiological responses to treadmill 
or cycle exercise tests in CFS. Two uncontrolled studies, one measuring on the seventh day 
after exercise8, and one every day up to 7 days9, did not ﬁnd any adverse effects of exercise 
on symptoms and activity. Conversely, two controlled studies did ﬁnd an increase of fatigue 
after exercise. One study measured after 24 hours10, one up to 4 days11. 
In the studies mentioned, assessment took place by just asking for adverse after-effects fol-
lowing testing8, by questionnaires like the modiﬁed version of the Proﬁle Of Mood Scales 
(POMS)9-11, an activity restriction index9, a symptom log9, and daily ratings of fatigue11. Only 
in one study an accelerometer was used to measure the effect of exercise on physical activ-
ity. An unexplained reduction in activity on the ﬁfth day after the exercise test was found for 
CFS but not for controls12. 
It has been shown that self-report questionnaires on physical activity do not correlate very 
well with accelerometer readings13. Whereas questionnaires that require simple ratings of 
actual activity were related to the accelerometer, instruments that require general subjective 
interpretations of activity were not. Furthermore, questionnaires like the POMS do not seem 
sensitive for day-to-day changes in repeated measurements. Standardized self-observation 
measures seem more appropriate to assess ﬂuctuations in fatigue14,15.
The purpose of the current study was to investigate the effect of a maximal exercise test 
(MET) on fatigue, muscle pain, rest and activity on the days surrounding the exercise test. 
In a former study16 the physiological aspects of a maximal exercise test in CFS compared to 
controls were described. No signiﬁcant differences in physical ﬁtness between CFS patients 
and their controls were found. In this same study self-observation measurements as well as 
an accelerometer were used. These results are presented now. Symptoms and activity were 
measured the hours before and after the test, as well as the days before, of and after the ex-
ercise test. CFS patients were compared with neighbourhood controls. It was expected that 
c
h
a
p
ter 5   |   im
pa
c
t o
f a m
a
xim
a
l exer
c
ise test 
58
after the MET for CFS patients as well as for controls fatigue, muscle pain and rest will be 
increased and physical activity will be decreased as compared with baseline. In this context, 
a signiﬁcant difference in the extent as well as in the duration of changes in symptoms and 
activity between CFS and controls was anticipated. CFS patients were expected to experience 
a more severe increase of symptoms, of longer duration, and a more prevalent and longer 
lasting decrease of activity. 
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Methods 
Subjects
Patients were recruited from a group of CFS patients diagnosed at the General Internal Medicine 
outpatient clinic of the University Medical Centre Nijmegen, a national referral expert centre for 
CFS. The diagnosis CFS was made after a thorough medical investigation. All patients fulﬁlled 
the Fukuda criteria for CFS17.
As a rule, screening questionnaires were sent to all patients at the outpatient clinic diagnosed with 
CFS. For the present study only CFS patients with a CIS fatigue severity score of 40 or more, and 
a total score of the SIP-8 of more than 800 were included to guarantee severe fatigue and disabil-
ity (see instruments)18. With these operational criteria severe fatigue and impairment in CFS can 
be distinguished from fatigue and impairment in other conditions18. Finally, patients had to be 
able to recruit a neighbour of the same gender and about the same age, as a control. Twenty-six 
CFS patients, living in the surroundings of our hospital, were asked to participate. Twenty of these 
met our additional CIS and SIP-8 criteria and found a neighbourhood control. Prior to their com-
mitment, all subjects were completely informed about the method and procedure of the study. 
Physiological characteristics of these subjects have been described in detail elsewhere16. 
Measures
Checklist Individual Strength 
The subscale fatigue severity of the fatigue questionnaire Checklist Individual Strength (CIS)18 
was used to assess overall fatigue. The subscale fatigue consists of 8 items asking for fatigue 
severity during the last two weeks. Each item was scored on a 7-point Likert scale, so the range 
is 8-56. Cronbach’s alpha is 0.88. This subscale has proved its usefulness in several studies, 
and, for instance, distinguishes fatigue in CFS patients from fatigue in patients with functional 
bowel disorder and healthy controls18.
Sickness Impact Proﬁle
Functional impairment was assessed using the Sickness Impact Proﬁle (SIP)19,20. This question-
naire measures the inﬂuence of complaints in different areas of daily functioning. The following 
eight subscales were used: alertness behaviour, sleep, homemaking, leisure activities, work, mo-
bility, social interactions and ambulation. The sum of the weights of items of these subscales is 
referred to as the SIP-8. These subscales of the SIP are often used in CFS and distinguish func-
tional impairment in CFS patients from patients with several other physical complaints18.
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Maximal exercise test
A bicycle ergometertest with incremental load was used as an exercise test21. The workload was 
increased every minute in steps of 10% of estimated maximal workload in order to complete 
all maximal exercise tests (MET) in approximately 10 minutes. Steps varied from 10 to 30 Watt 
per minute. Subjects were verbally encouraged to perform maximally until exhaustion. The time 
spent on the bicycle ergometer was 8.0±2.3 minutes for CFS and 9.2±1.9 minutes for controls. 
The percentage of the predicted maximal workload reached, (value reached / predicted value) 
x 100, was 83% for controls and 70% for CFS. 
Self observation
A self-observation list was used to assess fatigue, muscle pain and activity from three days be-
fore up to ﬁve days after the MET. 
Daily assessment
Except for the day before, the day of and the day after the MET, self-observation scores were ob-
tained at breakfast, lunch, dinner and bed time, with 9 a.m., noon, 6 p.m. and 10 p.m. as a direc-
tive, on a scale from 0 to 4. For daily observed fatigue and daily observed muscle pain, 0 meant 
‘no symptoms’ and 4 meant ‘very severe symptoms’. For daily observed activity, 0 meant ‘not 
active at all’ and 4 ‘very active’. Scores were added up for each day and divided by four, resulting 
in a score from 0 to 4 for daily observed fatigue, daily observed muscle pain and daily observed 
activity. In addition, every day the time spent resting was asked for. Daily observed rest was de-
ﬁned as the number of minutes rest during a day. The scores for the daily data the day before, 
the day of and the day after the MET were obtained as averages of the hourly scores. For daily 
observed fatigue, muscle pain and activity, only the data obtained after performing the MET 
were used to compute the mean of the day the MET was performed.
Hourly assessment
The day before, the day after, and the day of the MET, assessments of fatigue, muscle pain, and 
activity were made every hour to obtain hourly scores on the same scale as used in the daily 
assessment. On these three days the time spent resting was asked for every hour and recorded 
as the number of minutes spent resting during the last hour. 
Actometer
Physical activity was also assessed using the actometer, an accelerometer worn around the 
ankle for two weeks. The actometer consists of a piezo electric sensor that is sensitive in three 
directions. Accelerations of the sensor larger than a predeﬁned threshold are considered as ac-
tivity and are stored into an internal memory. Each second the micro controller reads and resets 
the counter of the actometer. The integration counter is set at ﬁve minutes providing every ﬁve 
minutes an activity score that is stored into the internal memory of the actometer. At the end 
of the registration period data are fed into an external computer. The actometer has been used 
in several previous studies on CFS and is a good measure of actual physical activity13,22. 
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Daily assessment
Based on the mean of the recorded number of movements every ﬁve minutes during a day, for 
each day an average daily actometer score was computed. As for the self-observation data, on 
the day of the MET only the data obtained after the maximal exercise test took place were used 
to compute the mean of that day. 
Hourly assessment
For the day before, the day of and the day after the MET mean scores per hour were com-
puted as the mean of the recorded number of movements of every ﬁve minutes during the 
past hour. 
Procedure
Daily procedure
All patients and controls were given the self-observation list and the actometer to keep for three 
days before up to ﬁve days after the MET. Daily scores of the three days before the MET were 
used to compute a baseline score. Daily scores obtained at the day of the MET and at the ﬁve 
days after the MET were compared with baseline to detect the impact of the MET on symptoms 
and activity on a daily level (see statistical analyses).
Hourly procedure
Within each couple a CFS patient and his control performed the MET at the same day of the 
week and within all but three of the couples the MET was also performed at the same time of 
the day, with a time difference of less than one hour. Within three couples the time difference 
of performing the MET was respectively one, two and three hours. Because between couples 
the time the MET was performed ranged from 9 AM to 4 PM, complete hourly data are only 
available from 1 hour before up to 6 hours after the MET. Hourly data were collected the day 
of, the day before and the day after the MET. To detect the impact of the MET on self observed 
and actometer scores at an hourly level, hourly data obtained at the day of the MET were com-
pared with the hourly data for the same relative time points on the day before and the day after 
the MET (see statistical analyses).
Statistical analyses
Data analyses were performed using SPSS (version 8.0). 
Analyses of baseline data
To control for day to day ﬂuctuations, baseline scores were computed as the average score of 
the three days before the MET. To test whether these baseline scores were stable, they were 
analysed by 2 (group) by 3 (day) general linear model repeated measures analyses of variance 
(GLM RMANOVA). 
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Analyses of daily data
To analyse the impact of the MET on self observed and actometer scores over days, a 2 (group) by 
7 (day) GLM RMANOVA was used, in which the day of and the days after the MET were compared 
with baseline. Simple contrasts with baseline data were tested for each group separately.
Analyses of hourly data
As within day ﬂuctuations in self observed and actometer scores were to be expected23,24, di-
urnal patterns of the day before, the day of and the day after the MET were compared using 
2 (group) by 3 (day) by 7 (hour) GLM RM ANOVA. Additionally, as a secondary analysis, a 2 
(group) by 3 (day) GLM RM ANOVA was performed for each hour separately. Within groups 
simple contrasts of one day before the MET compared with respectively the day of the MET and 
one day after the MET, were tested for each hour separately.
Because we were interested in whether changes in self observed and actometer scores after ex-
ercise would differ between CFS patients and their controls, only interaction effects with group 
are reported. For the same reason simple contrasts with baseline data were tested for each 
group separately. For exploratory reasons, statistically signiﬁcant results of these tests of con-
trasts are shown whether or not a statistically signiﬁcant interaction effect could be obtained. 
For all analyses the signiﬁcance level was set at 0.05. Effect sizes (η2) are shown. Due to failing 
actometers sample sizes concerning actometer data are 16 for CFS and 17 for controls. For all 
other variables there are 20 subjects in each group.
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Results
Patient and control characteristics
Demographic data, CIS-fatigue and SIP scores are shown in table 1. Differences in CIS-fatigue, 
SIP-8, and duration of complaints were as expected. 
Table 1
CHARACTERISTICS OF CFS PATIENTS AND CONTROLS (% OR MEAN (SD); MEDIAN (25TH AND 75TH PERCENTILE) FOR SIP-8)
CFS (N=20) Controls (N=20)
Female (%) 60 60
Age (yrs) 34.1 (8.3)  32.8 (7.2)
Fatigue (CIS; range 8-56) 51.7 (5.1)  13.4 (5.1)
Functional impairment (SIP-8) 1743 (1249-2058)  0 (0-0)
Duration of complaints (yrs) 3.2 (2.5) -
Impact of the MET on fatigue, muscle pain, rest and activity
Figure 1 shows the means of all daily observed variables and the actometer from three days 
before up to ﬁve days after the MET for CFS and controls.
Baseline of the daily scores
For daily observed fatigue, daily observed muscle pain, daily observed activity and the acto- 
meter the baseline scores of the three days before the MET did not reveal any systematic inter-
action or within-subjects differences. For these variables means of these three days were used 
as a baseline. Analyses of the daily observed rest scores of the three days before the MET did 
show a signiﬁcant within-subjects difference (F[2,37]=11.31, η2=0.38, p<0.001). No statistically 
signiﬁcant group by day interaction effect was found. For daily observed rest, scores of one day 
before the MET seemed to deviate from the scores at the other two time points in both groups. 
No average differences were found between the means of daily observed rest three and two 
days before the MET. Therefore, for both groups the mean of these days were used as a base-
line for daily observed rest.
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Figure 1
MEAN DAILY SELF OBSERVED AND ACTOMETER SCORES FROM THREE DAYS BEFORE (-3) UP TO FIVE DAYS AFTER (5) THE MET FOR 
CFS ( –––– ;  ò ) AND CONTROLS ( – – – ;  ô ); BASELINE IS REPRESENTED AS A HORIZONTAL LINE (AVERAGE OF THE THREE DAYS 
BEFORE THE MET; FOR DAILY OBSERVED REST THE AVERAGE OF THE THIRD AND SECOND DAY BEFORE THE MET; CFS ––––   AND 
CONTROLS  – – –)
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The daily scores of the days after the MET compared with baseline
For daily observed fatigue a statistically signiﬁcant day by group effect was found (F[6,33]=3.74, 
η2 =0.38, p=0.011). The contrast procedure revealed that for CFS the day of, one day after and 
two days after the MET, daily observed fatigue was signiﬁcantly increased compared with base-
line (see table 2). For controls, none of the simple contrasts with baseline were statistically sig-
niﬁcant. A signiﬁcant time by group effect was also found for daily observed rest (F[6,33]=2.66, 
η2 =0.33, p=0.033). For CFS the contrast procedure showed a signiﬁcant increase for daily ob-
served rest between baseline and the day of the MET as well as between baseline and one day 
after the MET (see table 2). In the control group daily observed rest differed only signiﬁcantly 
between one day after the MET and baseline. On daily observed muscle pain, daily observed 
activity, and the actometer the average proﬁles of scores after the MET appeared not signiﬁ-
cantly different for the two groups. 
Differences in hourly fatigue, muscle pain, rest and activity scores the day before, 
the day of and the day after the maximal exercise test.
Mean hourly self observed scores of fatigue, muscle pain, rest and activity the day before, the 
day of and the day after the MET are illustrated in ﬁgure 2. No statistically signiﬁcant group by 
day by hour effects were found, neither for any of the hourly self observed nor for the hourly 
actometer scores. Group by day GLM RM ANOVA’s on the hourly scores for each hour sepa-
rately as well as the accompanying contrast procedures are shown in table 3 and table 4a and 
4b respectively.
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Table 2
SIMPLE CONTRASTS COMPARING DAILY SCORES THE DAY OF (0) UP TO FIVE DAYS AFTER (5) THE MET WITH BASELINE (BL) FOR CFS 
AND CONTROLS
contrast with baseline1
day-BL CFS Controls
F η2 p-value F η2 p-value
Self observed fatigue 0-BL 27.99 0.42 <0.001 ns
1-BL 10.98 0.22 0.002 ns
2-BL 6.88 0.15 0.012 ns
3-BL ns ns
4-BL ns ns
5-BL ns ns
Self observed muscle pain 0-BL 6.99 0.16 0.012 ns
1-BL ns ns
2-BL ns ns
3-BL ns ns
4-BL ns ns
5-BL ns ns
Self observed rest 0-BL 39.65 0.51 <0.001 ns
1-BL 25.62 0.40 <0.001 5.68 0.13 0.022
2-BL ns ns
3-BL ns ns
4-BL ns ns
5-BL ns ns
Self observed activity 0-BL 7.27 0.16 0.010 ns
1-BL ns ns
2-BL ns ns
3-BL ns ns
4-BL 4.77 0.11 0.035 ns
5-BL ns ns
Actometer 0-BL ns ns
1-BL ns ns
2-BL ns ns
3-BL ns ns
4-BL ns ns
5-BL ns ns
1 df [1,38]; for actometer df [1,31]
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Figure 2
MEAN HOURLY SELF OBSERVED AND ACTOMETER SCORES FOR CFS ( ––– ; CLOSED SYMBOLS) AND CONTROLS ( - - - ; OPEN SYMBOLS) 
1 HOUR BEFORE (-1) UP TO 6 HOURS AFTER (6) THE MET, THE DAY OF THE MET (ò ô), COMPARED WITH THE HOURLY DATA OF THE 
RELATED POINTS OF TIME OF THE DAY BEFORE (¢ £) AND THE DAY AFTER (p r) THE MET
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Table 3
DAY-BY-GROUP INTERACTION EFFECTS FOR SELF OBSERVED AND ACTOMETER 
SCORES PER HOUR RELATIVE TO THE TIME OF THE DAY THE MET WAS TAKEN (DAYS 
COMPARED ARE THE DAY BEFORE, THE DAY OF, AND THE DAY AFTER THE MET
GLM RM ANOVA1
hour day x group
F η2 p-value
Self observed fatigue -1 4.80 0.21 0.014
1 4.39 0.19 0.020
2 4.54 0.20 0.017
3 5.74 0.24 0.007
4 ns
5 5.24 0.22 0.010
6 ns
Self observed muscle pain -1 ns
1 ns
2 ns
3 ns
4 ns
5 ns
6 ns
Self observed rest -1 ns
1 ns
2 ns
3 ns
4 ns
5 ns
6 ns
Self observed activity -1 ns
1 ns
2 ns
3 3.41 0.16 0.044
4 ns
5 ns
6 ns
 
Actometer -1 ns
1 ns
2 ns
3 ns
4 ns
5 ns
6 ns
1 df [2,37]; for actometer df [2,30]
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Table 4a
SIMPLE CONTRASTS OF HOURLY SELF OBSERVED AND ACTOMETER SCORES COMPARING THE DAY OF THE MET WITH THE DAY 
BEFORE (THE HOURS ARE RELATIVE TO THE TIME OF THE DAY THE MET WAS TAKEN), SEPARATELY FOR CFS AND CONTROLS
hour
contrast between
the day of and the day before the MET1
CFS Controls
F η2 p-value F η2 p-value
Self observed fatigue -1 ns ns
1 5.48 0.13 0.025 4.53 0.11 0.040
2 13.17 0.26 0.001 4.92 0.11 0.033
3 14.34 0.27 <0.001 ns
4 11.68 0.24 0.002 ns
5 18.61 0.33 <0.001 ns
6 8.66 0.19 0.006 ns
Self observed muscle pain -1 ns ns
1 ns ns
2 ns ns
3 ns ns
4 6.13 0.14 0.018 ns
5 6.16 0.14 0.018 ns
6 8.84 0.19 0.005 ns
Self observed rest -1 4.51 0.11 0.040 ns
1 6.04 0.14 0.019 ns
2 ns ns
3 ns ns
4 ns ns
5 ns ns
6 ns ns
Self observed activity -1 5.78 0.13 0.021 ns
1 8.33 0.18 0.006 9.11 0.19 0.005
2 ns ns
3 ns ns
4 ns ns
5 ns ns
6 ns ns
Actometer -1 ns ns
1 ns ns
2 ns ns
3 ns ns
4 ns ns
5 ns ns
6 ns ns
1 df [1,38]; for actometer df [1,31]
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Table 4b
SIMPLE CONTRASTS OF HOURLY SELF OBSERVED AND ACTOMETER SCORES COMPARING THE DAY AFTER THE MET WITH THE DAY 
BEFORE (THE HOURS ARE RELATIVE TO THE TIME OF THE DAY THE MET WAS TAKEN), SEPARATELY FOR CFS AND CONTROLS
hour
contrast between
the day after and the day before the MET1
CFS Controls
F η2 p-value F η2 p-value
Self observed fatigue -1 6.23 0.14 0.017 ns
1 8.56 0.18 0.006 ns
2 11.72 0.24 0.001 ns
3 11.11 0.23 0.002 ns
4 ns ns
5 ns ns
6 ns ns
Self observed muscle pain -1 ns ns
1 ns ns
2 ns ns
3 ns ns
4 ns ns
5 ns ns
6 ns ns
Self observed rest -1 ns ns
1 ns ns
2 ns ns
3 ns ns
4 ns ns
5 ns ns
6 ns ns
Self observed activity -1 4.66 0.11 0.037 ns
1 ns ns
2 ns ns
3 ns ns
4 ns ns
5 4.97 0.12 0.032 ns
6 ns ns
Actometer -1 ns ns
1 ns ns
2 ns ns
3 ns ns
4 ns 4.19 0.12 0.049
5 ns ns
6 6.75 0.18 0.014 ns
1 df [1,38]; for actometer df [1,31]
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Discussion
In CFS fatigue after exercise increased more and was of longer duration as compared with 
healthy controls. Whereas for controls fatigue returned to baseline after two hours, for CFS a 
signiﬁcant increase of daily observed fatigue was found up to two days after the exercise test. 
Muscle pain was increased only in CFS and only on the day of the exercise test, speciﬁcally four 
to six hours after the MET. This increase in CFS, however, is not signiﬁcantly different from the 
increase of muscle pain in controls. 
A striking result is that, for CFS as well as for controls, minutes spent resting increased the day 
before the exercise test. Both groups seem to anticipate the exercise test. Although both groups 
also reported more time spent resting the day after the MET, the reported minutes rest on the 
day of the exercise test increased more for CFS than for controls. For both groups the daily ob-
served minutes spent resting returned to normal not earlier than on the  second day after the 
exercise test. Due to an increase of daily observed rest on the day before, the day of, and the day 
after the MET for both groups, diurnal patterns did not show many differences. CFS patients 
only seemed to spend fewer minutes resting during the hour before as well as the hour after the 
MET, compared with the related hourly scores of the day before. Probably this is a consequence 
of travelling to the hospital for the exercise test. 
Contrary to what was expected, the actometer did not reveal a decrease of physical activity 
after the exercise test. The self observed daily level of activity increased in CFS the day of the 
MET, when compared with baseline. Furthermore, both CFS patients and controls considered 
themselves to have been more active during the hour after the exercise test, whereas CFS pa-
tients also showed a somewhat increased daily observed level of activity the hour before the 
exercise. Probably, again these reported increases of activity surrounding the exercise test are 
a consequence of the subjects travel to the hospital. The few other statistically signiﬁcant ﬁnd-
ings concerning activity are hard to explain. Whereas these late effects were not hypothesized 
and are not congruent, they probably have to be considered random ﬂuctuations. So, although 
there are some ﬁndings that activity increases after exercise, no decrease of activity after exer-
cise was found.
One might argue that the maximal exercise test was not strenuous enough to ﬁnd an effect 
on activity. This is however unlikely. Data concerning physiological aspects of the MET showed 
that both CFS patients and controls reached a highly increased level of perceived exertion at 
maximal workload16. As we have shown now, CFS patients were even more fatigued several days 
thereafter, while their level of physical activity remains unchanged. 
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Another hypothesis is that, although the ﬁtness of the CFS patients in this study is not different 
from controls16, ﬁtness inﬂuences the extent of exacerbation of symptoms and decrease of activ-
ity after exercise. It can be hypothesized that CFS patients with a lower physical ﬁtness perceive 
a greater increase of fatigue after exercise than CFS patients having a better physical ﬁtness. 
Finally it might be that the maximum workload reached during the exercise test inﬂuences the 
effect of the MET on symptoms and activity. However, studying these hypotheses would need 
much larger sample sizes. 
Conﬁdence intervals for the actometer were broad for both groups (data not shown). Therefore 
changes are not easily signiﬁcant and interpreting actometer scores is difﬁcult. Possibly, 
heterogeneity of the CFS group might hide effects for subgroups of patients. It has been found 
that, based on their level of physical activity as assessed with the actometer, different groups 
of CFS patients can be distinguished22. Some CFS patients appeared to be really inactive, called 
passive CFS patients, whereas others are still rather active, called pervasively active CFS patients. 
In between, most CFS patients have a ﬂuctuating activity pattern, called moderately active. One 
might hypothesize that the impact on symptoms and activity of an exercise test might be more 
present in passive CFS patients. In the present study sample sizes are too small to test this 
hypothesis. Only three CFS patients in our study were passive patients. This percentage of 
passive CFS patients in our sample is congruent with the number of passive CFS patients in 
other samples22. 
Although actometer results seem rather congruent with daily observed activity scores, there is 
a striking discrepancy between the actometer results and self-observed minutes spent resting. 
Post-hoc analyses do not show any signiﬁcant correlations between the actometer and daily ob-
served rest or daily observed activity. This agrees with ﬁndings of Vercoulen and colleagues13 
who found that daily observed activity is a subjective rating of activity, whereas the actometer 
is a behavioural measure. The same might account for daily observed rest. It might be that CFS 
patients as well as controls perceive themselves to rest more, but actually don’t. An alterna-
tive explanation is that subjects do not so much diminish physical activities but withdraw from 
other, e.g. mental and social, activities.
In our study weekday patterns are not taken into account. In a similar study De Vries and col-
leagues25 showed that for symptomatic Cambodia veterans as well as for healthy Cambodia 
veterans, activity levels on Saturday and Sundays were lower in comparison with weekdays. The 
couples in our study did not all perform the MET on the same weekday, nor did all couples 
perform the MET at exactly the same time of the day. However, within each couple the exercise 
test was performed on the same day and mostly at the same time, thus controlling for weekday 
and time of the day effects. 
One might speculate about the inﬂuence of CFS patients selecting their own controls. We used 
neighbourhood controls, matched by age and sex, and – more or less by nature – for social 
background. Although we have not characterized these controls with regard to sedentary be-
haviour, it is likely that the social selection controls for that. 
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Finally, due to a small sample size, our analyses may not have had enough power to detect 
all relevant effects. Especially for the actometer data, in which data for four CFS patients and 
three controls were missing. To prevent the sample sizes to become smaller, the accompanying 
subject in the other group was not deleted. So, actometer data were not completely matched 
anymore. Our use of contrast tests, however, increased power somewhat. The signiﬁcant ef-
fects found were moderate to large in terms of proportion of variance explained (η2). Another 
methodological difﬁculty is the use of the data of the day of the MET. The scores on the vari-
ables for this day were based solely on measurements taken after the MET was performed. 
This was done because our focus was on the effect of the MET. One could argue that within-
day ﬂuctuations might cause a difference between days only based on the fact that scores in 
the afternoon might differ from scores of a complete day. Because the ﬁndings of the analyses 
over days are congruent with ﬁndings over hours, this is not very likely. 
So, the perception of CFS patients that they remain more fatigued for days after strenuous ex-
ercise is in accordance with the ﬁndings in this study. However, their level of physical activity 
does not change. Still, both CFS patients and controls report more minutes spent resting the 
day before, the day of and the day after exercise.
c
h
a
p
ter 5   |   im
pa
c
t o
f a m
a
xim
a
l exer
c
ise test 
74
References
1. Silver A, Haeny M, Vijayadurai P, Wilks D, Pattrick M, Main CJ. The role of fear of physical movement and 
activity in chronic fatigue syndrome. J Psychosom Res 2002;52:485-493.
2. Sharpe M, Hawton K, Simkin S, Suraway C, Hackman A, Klimes I, Peto T, Warell D, Seagroatt V. Cognitive 
behaviour therapy for the chronic fatigue syndrome: a randomised controlled trial. BMJ 1996;312:22-26.
3. Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic fatigue syndrome: a random-
ized controlled trial. Am J Psychiatry 1997;154:408-414.
4. Fulcher KY, White PD. Randomised controlled trial of graded exercise in patients with the chronic fatigue 
syndrome. BMJ 1997;314:1647-1652.
5. Wearden AJ, Morriss RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, Campbell IT, Morris JA. Randomised, 
double-blind, placebo-controlled treatment trial of ﬂuoxetine and graded exercise for chronic fatigue 
syndrome. Br J Psychiatry 1998;172:485-490.
6. Powell P, Bentall RP, Nye FJ, Edwards KHT. Randomised controlled trial of patient education to encourage 
graded exercise in chronic fatigue syndrome. BMJ 2001;322:387-390.
7. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, Boo TM de, Severens JL, Wilt GJ van der, Spinhoven P, 
Meer JWM van der. Cognitive behaviour therapy for chronic fatigue syndrome: a multicenter randomised 
controlled trial. Lancet 2001;357:841-847.
8. Mullis R, Campbell IT, Wearden AJ, Morriss RK, Pearson DJ. Prediction of peak oxygen uptake in chronic 
fatigue syndrome. Br J Sports Med 1999;33:352-356.
9. Clapp LL, Richardson MT, Smith JF, Wang M, Clapp AJ, Pieroni RE. Acute effects of thirty minutes of light-
intensity, intermittent exercise on patients with chronic fatigue syndrome. Phys Ther 1999;79:749-756. 
10. LaManca JJ, Sisto, SA, Zhou XD, Ottenweller JE, Cook S, Peckerman A, Zhang Q, Denny TN, Gause WC, 
Natelson BH. Immunological response in chronic fatigue syndrome following a graded exercise test to 
exhaustion. J Clin Immunol 1999;19:135-142.
11. Sisto SA, LaManca J, Cordero DL, Bergen MT, Ellis SP, Drastal S, Boda WL, Tapp WN, Natelson BH. Metabolic 
and cardiovascular effects of a progressive exercise test in patients with chronic fatigue syndrome. Am J Med 
1996;100:634-640.
12. Sisto SA, Tapp WN, LaManca JJ, Ling W, Korn LR, Nelson AJ, Natelson BH. Physical activity before and after 
exercise in women with chronic fatigue syndrome. Q J Med 1998;91:465-473.
13. Vercoulen JHMM, Bazelmans E, Swanink CMA, Fennis JFM, Galama JMD, Jongen PJH, Hommes O, Meer 
JWM van der, Bleijenberg G. Physical activity in Chronic Fatigue Syndrome: assessment and its role in fatigue. 
J Psychiatr Res 1997;31:661-673.
14. Dougall AL, Baum A, Jenkins FJ. Daily ﬂuctuation in chronic fatigue syndrome severity and symptoms. J Appl 
Biobeh Res 1998;3:12-28.
15. Jason LA, King CP, Frankenberry EL, Jordan KM. Chronic fatigue syndrome: assessing symptoms and activity 
level. J Clin Psychol 1999;55:411-424.
16. Bazelmans E, Bleijenberg G, Meer JWM van der, Folgering H. Is physical deconditioning a perpetuating fac-
tor in Chronic Fatigue Syndrome? A controlled study on maximal exercise performance and relations with 
fatigue, impairment and physical activity. Psychol Med 2001;31:107-114.
c
h
a
p
ter 5   |   im
pa
c
t o
f a m
a
xim
a
l exer
c
ise test
75
17. Fukuda K, Strauss SE, Hicki I, Sharpe MC, Dobbins JG, Komaroff A, the International Chronic Fatigue Study 
Group. The chronic fatigue syndrome: a comprehensive approach to its deﬁnition and study. Ann Intern Med 
1994;121:953-959.
18. Vercoulen JHMM, Swanink CMA, Fennis JFM, Galama JMD, Meer JWM van der, Bleijenberg G. Dimensional 
assessment of Chronic Fatigue Syndrome. J Psychosom Res 1994;38:383-392.
19. Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Proﬁle: development and ﬁnal revision 
of a health status measure. Med Care 1981;19:787-805.
20. Jacobs HM, Luttik A, Touw-Otten FWMM, Melker RA. De ‘Sickness Impact Proﬁle’: resultaten van een 
valideringsonderzoek van de Nederlandse versie. Ned Tijdschr Geneeskd 1990;134:1950-1954.
21. Folgering H, Doorn P van, Cox N. A prediction equation for Wmax in COPD-patients. Eur Respir J 
1988;1:67S.
22. Werf SP van der, Prins JB, Vercoulen JHMM, Meer JWM van der, Bleijenberg G. Identifying physical activity 
patterns in chronic fatigue syndrome using actigraphic assessment. J Psychosom Res 2000;49:373-379.
23. Wood C, Magnello ME, Sharpe MC. Fluctuations in perceived energy and mood among patients with chronic 
fatigue syndrome. J R Soc Med 1992;85:195-198.
24. Stone AA, Broderick JE, Porter LS, Krupp L, Gnys M, Paty JA, Shiffmann P. Fatigue and mood in chronic 
fatigue syndrome patients: results of a momentary assessment protocol examining fatigue and mood levels 
and diurnal patterns. Ann Behav Med 1994;16:228-234.
25. Vries M de, Soetekouw PMMB, Meer JWM van der, Folgering H, and Bleijenberg G. Physical activity and 
exercise performance in symptomatic Cambodia veterans. Q J Med 2002;95:99-105.

E Bazelmans 1
JB Prins 1 
R Lulofs 2
JWM van der Meer 3
G Bleijenberg 4
1 DEPARTMENT OF MEDICAL PSYCHOLOGY, UNIVERSITY MEDICAL CENTRE ST RADBOUD, NIJMEGEN, THE NETHERLANDS
2 DEPARTMENT OF CLINICAL GENETICS, UNIVERSITY HOSPITAL MAASTRICHT 
3 DEPARTMENT OF GENERAL INTERNAL MEDICINE, UNIVERSITY MEDICAL CENTRE ST RADBOUD, NIJMEGEN, THE NETHERLANDS
4  EXPERT CENTRE CHRONIC FATIGUE, UNIVERSITY MEDICAL CENTRE ST RADBOUD, NIJMEGEN, THE NETHERLANDS
6Cognitive behaviour group therapy  for chronic fatigue syndrome:  
a non-randomised wait list  
controlled study
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Abstract
Background. It has been demonstrated that individual cognitive behaviour therapy is an effec-
tive treatment for chronic fatigue syndrome (CFS). Aim of the present study was to investigate 
the effectiveness of cognitive behaviour group therapy (CBGT) in an unselected group of CFS 
patients. Additionally, pre-treatment characteristics of CFS patients who improve after CBGT 
were explored. 
Methods. In a non-randomised wait list controlled design 31 patients were allocated to CBGT, 
and 36 to the wait list condition. CBGT consisted of 12 two-hour sessions during six months. 
Main outcome measures were fatigue (CIS-fatigue) and functional impairment (SIP-8). 
Results. A moderate effect on fatigue in favour of CBGT was found. For functional impairment 
the effect was opposite to what was expected. Patients improved after CBGT had less com-
plaints at baseline compared to non-improved patients. 
Conclusions. An explanation for the moderate effect might be that during CBGT rest and re-
laxation were too much emphasised. Furthermore, an unselected group of CFS patients and 
therapists inexperienced with CB(G)T for CFS participated. Suggestions to improve CBGT for 
future research are given. 
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Introduction
Chronic fatigue syndrome (CFS) is characterised by severe fatigue lasting for at least six months, 
for which no somatic explanation can be found, and which leads to severe disability in daily life1. 
Although the cause of CFS is still unknown, several perpetuating factors have been identiﬁed. A 
model of perpetuating factors in CFS showed that a strong focus on bodily symptoms, low levels 
of physical activity and a poor sense of control contribute to an increase in the severity of fatigue 
and functional impairment2. Strong somatic attributions lead to lower levels of physical activity. 
Several protocols for cognitive behaviour therapy (CBT) for CFS have been developed3-6. In sev-
eral studies individual CBT for CFS has proven to be effective, even at follow up7-12. Three recent 
reviews conclude that CBT and graded exercise are the only interventions in CFS with proven 
effectiveness13-15. Further research on CBT for patients with milder forms of CFS or for CFS in-
patients as well as research on the effectiveness of cognitive behaviour group therapy (CBGT) 
was recommended13.
Some ﬁrst reports on the feasibility and effectiveness of forms of CBT for CFS other than am-
bulatory individual therapy show positive results. These uncontrolled studies concern CBT in 
an inpatient setting, CBT as a part of a multidisciplinary intervention, CBT in a general hospital 
setting and CBT for adolescents with CFS16-20. There is no literature on the effect of CBGT for 
CFS. Only one study evaluated the effect of focused group therapy for CFS, in a controlled de-
sign21. This non-CBT group intervention had no effect on fatigue and impairment. In another 
study it was shown that support groups for CFS patients had no effect on fatigue and impair-
ment either9. 
Aim of the present controlled study was to investigate the effectiveness of CBGT for CFS. 
Additionally pre-treatment characteristics of CFS patients who improve after CBGT were 
explored.
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Method
Design
CBGT was compared with a wait list condition. CBGT, lasting six months, was offered in two 
centres, the Department of Psychotherapy of the Maastricht Mental Health Institute and the 
Department of Medical Psychology of the University Medical Centre Nijmegen. For ethical rea-
sons patients in the wait list condition were offered CBGT after the wait period of six months. 
Only data of the controlled part of the study were used to test the effectiveness of CBGT. 
Participants
CFS patients were diagnosed and referred by the outpatient clinic of the departments of General 
Internal Medicine of the University Medical Centre of Nijmegen or Maastricht. All patients ful-
ﬁlled the Fukuda criteria for CFS or idiopathic chronic fatigue1. Consecutive patients with the di-
agnosis CFS or idiopathic chronic fatigue were asked to participate in the current study. Patients 
were included if they had a CIS-fatigue score of 35 or more and a SIP-8 score of 700 or more 
(see baseline measures). Furthermore, they had to be willing to stop other treatments for CFS 
during CBGT. Pivotal to CBT for CFS is that the patient becomes aware that the progress made 
can be attributed to the changes in his or her cognitions and behaviours. When the patient is 
undergoing two treatments simultaneously it is difﬁcult to say which of the two interventions 
accounts for the improvements. To prevent withdrawal after inclusion, we added this prerequi-
site for CBGT before inclusion. If both of the inclusion criteria were fulﬁlled, informed consent 
was obtained. Patients were allocated to CBGT until the ﬁrst group was full. The next groups 
consisted partly of patients from the wait list condition and partly of recently referred patients. 
Baseline assessment took place in the two weeks prior to the start of CBGT, for the wait list 
condition six months prior to the start of the next CBGT. Ultimately, eight groups of seven to 
ten patients were completed.
Cognitive Behaviour Group Therapy
In CBGT cognitions and behaviour known to perpetuate fatigue in CFS were the focus of 
change2. Cognitions concerning a negative self-efﬁcacy and somatic attributions were chal-
lenged. Further, CFS patients were taught to behave according to their own limits and to 
have adequate periods of rest and relaxation. Thereafter, a graded activity program took 
place. Homework assignments and a course book were used. CBGT consisted of 12 two-
hour sessions during six months. CBGT was presented as a course in ‘coping with fatigue’. 
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There were two therapists for each group. Six therapists in four different couples partici-
pated. All therapists were inexperienced with group therapy and inexperienced with CBT for 
CFS. They were weekly supervised by a therapist experienced in working with groups and 
CBT for CFS. 
Wait list condition
Patients in the wait list condition had no restrictions. They were free to undertake everything 
they would usually do. 
Measurements
Primary outcome measures
The subscale fatigue of the Checklist Individual Strength (CIS-fatigue) was used to measure fa-
tigue22. This subscale has eight items scored on a 7-point Likert scale (range 8-56). High scores 
reﬂect high levels of fatigue.
Eight subscales of the Sickness Impact Proﬁle (SIP-8) were used to measure functional impair-
ment22-23. The eight subscales used were home management, mobility, alertness behaviour, 
sleep/rest, ambulation, social interactions, work, and recreation and pastimes. A total score was 
calculated by addition of the weights of items (range 0-5799). High scores reﬂect high levels of 
functional impairment. Comparison data were available22.
Secondary outcome measures
Fatigue was also assessed using a 12-day self-observation list24. Scores were obtained four 
times a day (9 a.m., noon, 6 p.m., 10 p.m.) on a scale from 0 (not fatigued) to 4 (very severe 
fatigued). Daily-observed fatigue is represented as the mean of the total daily-observed fatigue 
scores over 12 days. So the range for daily-observed fatigue is 0 to 16. In the same way as for 
fatigue daily-observed pain was measured. 
In a general questionnaire an item concerning the hours that the patient had been working in 
a job the last week was added.
Psychological distress was measured with the Symptom Checklist 90 (SCL-90)25. This scale 
consists of 90 items scored on a 5-point Likert scale (range 90-450). High scores reﬂect high 
psychological distress. Depression was measured with the Beck Depression Inventory (BDI)26. 
High scores reﬂect high levels of depression (range 0-63). 
Self-rated improvement was only asked for after CBGT. Answers were given on a 4 point scale: 
‘completely recovered’, ‘better or much better’, ‘the same’, or ‘worse’ 27-28. This variable is di-
chotomised in ‘better or recovered’ and ‘the same or worse’. 
Perpetuating factors
Physical attributions were measured with four items concerning the conviction that CFS is a con-
sequence of ‘something physical’, ‘a virus’, ‘the immune system’, or ‘some physical disease’ 28. 
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Items are answered on a Likert scale from 1 (not convinced at all) to 4 (completely convinced). 
Scores range from 4 (no physical attributions) to 16 (strong physical attributions).
Self-efﬁcacy was measured with ﬁve items concerning whether the patient thinks he can inﬂu-
ence his complaints9,28. Four questions were answered on a 5-point Likert scale, 1 question on 
a 4-point Likert scale. Scores range from 5 (low self-efﬁcacy) to 24 (high self-efﬁcacy). 
Avoidance of activity was measured with ﬁve items scored on a 4-point Likert scale22. Questions 
were asked with respect to avoidance of physical activity as a way of coping with complaints. 
Scores range from 5 (no avoidance of activity) to 20 (strong avoidance of activity). 
Focusing on bodily symptoms was measured by the subscale somatisation of the SCL-9025,27. The 
subscale consists of 12 items scored on a 5-point Likert scale. Scores ranges from 0 to 60.
Statistical analyses
Two (group) by two (time) interaction effects of repeated measures analyses of variance (RM 
ANOVA’s) were used to analyse treatment effect. 
Patients were divided in improved or non-improved after CBGT according to self-rated improve-
ment. Predictors of treatment outcome were explored comparing baseline characteristics of 
these improved and non-improved CFS patients. Because of small sample sizes, pre-treatment 
differences were analysed with the Mann-Whitney U test for continuous variables. For discrete 
variables Pearson Chi-Squares were used. 
The signiﬁcance level was set at 0.05. Effects with a p-value between 0.05 and 0.10 were ac-
cepted as a trend. All analyses were performed using SPSS version 10.0.
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Results
Patient ﬂow is displayed in ﬁgure 1. Of the total 67 eligible patients, 31 CFS patients were allocated 
to CBGT and 36 CFS patients were allocated to the wait list condition. Two patients dropped out 
during treatment. No post-test data are available from these patients. So, 29 CFS patients in the 
CBGT condition and 36 CFS patients in the wait list control condition entered into post-test. 
Figure 1
PATIENT FLOW
40 excluded 
1 did not meet CIS or SIP 
inclusion criteria
11 did not want to stop other 
treatments for CBGT
28 other reasons, like 
travelling distance, pregnancy, 
considering themselves too 
depressed or having too much 
complaints, did not believe 
that this CBGT would add to 
prior psychological treatment 
32 excluded 
9 did not meet CIS or SIP 
inclusion criteria
8 did not want to stop other 
treatments for CBGT
15 other reasons, like 
travelling distance, pregnancy, 
considering themselves too 
depressed or having too much 
complaints, did not believe that 
this CBGT would add to prior 
psychological treatment 
74 assessed for eligibility in Nijmegen 65 assessed for eligibility in Maastricht
34 included 33 included 
14 allocated to CBGT 
13 received allocated 
intervention
1 discontinued CBGT 
(dropped out) 
20 allocated to WL 17 allocated to CBGT 
16 received allocated 
intervention 
1 discontinued CBGT 
(dropped out) 
16 allocated to WL 
13 analysed 20 analysed 16 analysed 16 analysed 
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Table 1
DEMOGRAPHIC CHARACTERISTICS OF PATIENTS IN THE CBGT AND THE WAIT LIST CONDITION (WL); VALUES DISPLAYED ARE MEANS 
(SD) OR PERCENTAGE (N)
CBGT (N=31) WL (N=36)
Age  (yrs)  37.4 (8.6)  35.8 (9.0)
Educational attainment (1=low, 7=high)  4.3 (1.7)  4.7 (1.6)
 Female (%)  67.7 (21)  77.8 (28)
Patient characteristics at baseline 
Demographic data are displayed in table 1. No apparent differences between CBGT and the 
wait list condition emerged. Two patients’ only fulﬁlled Fukuda criteria for idiopathic fatigue, 
the others fulﬁlled Fukuda criteria for CFS. Mean duration of complaints was 6.2 years (sd 5.2) 
and 5.3 years (sd 4.5) in the CBGT and wait list condition respectively. All baseline data (table 
2) were as expected for CFS22, 27, 28.
CBGT compared to the wait list control group
Interaction effects of the RM ANOVA’s are displayed in table 2. 
Primary outcome measures
On CIS-fatigue an interaction effect with a p-value of 0.099 was found, in favour of CBGT. Functional 
impairment showed a signiﬁcant interaction effect (p=0.004) in favour of the wait list condition. 
Functional impairment did not change after CBGT, but declined in the wait list condition
Secondary outcome measures
For daily observed fatigue, daily-observed pain, hours working, psychological well-being and 
depression, no signiﬁcant interaction effects were found. 
Self-rated improvement scores were available of 27 of 29 patients after CBGT. Ten (37%) of 
these CFS patients rated themselves improved.
Perpetuating factors
Concerning perpetuating factors, a signiﬁcant interaction effect was found for physical attri-
butions (p=0.023) and avoidance of activity (p=0.001). Physical attributions decreased after 
CBGT and increased in the wait list condition. Avoidance of activity increased after CBGT and 
decreased in the wait list condition. On self-efﬁcacy and focusing on bodily symptoms no in-
teraction effects were found.
Pre-treatment differences of CFS patients improved and non-improved after CBGT
Comparing the CFS patients who rated themselves improved after CBGT with those who did 
not, it was found that improved patients reported signiﬁcantly less functional impairment, less 
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Table 2
INTERACTION EFFECTS OF RM ANOVA’S BETWEEN BASELINE AND 6 MONTHS, CBGT COMPARED TO THE WAIT LIST CONDITION (WL)
CBGT WL interaction effect
Mean (sd) 95% CI Mean (sd) 95% CI F-value [df ] p-value
Primary outcome measures
Fatigue (CIS-fatigue)
baseline 51.0 (5.0) 49.0-53.1 50.8 (5.6)  49.0-52.6
6 months 45.6 (9.6) 42.6-48.7 48.4 (6.2)  45.7-51.1  2.807 [1,61] 0.099
Functional impairment (SIP-8)
baseline 1707 (713) 1474-1940 1710 (528)  1502-1919
6 months 1736 (714) 1516-1955 1417 (444)  1221-1613  9.117 [1,61] 0.004
Secondary outcome measures
Daily-observed fatigue
baseline 8.6 (2.7) 7.6-9.6 9.4 (2.4)  8.6-10.3
6 months 8.2 (3.4) 6.9-9.4 9.0 (3.0)  7.9-10.1  0.005 [1,58] 0.943
Daily-observed pain
baseline 6.0 (3.8) 4.7-7.4 6.9 (3.2)  5.7-8.1
6 months 6.2 (4.3) 4.7-7.8 6.7 (3.7)  5.3-8.1  0.460 [1,57] 0.500
Hours working (mean/week)
baseline 5.5 (9.9) 1.8-9.2 5.6 (9.6)  2.3-9.0
6 months 6.4 (11.7) 2.3-10.6 6.7 (10.5)  2.9-10.5  0.003 [1,60] 0.958
Psychological distress (SCL-90)
baseline 165.4 (39.1) 150.6-180.2 162.7 (37.8)  149.3-176.0
6 months 162.1 (48.0) 145.6-178.6 154.2 (38.1)  139.3-169.1  0.580 [1,58] 0.449
Depression (BDI)
baseline 15.2 (8.3) 12.5-17.8 13.7 (6.0)  11.2-16.1
6 months 11.9 (6.8)   9.7-14.2 11.4 (5.3)  9.3-13.5  0.643 [1.63] 0.426
Perpetuating factors
Physical attributions
baseline 11.2 (2.0) 10.4-11.9 11.8 (1.8)  11.1-12.6
6 months 10.6 (2.4)   9.7-11.4 12.2 (1.9)  11.4-13.0  5.502 [1,51] 0.023
Self-efﬁcacy
baseline 15.9 (3.2) 14.5-17.3 14.9 (3.8)  13.7-16.1
6 months 18.5 (3.3) 17.1-19.8 16.9 (3.6)  15.7-18.1  0.453 [1,58] 0.504
Avoidance of activity
baseline 7.6 (2.6) 6.4-8.7 8.0 (3.3)  6.9-9.1
6 months 9.1 (2.4) 8.2-10.0 7.4 (2.2)  6.6-8.3  12.743 [1,54] 0.001
Focusing on bodily symptoms
baseline 28.8 (8.2) 25.9-31.8 31.5 (7.1)  28.9-34.2
6 months 27.9 (9.0) 24.7-31.1 29.2 (7.6)  26.3-32.1  0.714 [1,58] 0.402
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daily observed fatigue, and less daily observed pain at baseline (table 3). For the pre-treatment 
variable ‘mean hours working a week’ a trend was found with improved patients working more 
hours at baseline compared to non-improved patients. 
Table 3
PRE-TREATMENT DIFFERENCES OF CFS PATIENTS IMPROVED AND NON-IMPROVED AFTER CBGT FOR DISCRETE VARIABLES 
(% PRESENTED) AND CONTINUOUS VARIABLES (MEAN (SD) PRESENTED) RESPECTIVELY.
Better or much 
better  (N=10)
Same or worse
(N=17)
Chi-Square p-value a
CBGT in Nijmegen 50 41 0.199 ns
Being female 80 65 0.706 ns
Better or much 
better  (N=10)-
Same or worse
(N=17)
MWU Z p-value a
Age  38.0 (7.2)  36.2 (8.9) 76.0 -0.453 ns
Educational attainment  4.7 (1.6)  4.2 (1.7) 70.5 -0.741 ns
Duration of complaints  4.9 (4.5)  6.8 (5.6) 66.0 -0.961 ns
Fatigue (CIS-fatigue)  50.7 (4.2)  52.1 (4.2) 63.0 -1.113 ns
Functional impairment (SIP-8)  1330 (417)  1985 (730) 42.0 -2.159 0.031
Daily-observed fatigue  7.4 (2.6)  9.7 (2.3) 34.0 -2.277 0.023
Daily-observed pain  4.5 (2.6)  7.8 (3.5) 35.0 -2.220 0.026
Hours working (mean/week)  10.9 (12.8)  2.6 (6.6) 55.0 -1.867 0.062
Psychological distress (SCL-90)  151.8 (51.1)  168.8 (36.1) 60.5 -1.231 ns
Depression (BDI)  12.1 (6.7)  17.4 (9.0) 53.5 -1.590 ns
Physical attributions  10.9 (1.8)  11.5 (2.2) 64.5 -0.656 ns
Self-efﬁcacy  16.7 (3.3)  15.4 (3.2) 57.5 -1.195 ns
Avoidance of activity  7.6 (2.8)  7.0 (2.5) 68.5 -0.835 ns
Focusing on bodily symptoms  10.9 (1.8)  11.5 (2.2) 68.0 -0.855 ns
a  p-values <0.10 are displayed
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Discussion
A trend was found that CBGT has a positive effect on fatigue in CFS. The changes in functional 
impairment were opposite to what was expected. On secondary outcome measures no signiﬁ-
cant improvement was found. After CBGT 37% considered themselves improved. Although it 
was not the focus of this study, post hoc analyses showed no signiﬁcant differences in the ef-
fectiveness of CBGT between the two participating centres.
Treatment effect in our study is low compared to most studies on individual CBT for CFS7-10. 
Whereas in these studies self-rated improvement ranged from 57% up to 70%, ours was 37%. 
In the control conditions of these other studies, self-rated improvement ranged from 23% up 
to 31%. Unfortunately, in our study self-rated improvement was not assessed after the wait list 
period. 
Contrary to our ﬁndings, most studies on individual CBT for CFS ﬁnd an effect on functional im-
pairment in favour of the treatment condition. In the study of Prins and colleagues9, functional 
impairment also declined in the support groups as well as in the natural course condition, but 
after CBT functional impairment declined more. It seems that in our CBGT improvement on 
functional impairment was interfered. This might be related to the ﬁnding that avoidance of ac-
tivity increased after CBGT, and not after the wait list period. Asking the therapists afterwards, 
it seems that during CBGT there has been spent too much time on rest and relaxation, whereas 
starting the graded activity program was postponed for too long. It seemed to have been too 
difﬁcult to get a group of patients starting and sustain the activity program. Furthermore, CBGT 
was presented as a course in ‘coping with fatigue’. Once avoidance of activity had led to less 
fatigue, patients may have been satisﬁed yet. On this point, patients may have reinforced each 
other’s maladaptive behaviours.
One might dispute the effectiveness and suitability of CBGT for CFS. The main advantage of 
group therapy lies in the fact that several patients can be treated simultaneously. Modelling 
processes by seeing other members of the group might facilitate behaviour change. However, 
group therapy for CFS also has disadvantages. In group therapy CFS patients may reinforce 
dysfunctional behaviour and resistance against psychological treatment. Furthermore, in group 
therapy it is much harder to individualise CBT treatment to individual needs. 
Yet, based on our current study and some recent studies on individual CBT for CFS, recommen-
dations to improve the effectiveness and suitability of CBGT for CFS can be made. In trials on 
individual CBT for CFS it was found that engagement in a claim for a disability related beneﬁt 
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during CBT predicted less improvement after individual CBT for CFS12,29. Our CBGT started be-
fore completion of these studies. In the present study it was found that CFS patients with less 
severe complaints did proﬁt most of CBGT. In future research on the effectiveness of CBGT for 
CFS these ﬁndings will have to be taken into account. 
Another explanation for the moderate effect of CBGT might be that the therapists had no prior 
experience with CB(G)T for CFS. Only Prins and colleagues9 performed a multi-centre trial us-
ing therapists inexperienced with CBT for CFS as well. In that study 83% of the therapists stated 
that they agreed that ‘CFS patients are more difﬁcult to treat than patients with psychological 
complaints’, and 64% agreed that ‘CFS patients are more difﬁcult to treat than other patients 
with somatic complaints’30. For our study this might count even more, since the therapists were 
inexperienced both in group therapy and in CBT for CFS. 
Finally, based on this and former studies the treatment protocol CB(G)T for CFS has been im-
proved. Rest and relaxation are less emphasised, and for passive CFS patients the treatment 
protocol has been adapted9. Recently, lack of social support has been identiﬁed as an important 
determinant of CFS and a new perpetuating factor31, 32. Dealing with a lack of social support may 
also have to become a more prominent aspect of CBT for CFS. 
For future research on CBGT in CFS it is recommended to select CFS patients not engaged in a 
claim for a disability related beneﬁt during CBT and with less severe complaints. Furthermore, 
therapists should be experienced in group therapy as well as CBT for CFS. 
In the current study we found a moderate effect of CBGT on fatigue, in an unselected group of 
CFS patients, and with newly trained therapists. Future research is necessary to further investi-
gate the suitability of CBGT for (subgroups of) CFS patients. 
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Abstract
Background. Cognitive behaviour therapy (CBT) seems a promising treatment for chronic fa-
tigue syndrome (CFS), but the applicability of this treatment outside specialised settings has 
been questioned. We compared CBT with guided support groups and the natural course in a 
randomised trial at three centres.
Methods. Of 476 patients diagnosed with CFS, 278 were eligible and willing to take part. 93 
were randomly assigned CBT (administered by 13 therapists recently trained in this technique 
for CFS), 94 were assigned the support-group approach, and 91 the control natural course. 
Multidimensional assessments were done at baseline, 8 months, and 14 months. The primary 
outcome variables were fatigue severity (on the checklist individual strength) and functional 
impairment (on the sickness impact proﬁle) at 8 and 14 months. Data were analysed by inten-
tion to treat.
Findings. 241 patients had complete data (83 CBT, 80 support groups, 78 natural course) at 8 
months. At 14 months CBT was signiﬁcantly more effective than both control conditions for fa-
tigue severity (CBT vs support groups 5.8 [2.2-9.4]; CBT vs natural course 5.6 [2.1-9.0]) and for 
functional impairment (CBT vs support groups 263 [38-488]; CBT vs natural course 222 [3-441]. 
Support groups were not more effective for CFS patients than the natural course. Among the 
CBT group, clinically signiﬁcant improvement was seen in fatigue severity for 20 of 58 (35%), 
in Karnofsky performance status for 28 of 57 (49%), and self-rated improvement for 29 of 58 
(50%). Prognostic factors for outcome after CBT were higher sense of control predicting more 
improvement, and a passive activity pattern and focusing on bodily symptoms predicting less 
improvement. 
Interpretation. CBT was more effective than guided support groups and the natural course in 
a multicentre trial with many therapists. Our study showed a lower proportion of patients with 
improvement than CBT trials with a few highly skilled therapists.
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Introduction
Chronic fatigue syndrome (CFS) is characterised by persistent or relapsing unexplained fatigue, 
of new or deﬁnite onset and lasting for at least six months. Fatigue is not the result of an organic 
disease or ongoing exertion, rest does not alleviate it, and there is substantial limitation of occu-
pational, educational, social and personal activities1. No cause of CFS has been found, and most 
patients do not recover. No somatic or pharmacological treatments have proven to be effective2. 
Cognitive behaviour therapy (CBT) seems to be a promising treatment of CFS3-5. Two randomised 
controlled trials reported positive results6,7. A recent review questioned whether these results can 
be generalised outside specialist centres were only a few highly skilled therapists, or even a single 
therapist administered CBT. Furthermore, in both studies the primary outcome variable was func-
tional impairment and not fatigue, the main complaint of CFS patients. 
In our study, criticisms of both previous randomised trials were addressed. The effectiveness of 
CBT was tested in a multicentre randomised trial. CBT was compared with a treatment condi-
tion, guided support groups, and a control condition, the natural course. CBT was administered 
in three different centres rather than one specialist centre. Experts taught the treatment pro-
tocol to many therapists with no previous experience in CBT for CFS. Guided support groups 
should control for the absence of speciﬁc cognitive-behavioural interventions and the presence 
of therapist attention and treatment expectations. We assumed that support groups, as in other 
chronic diseases8,9, might contribute to a feeling of mutual understanding, acceptance and sup-
port and thereby have a healing effect. 
In this study, the outcome variables were fatigue severity and functional impairment, with the 
same instruments for inclusion and outcome. Moreover, CBT for CFS was based on a statistically 
tested model of perpetuating factors in CFS10,11 rather than on hypothesised factors in CFS or on 
treatments of other medically unexplained syndromes. The model of CFS is shown in ﬁgure 1. 
Focusing on bodily symptoms, low levels of physical activity and sense of control contribute to 
increasing severity of fatigue and functional impairment. CBT is directed at these perpetuating 
factors. The main aim of our multicenter trial was to show the effectiveness of CBT for patients 
with CFS. Our hypothesis that fatigue severity and functional impairment should decrease sig-
niﬁcantly more in the group of patients assigned CBT than in patients in the control groups. 
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Figure 1
MODEL OF CFS DEVELOPED AND TESTED WITH LISREL (A PROGRAM FOR THE ESTIMATION OF LINEAR STRUCTURAL RELATIONS) 
10
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Patients and methods 
Patients
All patients with a major complaint of fatigue referred to the outpatient clinic of the departments 
of internal medicine of the University Medical Centre Nijmegen and the University Hospital 
Maastricht between October, 1996, and January, 1998, were assessed by means of detailed his-
tory, physical examination, and computer assessment of questionnaires. Patients were eligible 
for the study if they met the US Centers for Disease Control and Prevention criteria for CFS1, 
with the exception of the criterion requiring four of eight additional symptoms to be present. 
Severe fatigue and severe functional impairment were deﬁned by cut-off scores: a score of 40 
or more on the subscale fatigue severity of the Checklist Individual Strength and a score of 800 
or more on the Sickness Impact Proﬁle. Additional inclusion criteria for this study were age be-
tween 18 and 60 years, and residence within 1.5 hour travelling time of one of the study centres. 
Additional exclusion criteria were previous or current participation in CFS research, pregnancy, 
and current treatment to achieve pregnancy.
A sample size of 80 patients per group was estimated assuming signiﬁcance of 5%, power of 
90%, a dropout rate of 20%, and a medium effect size on the actometer, the measure of our 
multidimensional approach in need of most individuals to show improvement. Multidimensional 
assessment has been recommended for studies assessing the effect of therapeutic interven-
tions for CFS, to measure change in different dimensions of the patients’ functioning12. During 
the trial the dropout rate was higher than that estimated in the calculation of sample size. 
Therefore, the target sample size for inclusion was set at 90 patients per study group.
Design and procedures
The study was an open multicentre randomised controlled trial in which individual CBT was 
compared to participation in guided support groups and with the natural course, a control 
condition in which no treatment was offered. The ethics committees of the three participating 
centres gave approval for the study. Treatment effects were expected in the primary outcome 
variables fatigue severity and functional impairment and were explored in the secondary out-
come variables: Karnofsky performance status, psychological well-being, quality of life, and work. 
The predictive role of perpetuating factors in the model of CFS was tested exploratively also.
Patients who met the trial criteria and were willing to take part in the trial had to give informed 
written consent. To ensure adequate generation and adequate concealment in the allocation 
process13, patients were allocated sequentially to one of three conditions, by blockwise random-
c
h
a
p
ter 7   |   c
o
g
n
itive beh
avio
u
r th
er
a
p
y fo
r c
h
r
o
n
ic fatig
u
e syn
d
r
o
m
e
96
isation (block size six), separately for each centre. The allocation was concealed in series of en-
velopes for each centre and assigned by (assistant) researchers before baseline in the presence 
of the patient, in order of enrolment in the trial. 
CBT and support groups took place in three different settings, the Department of Medical 
Psychology of the University Medical Centre Nijmegen, the Department of Psychiatry of the 
Leiden University Medical Centre, and the Department of Psychotherapy of the Maastricht 
Mental Health Institute. CBT and support groups were administered by different therapists and 
on different days to prevent contamination. 
CBT consisted of 16 sessions of one hour over 8 months. Patients in this group had to meet the 
requirements of no further medical examinations or other treatments for CFS during the trial. 
These conditions were essential in reducing focusing on bodily symptoms and somatic attribu-
tions. A preliminary version of CBT has been extensively described. An essential part of CBT 
is self-control: this means that the CFS patient is acquiring control over symptoms instead of 
dependence on physicians prescribing treatments or medications. In this study, CBT was out-
lined in a treatment protocol. First, the model of perpetuating factors was explained, and the 
therapist attempted to motivate the patient for CBT. Next, fatigue-related cognitions were chal-
lenged to diminish somatic attributions, to improve sense of control over symptoms, and to fa-
cilitate behaviour change. Patients were encouraged to attain and maintain a base level of physi-
cal activity needed to prevent bursts of activity and resultant extreme fatigue. Subsequently, a 
structured activity programme was started. After a gradual increase of physical activity, a plan 
for work rehabilitation was outlined and carried out. For patients without a job, rehabilitation 
in other personal activities was achieved. The ﬁnal sessions dealt with relapse prevention and 
further improvement of self-control.
Thirteen behaviour therapists of three different disciplines (psychologist, psychiatrists, and 
health scientists) took part. Therapists varied in previous CBT (non-CFS-related) experience, 
because the study was done with the therapists available within the three centres. However, 
none of the therapists was familiar with CBT for CFS at the start of the trial. Two experts in CBT 
for CFS (GB, EB) trained the therapists in using the treatment protocol in a workshop, consist-
ing of two blocks of two days each, separated by a month, in which the therapists started the 
treatment of two CFS patients in a pilot study. Therapists were supervised once every two weeks 
throughout the trial. Patients were allocated to therapists in a ﬁxed sequence by the researcher 
in order of patients’ random allocation to CBT in each centre separately. An integrity check of 
a random sample of 5% of all audiotaped CBT sessions was done. An independent judge used 
a checklist to rate the degree and the amount of time spent on the basic elements of CBT (re-
structuring of fatigue-related cognitions, attaining a base level of daily activity, gradual increase 
of physical activity, and returning to work or personal activities) in each session. The analyses 
showed that 91.5% of the time spent in therapy was relevant for CBT and that 87% of the ses-
sions were adequate or good overall.
The guided support groups were similar to CBT in terms of time spent and treatment schedule. 
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Each group, consisting of about eight patients, had 11 meetings of one and an half hour over 8 
months. One social worker was available for all 11 groups in the three centres. The treatment 
orientation was non-directive and client-centred. The social worker was supervised once every 
two weeks by a psychotherapist, who had no links with CBT or CFS. The goal of the support 
groups was to offer mutual understanding and recognition by means of exchanging experiences 
with one central theme during each meeting. In this study group, patients were free to have 
other examinations or treatments. All support-group sessions were videotaped, and the tapes 
were randomly checked to make sure that the social worker was not using CBT-like strategies. 
In the control condition natural course, no interventions were offered, and no further require-
ments were made. Patients were free to have other examinations or treatments.
Assessment 
Multidimensional assessments were made at baseline, at 8 months, and a follow-up (14 
months). The baseline assessment included the screening assessment before randomisation 
(fatigue, functional impairment, criteria of the Centers for Disease Control and Prevention) and 
those made immediately after randomisation.
Fatigue severity was assessed by a subscale of the checklist individual strength14. In this question-
naire, the patient is asked about fatigue in the two weeks preceding the assessment. The subscale 
consists of eight items, each scored on a 7-point Likert scale (range 8-56). The questionnaire has 
good reliability (Cronbach’s alpha varying from 0.83 to 0.92) and discriminative validity12,14,15.
Functional impairment was measured by the sickness impact proﬁle16,17. This widely used 
measure has good reliability and content validity18. As in our previous studies, a total score 
was calculated by addition of the weights of items (range 0-5799) in eight subscales: home 
management, mobility, alertness behaviour, sleep/rest, ambulation, social interactions, work, 
and recreation and pastimes. Comparison data for CFS patients were available12. 
The Karnofsky performance status scale is a descriptive, ordinal scale. An independent clinical 
psychologist rated the patient’s functional status in 10-point intervals from 0 to 100. The vali-
dity and reliability of this scale have been shown in several populations19,20. Comparison data 
for CFS patients were available6. 
The symptom checklist 9021 measured psychological well-being. The scale consists of 90 items 
scored on a 5-point Likert scale. The total score ranges from 90 to 450. A low total score reﬂects 
high psychological well-being. This scale is widely used and the reliability and discriminating 
validity are good.
The visual analogue scale of the EuroQol22 measured quality of life. The scale ranges from 0 (worst 
health status) to 100 (best health status). The EuroQol has been validated in normal populations, 
patients and in CFS patients23. 
Hours working in a job were recorded on a 24 hour timetable of the 12-day self-observation list24. 
Self-rated improvement was measured at 8 months and at follow-up by one speciﬁc question: 
patients indicated whether they had completely recovered, felt much better, had the same com-
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plaints or had become worse compared with the previous measurement. This measure has been 
validated in several of patients populations and was used in this study as one of the measures 
for clinically signiﬁcant improvement24-26.
The self-efﬁcacy scale, consisting of ﬁve questions, measured sense of control in relation to 
CFS complaints. Four items were scored on a 5-point Likert scale and one item on a 4-point 
Likert scale. The total score ranges from 5 to 24, a higher score reﬂecting more sense of control. 
Cronbach’s alpha reliability coefﬁcients range from 0.70 to 0.7710,12,25.
Somatic attributions with respect to CFS were measured by the causal attribution list consisting 
of ﬁve questions scored on a 4-point Likert scale. The total score ranges from 5 to 20, a higher 
score indicating stronger somatic attributions. Cronbach’s alpha reliability coefﬁcients range 
from 0.71 in previous studies12,25 to 0.74 in this study.
Physical activity was measured by the actometer, a motion-sensing device attached to the ankle 
and worn continuously for 12 days. Such devices are reliable and valid measures of physical ac-
tivity27. The activity pattern of each patient was typiﬁed by comparison of daily activity scores 
with the reference score of CFS patients. Three categories were deﬁned: pervasively passive 
(90% or more beneath the reference score); moderately active; pervasively active (90% or more 
above the reference score)28.
Focusing on bodily symptoms was measured by the subscale somatisation of the symptom 
checklist 9021, as in previous studies in which CFS patients were compared with healthy indi-
viduals and patients with multiple sclerosis10,29. The subscale consists of 12 items scored on a 
5-point Likert scale. The score ranges from 0 to 60.
Analysis
A general linear model for repeated measurements (by the method of mixed linear models) was 
used to analyse the effects of CBT on the two primary variables (fatigue severity and functional 
impairment) and the secondary variables Karnofsky performance status, symptom checklist 
90, Euroqol, and hours working in a job. Differences at 8 months and 14 months from baseline 
were used as repeated measurements, with treatment (three levels), centre (three), time (two 
levels) and their ﬁrst-order interactions as ﬁxed factors. The covariance matrix was speciﬁed as 
unstructured (implying a general structure), estimation method used was restricted maximum 
likelihood, and Satterthwaite’s method was used to estimate denominator degrees of freedom. 
First, we tested, for the primary variables, whether the centre terms could be regarded as redun-
dant (likelihood ratio test comparing the two models). If this was the case for both variables, 
reduced models with treatment and time factors and their interaction were used in all subse-
quent analyses. All treatment effects, as well as differences between treatments were estimated 
within these models; 95% CI were computed from these estimates and their standard errors. 
We used the procedure MIXED from the SAS package (version 6.12). Although the methods of 
analysis for the primary and secondary variables are the same, results for the latter should be 
regarded as exploratory.
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To deﬁne clinically signiﬁcant improvement in fatigue severity, we ﬁrst calculated for each pa-
tient a reliable change index to decide whether statistically signiﬁcant improvement had oc-
curred (reliable change >1.64, p<0.05). Second, a cut-off score of 36 or lower was calculated 
to decide whether a patient’s score had moved from the range of CFS patients to the range of 
healthy individuals30. A patient was classiﬁed as showing clinically signiﬁcant improvement if 
both criteria were met.
Improvement in the Karnofsky performance status was explored also, so that we could compare 
the results with those of Sharpe and colleaques6. Clinically signiﬁcant improvement was deﬁned 
as an improvement of 10 points or more and a score of 80 or more.
Self-rated improvement was deﬁned as a patient’s indication that he or she was completely re-
covered or felt much better. The categorical variables which were calculated by the procedures 
applied on the original variables checklist individual strength, Karnofsky performance status 
and self-rated improvement, were compared between treatments by Fisher’s exact test at 8 
months and 14 months.
Analyses of possible predictors were done with multiple linear regressions. The predictors were 
included and excluded with the stepwise method. Independent variables were treatment, base-
line value of the dependent variable, age, sex, duration of complaints, education, and the base-
line values of the perpetuating factors: sense of control, activity pattern, focusing on bodily 
symptoms, and somatic attributions, and all ﬁrst-order interactions between treatment and 
other factors. The main interest was the relation between predictors and the direct treatment 
effect. Therefore, only the outcomes at 8 months were analysed. Results from these analyses 
should be regarded as exploratory.
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Figure 2
TRIAL PROFILE
278 randomised
  153 at Nijmegen    80 at Leiden   45 at Maastricht   
476 patients diagnosed with CFS
198 did not take part
99 refused
99 not eligible
93 assigned CBT 94 assigned guided 
support groups
91 assigned  
natural course
4 withdrew 4 withdrew 9 withdrew
55 completed trail 61 completed trail 70 completed trail
59 completed 
post-test
65 completed 
post-test
79 completed 
post-test
34 did not  
complete  
post-test
1 excluded
10 did not 
start CBT
23 withdrew
29 did not  
complete  
post-test
4 excluded
8 did not 
start CBT
17 withdrew
12 did not  
complete  
post-test
3 excluded
9 withdrew
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Results
518 patients were referred to the University Medical Centre Nijmegen with a major complaint 
of fatigue; CFS was diagnosed in 410. Another 66 patients were diagnosed with CFS at the 
University Hospital Maastricht. Of these 476 patients, 99 did not meet the eligibility criteria and 
99 refused to take part. The remaining 278 patients were randomly assigned to the study groups 
at the centres of Nijmegen, Leiden and Maastricht (ﬁgure 2). In total, 93 patients entered the 
CBT group, 94 the support groups, and 91 the control natural course group. Six patients were 
excluded: ﬁve developed other diseases during the trial and one was pregnant at baseline. After 
randomisation, two patients were found not to meet the criteria for CFS because they had pre-
morbid anorexia nervosa. Thus, the trial consisted of 270 patients (92 CBT, 90 support groups, 
88 control groups), of whom 203 (75%) completed 8 months and 186 (69%) 14 months in the 
trial. 18 patients did not start treatment. 49 withdrew during the test phase and 17 withdrew 
during follow-up. Withdrawal was deﬁned differently for the three groups. In the natural course 
group, only patients not attending the assessments were classiﬁed as withdrawing, whereas 
in the two intervention groups those who stopped treatment were also counted. Moreover, in 
contrast to CBT, frequent non-attendance in the guided support groups had no consequences 
for further treatment, unless a patient declared the intention to withdraw. This difference was 
reﬂected in the signiﬁcant difference in mean hours of attending treatment between CBT group 
and the guided support group (15.6 vs 13.2; p<0.001). Table 1 shows the baseline characteris-
tics of the three groups.
At 8 months, 241 patients (89%) had complete data (83 CBT, 80 support groups, 78 natural 
course). At 14 months, 196 patients (73%) had complete data (58 CBT, 62 support groups, 76 
natural course). The data of these patients were included in the analyses. Only 9% of the pa-
tients had missing data at one or both post-treatment assessments.
For both primary outcome variables, a reduced model without any centre term could be used 
(p=0.437 for checklist individual strength, fatigue; p=0.202 for sickness impact proﬁle, likelihood 
ratio test with 8 df). Consequently, all subsequent analyses were done with such models.
In the primary outcome variables, signiﬁcant differences between the treatment effects of CBT 
support groups, and natural course were found (ﬁgure 3). Estimated differences are shown in 
table 2. 
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Table 1
BASELINE CHARACTERISTICS OF STUDY PARTICIPANTS
CBT
(N= 92)
Guided support
groups (N= 90)
Natural course
(N= 88)
Demography
Age in years  36.2 (9.4)  37.1 (10.6)  36.7 (10.3)
Educational attainment  3.9 (1.6)  4.3 (1.4)  4.4 (1.6)
(1=low to 7=high)
M/F * 22/70 19/71 17/71
CFS features
Duration in years  4.9 (4.8)  6.6 (6.4)  5.3 (5.4)
CIS fatigue  52.2 (3.9)  52.3 (4.0)  51.9 (4.1)
SIP total  1755 (613)  1842 (560)  1859 (671)
Karnofsky  71.5 (8.5)  71.2 (7.5)  70.8 (7.9)
SCL-90  170 (38.5)  169 (41.5)  166 (36.0)
EuroQol  46 (17)  43 (16)  40 (14)
Work, hours in 12 days  16.3 (21.1)  12.8 (19.1)  13.5 (18.6)
Sense of control  14.8 (3.5)  14.6 (3.1)  14.6 (3.6)
Somatic attributions  13.9 (2.8)  14.1 (2.5)  13.5 (2.4)
Focusing on bodily symptoms  30.7 (6.9)  30.0 (7.6)  29.8 (7.2)
Activity pattern# 
Generally passive*  21 (23%)  16 (19%)  24 (29%)
Moderately active*  56 (62%)  53 (62%)  50 (59%)
Generally active*  13 (15%)  16 (19%)  10 (12%)
CIS = checklist individual strength; SIP = sickness impact proﬁle; SCL-90 = symptom checklist 90.  
Data are mean (sd) or *numbers of participants.  # 11 cases had incomplete actometer data and are not included
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Figure 3
EFFECT OF THREE STUDY CONDITIONS ON THE TWO PRIMARY OUTCOME VARIABLES, FATIGUE SEVERITY (CIS) AND FUNCTIONAL 
IMPAIRMENT (SIP)   
Table 2
ESTIMATED EFFECT OF CBT COMPARED WITH SUPPORT GROUPS AND NATURAL COURSE ON FATIGUE SEVERITY (CIS) AND 
FUNCTIONAL IMPAIRMENT (SIP) 
CBT vs support groups CBT vs natural course
Treatment effect
( 95%CI )
p-value Treatment effect
( 95%CI )
p-value
CIS   8 months  6.0 (3.1-9.0) 0.0001  6.0 (3.1-9.0) 0.0001
14 months  5.8 (2.2-9.4) 0.0015  5.6 (2.1-9.0) 0.0016
SIP  8 months  217 (26-408) 0.0261  213 (22-403) 0.0287
14 months  263 (38-488) 0.0223  222 (3-441) 0.0470
Time since randomisation(months)
Fatigue severity Functional impairment 
Time since randomisation(months)
Support groups
Natural course
CBT
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Error bars = SE
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Table 3
ESTIMATED EFFECT OF CBT COMPARED WITH SUPPORT GROUPS AND NATURAL COURSE ON SECONDARY ENDPOINTS
CBT vs support groups CBT vs natural course
Treatment effect
( 95% CI )
p-value Treatment effect
( 95% CI )
p-value
Karnofsky   8 months  -5.7 (-8.4 to -3.1) 0.0001  -5.2 (-7.8 to -2.6) 0.0001
14 months  -6.3 (-9.6 to -3.0) 0.0002  -5.4 (-8.6 to -2.2) 0.0009
SCL-90   8 months  13.9 (4.3 to 23.5) 0.0048  13.4 (4.0 to 22.7) 0.0053
14 months  11.2 (1.1 to 21.3) 0.0304  6.7 (-3.0 to 16.5) 0.1767
EuroQol   8 months  -7.8 (-14.0 to -1.8) 0.0114  -4.0 (-10.0 to 2.0) 0.1878
14 months  -9.2 (-15.6 to - 2.8) 0.0049  -2.3 (-8.4 to 3.8) 0.4619
Work   8 months  -5.6 (-11.7 to 0.4) 0.0681  -2.9 (-8.8 to 3.0) 0.3362
14 months  -9.6 (-17.1 to - 2.0) 0.0132  -5.9 (-13.2 to 1.4) 0.1134
Table 3 gives the estimated differences between the study groups in secondary outcome variables. 
At 8 months, improvement in Karnofsky performance status, psychological well-being and qual-
ity of life was statistically signiﬁcantly greater in the CBT group than in either of the other groups. 
Differences in the time spent working in a job did not reach the 5% level of signiﬁcance. Statistically 
signiﬁcant treatment effects between CBT and support groups were found in all secondary out-
come variables at 14 months. Treatment effects of CBT and natural course showed statistically 
signiﬁcant differences for the Karnofsky performance status at both 8 and 14 months and for psy-
chological well-being at 8 months. 
Table 4 shows the proportions of patients with clinically signiﬁcant improvements in fatigue 
severity, Karnofsky performance status, and self-rated improvement. For these three variables, 
the proportion with clinically signiﬁcant improvement was statistically signiﬁcantly higher in 
CBT than in the control conditions.
All factors in the stepwise regression related to the outcome measures fatigue severity and func-
tional impairment at p<0.05 are presented in order of entrance in the model in table 5. The im-
provement in fatigue severity at 8 months was predicted by interactions of CBT with sense of con-
trol and by a passive activity pattern, rather than by CBT alone. In the CBT study groups, patients 
with a greater sense of control at baseline had a larger decrease in fatigue severity at 8 months, 
immediately after CBT, than patients with lower sense of control. The reverse was true for patients 
with a passive activity pattern; they improved less than patients with other activity patterns. 
Improvement in functional impairment at 8 months was predicted by CBT alone and by inter-
action of CBT and focusing on bodily symptoms. Patients assigned CBT improved more than 
patients in both control groups. However, patients in CBT with a high level of focusing on bodily 
symptoms were improved less than patients with lower scores on this factor
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Table 4
CLINICALLY SIGNIFICANT IMPROVEMENT IN THE TREATMENT GROUPS FOR FATIGUE SEVERITY (CIS), KARNOFSKY PERFORMANCE 
STATUS, AND SELF-RATED IMPROVEMENT 
Number of patients with improvement/total p-value*
CBT
Support
groups (SG)
Natural
course (NC)
CBT
vs SG
CBT
vs NC
8 months CIS fatigue  27/83 (33%)  10/80 (13%)  10/78 (13%)  0.003  0.005
Karnofsky  29/71 (41%)  11/69 (16%)  9/75 (12%)  0.001  <0.001
Self-rated 
improvement
 42/74 (57%)  12/71 (17%)  23/78 (30%)  <0.001  0.001
14 months CIS fatigue  20/58 (35%)  8/62 (13%)  13/76 (17%)  0.009  0.026
Karnofsky  28/57 (49%)  12/62 (19%)  17/75 (23%)  0.001  0.001
Self-rated 
improvement
 29/58 (50%)  9/62 (15%)  24/76 (32%)  <0.001  0.034
* Fisher’s exact test
Table 5
PARAMETER ESTIMATES, SE AND PARTIAL R2 OF ALL FACTORS RELATED TO THE OUTCOME MEASURE FATIGUE SEVERITY OR 
FUNCTIONAL IMPAIRMENT (BASELINE MINUS 8 MONTHS) AT p<0.05 IN ORDER OF ENTRANCE TO THE MODELS
Factor Coefﬁcient (SE) Partial R2
Fatigue severity (CIS)
   CBT x sense of control  0.5088 (0.0883)  0.0856
Baseline CIS  0.7010 (0.1469)  0.0515
Focusing on bodily symptoms  -0.2611 (0.0838)  0.0368
   CBT x passive activity pattern  -8.902 (2.545)  0.0208
Moderately activity pattern  -3.439 (1.229)  0.0229
Sense of control  0.3535 (0.1723)  0.0147
Sex (female)  2.761 (1.386)  0.0133
Functional impairment (SIP)
Baseline SIP  0.4767 (0.0604)  0.1788
CBT  1005 (281.9)  0.0321
CBT x focusing on bodily symptoms  -25.06 (8.838)  0.0266
CIS=checklist individual strength; SIP=sickness impact proﬁle
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Discussion
In this study, CBT was more effective for CFS patients than guided support groups or the natu-
ral course. Intention-to-treat analyses showed clinically signiﬁcant improvement in fatigue sever-
ity, Karnofsky performance status, and self-rated improvement in substantial proportions of pa-
tients treated with CBT. An unexpected ﬁnding was that support groups were no more effective 
than the natural course (ﬁgure 3). This ﬁnding contrasts with other chronic diseases in which 
support groups are beneﬁcial. However, 80% or more of the patients experienced mutual under-
standing in the support group, and rated the contact with the therapist and the atmosphere in the 
group as good. These ﬁndings suggest that clinical improvement and patients’ satisfaction are not 
correlated and may be independent.
There was a large withdrawal rate in the trial, especially in the CBT and support groups. Many 
CFS patients eagerly expect a medical solution for their complaints and are quite sceptical 
about psychological treatments. Others expected more beneﬁt from medical examinations or 
alternative treatments. These patients may have withdrawn prematurely. The physical burden 
of travelling to the centre for therapy was another reason for patients to withdraw. However, 
many patients who withdrew during treatment were willing to attend for assessment of the pri-
mary outcome variables. At 8 months, there was a withdrawal rate of 25%, but only 11% of the 
patients had missing data. Results of the analyses depend among other assumptions on that 
of ‘missingness at random’ which means that missingness is possibly related to the observed 
data, but, conditional on these data, not to the (unknown) value of the variable itself. Although 
we cannot prove the assumption, we can partially check it as follows31: comparison of charac-
teristics of completers and non-completers (age, sex, duration of complaints, centre, and all 
baseline measures) showed no differences. Furthermore, the results of the intention-to-treat 
analyses and those of the analyses of the completers, were mostly qualitatively similar.
Supporting evidence of the effectiveness of CBT was found in the signiﬁcant improvement in 
Karnofsky performance status rated by an independent clinical psychologist in the group of 
patients treated with CBT compared with the control groups. A signiﬁcant treatment effect on 
quality of life, psychological well-being, and work rehabilitation was only found in the compari-
sons of CBT with support groups and not between CBT and natural course. We were especially 
interested in work rehabilitation, a new element in the tested treatment protocol. The ﬁnal goal 
of CBT for CFS included work rehabilitation for patients who used to be active in a job and 
resumption of other personal activities for patients without a job. We could not conclude the 
extent to which this goal was reached, because only hours working in a job were measured. 
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However, in our sample of 270 patients only 33% had a job at baseline, whereas 76% had been 
employed before the onset of CFS. For the unemployed patients, securing employment within 
the limited period of treatment and follow-up would be difﬁcult, although most of these patients 
did resume personal activities. The development of adequate measures of rehabilitation should 
have high priority in future research on CBT for CFS. 
The proportions of patients with clinically signiﬁcant improvement in this study were lower than 
in other CBT trials. We suggest several explanations for this discrepancy. First, therapists in this 
study had no clinical experience with CFS patients at the start of the trial. Afterwards, 82% of the 
therapists agreed with the statement that CFS patients are more difﬁcult to treat than patients with 
psychiatric diagnoses, and 54% agreed that CFS patients are more difﬁcult to treat than patients 
with other functional somatic syndromes. Second, criteria for statistical and clinical signiﬁcance 
in this study were more stringent than in the previous trials. The cut-off score for clinically signiﬁ-
cant improvement was based on normative comparisons of CFS patients and healthy individu-
als and was perhaps overly stringent. In a recent evaluation of the concept of clinically signiﬁcant 
improvement32, Kendall and colleagues questioned whether patients should be compared with a 
non-representative ‘supernormal’ sample of healthy people, from which all individuals with any 
psychological or physical disorders are excluded. Third, the treatment protocol seemed not to be 
suitable for a group of CFS patients who showed passive activity patterns. Analyses of prognostic 
factors showed that patients with this activity pattern and patients with a strong tendency to focus 
on bodily symptoms improved less than did patients not characterised by one of these factors. In 
our clinical practice, the treatment protocol has now been adjusted to both aspects. In the new 
treatment protocol, the emphasis is now on impeding cognitions and behaviour rather than on 
symptoms. Furthermore, a different treatment protocol has been developed for patients with a 
passive activity pattern. The early emphasis in CBT on a base level of daily activity, so important 
for moderately active CFS patients, seems to increase the fear of physical activity in passive CFS 
patients and impedes the subsequent gradual increase of physical activity. Therefore, CBT for pa-
tients with passive activity patterns starts with building up physical activity, whereas more active 
patients still start with attaining and maintaining a base level of daily activity.
The results of this trial suggest that CBT can be transferred from CFS research clinics to thera-
pists with no previous experience in CBT. This transfer is essential to detach the treatment from 
medical research settings, in which only a limited number of CFS patients can be treated. To 
increase accessibility of this treatment for all CFS patients in future, CBT will have to be imple-
mented outside university medical settings. This idea accords with Wessely and colleagues’ 
suggestion of transferring the diagnosis and treatment of functional somatic syndromes from 
medical subspecialists to more broadly based general physicians aided by psychiatrists or psy-
chologists33. Ideally, general practitioners should diagnose CFS and refer patients to psycho-
therapists for CBT, without detours to medical specialists, as in other functional somatic syn-
dromes33. Before this goal can be reached, expertise needs to be generalised from specialist 
centres to general practitioners and behaviour therapists in general (mental) health settings. 
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Abstract
Several randomised controlled trials have indicated that cognitive behaviour therapy is an effec-
tive treatment for chronic fatigue syndrome. In one of these studies 13 therapists applied cogni-
tive behaviour therapy for chronic fatigue syndrome in 83 chronic fatigue syndrome patients. In 
the present study therapists’ adherence and perceptions of the manual are studied. Following 
completion of the study the therapists were asked to complete a questionnaire. Audio taped 
sessions were conducted to verify the therapists’ adherence. Analyses of the audiotapes showed 
that in 87% of the sessions this appeared to be the case. The questionnaire revealed that the 
therapists found it more difﬁcult to treat patients with chronic fatigue syndrome than to treat 
patients with psychological or other physical problems. Treatment aspects posing the most 
problems were integrating individual problems into the standardized treatment, dealing with 
the patients’ lack of conﬁdence in the treatment and handling insufﬁcient motivation. 
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Introduction
Several randomised controlled trials have shown that cognitive behaviour therapy is an effec-
tive treatment for chronic fatigue syndrome (CFS)1-4, even at follow-up5,6. Reviews showed that 
graded exercise and cognitive behaviour therapy are the treatments of choice for CFS7-9. In our 
multi-centre randomised controlled trial cognitive behaviour therapy was compared with guided 
support groups and natural course3. The study included 270 CFS patients. Thirteen therapists 
treated 83 CFS patients with cognitive behaviour therapy. Intention-to-treat analyses showed 
cognitive behaviour therapy to be more effective than the two other conditions for both of the 
two main outcome measures, i.e. fatigue severity and functional impairment.
In the present study the transference of the treatment manual is explored. Two questions are 
relevant in this context. First, to what extent did the therapists, who were extensively trained 
and supervised, comply with the various aspects of the treatment manual during the actual 
sessions? Secondly, what is their judgement as to the treatment’s suitability for transfer? What 
are, in their views, the difﬁcult and less difﬁcult aspects of the prescribed treatment, what are 
the manual’s shortcomings, and which of the treatment aspects do they think are suitable to 
be applied by therapists without additional training?
To ﬁnd answers to these questions each of the therapists completed a questionnaire, following 
conclusion of all treatment sessions.
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Method
Treatment manual
The treatment manual ‘CBT for CFS’ was founded on empirical knowledge and experience with 
CFS patients in clinical practice. The rationale of the intervention was based on the model of 
perpetuating factors in CFS10,11. This model claims that a negative self-efﬁcacy (the idea of having 
no control over symptoms), strong somatic attributions, a low activity level and a tendency to 
focus on bodily sensations, negatively affect fatigue severity and functional impairment in CFS 
patients. When complaints are attributed to a somatic cause (somatic attributions) this will lead 
to a reduced level of physical activity, which in turn affects the severity of the fatigue. A negative 
self-efﬁcacy and strong focus on physical sensations will have a direct impact on the severity 
of the fatigue. Based on this model, the standardized cognitive behaviour therapy for the treat-
ment of CFS was aimed at decreasing somatic attributions, increasing self-efﬁcacy, and restoring 
the balance in activity patterns. The underlying principle of the treatment was that although we 
do not know what actually caused the complaints, we do know which factors help maintain the 
symptoms. The treatment therefore challenged the perpetuating factors. The ﬁnal treatment goal 
was the patient’s full recovery and a resumption of his or her normal activities.
The manual starts with a general outline of the treatment (table 1). Next, for each session the 
goal is described, together with the associated target cognitions for the patient, the therapist’s 
aims and objectives, and the session’s program. Also, an indication of time, in minutes, to be 
allotted to each treatment aspect was provided. The manual further contained practical sugges-
tions on how to effectuate the various interventions, sometimes with verbatim descriptions and 
detailed examples using the same two ﬁctitious patients throughout the manual. The treatment 
consisted of 16 sessions distributed over a period of eight months. The ﬁrst sessions were on 
a weekly basis with the frequency of the subsequent sessions decreasing from once every two 
weeks to once every three weeks down to once a month. The content of the ﬁrst eight sessions 
was fully structured. The subsequent sessions could be tailored more to the individual patient. 
The manual comprised 79 pages. Preparation and evaluation forms were provided separately. 
With these forms the therapists were encouraged to reﬂect, both prior to and following each 
session, on how to integrate the patient’s individual situation with the manual.
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Table 1
OUTLINE OF THE TREATMENT MANUAL
Step Session Methodology Homework assignment
1. Referral and intake 1 introduction; discussion of 
assessment; ﬁne-tuning of 
expectations; role of spouse; 
modus operandi
2. Preparing patient for 
treatment and explana-
tion of treatment goal
1, 2 discussion of goal; return to 
work 
3. Explanation of the 
model
1, 2 views on somatic factors; role of 
cognitions and behaviours
4. Exercises to prevent 
the fatigue from getting 
worse
1, 2, 3 ....
(through  
- out)
learning to think differently; 
accepting cognitions; peak-stop 
exercise 
registration of cognitions; 
peak-stop exercise
5. Learning to recognize 
and respect limitations, 
and following this 
through
2, 3, 4 ....
(through  
- out)
peak-stop exercise; learning to 
rest; base level; rationale activity 
program; coping with the 
environment: learning to say no; 
lowering demands: changing 
way of thinking
registration of cognitions; 
peak-stop exercise; writing 
down base level
6. Practicing gradual 
expansion of limits
5, 6, 7 .... 
(through  
- out)
activity program: graphs; 
drawing up a plan for a return 
to work
peak-stop exercise; activity 
program: graphs;  
plan for return to work
7. Changing lifestyle and 
relapse prevention 
8, 9, 10, 
11, 12, .... 
(through          
-out)
ﬁrst step return-to-work 
plan; discussion of impeding 
circumstances; environmental 
factors; cognitions and other 
likely problems
activity program: graphs; 
steps for return to work
13, 14, 15, 16 dealing with setbacks; preparing 
for therapy completion; 
evaluation
Therapists, training and supervision
Thirteen psychotherapists participated in the research project ‘Cognitive behaviour therapy for 
chronic fatigue syndrome: a multi-centre randomised controlled trial’3. The therapists worked 
at three different locations: Leiden, Maastricht and Nijmegen. The therapists were psycholo-
gists, psychiatrists or health scientists and all were qualiﬁed or assistant behaviour therapists. 
At the start of the project none had any earlier experience with cognitive behaviour therapy for 
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CFS. Prior to the start of the treatments all therapists received extensive training in the use of 
the manual ‘CBT for CFS’. The training course comprised two two-day meetings, followed by 
several follow-up sessions. Preceding the training sessions all therapists had studied the treat-
ment manual as well as literature on CFS and cognitive behaviour therapy. For the training ses-
sions and subsequent supervisions use was made of, among other techniques, video recordings, 
audiotapes, ﬁctitious problems, role-plays with simulated patients and the therapists’ own cases. 
The in-situ supervisions were initially conducted on a weekly basis and, at a later stage, every 
other week. Every other month a plenary supervision was arranged to discuss those issues that 
had caused the therapists problems. The therapists of one of the three locations selected these 
topics, together with the supervisor, and they provided their own CFS cases. During these cen-
tral supervisions, additionally, role-plays were practised or the supervisor raised speciﬁc points 
for discussion based on the experience of the preceding months. In total eight such plenary 
sessions were held over a period of 18 months. The main topics discussed in these sessions 
are listed in table 2.
Table 2
THE MAIN TOPICS DISCUSSED DURING THE PLENARY SUPERVISION SESSIONS
• How to recognize individual cognitions, deﬁne new (target) cognitions, and achieve the desired changes  
in cognitions (Socratic dialogue).
• How to enhance the patient’s self-efﬁcacy.
• What to do with a patient using a wheelchair.
• What to do with a patient using medication.
• What to do with sleeping problems and sleeping during the day.
• How to alternate periods of rest and activity: base level and peak-stop exercise.
• What constitutes a good activity program, and how to respond to the activity graphs.
• How to handle passive patients.
• What to do with company doctors and work-related problems.
• What is improvement, what is recovery.
• How ﬂexible are you allowed to be with the manual.
• How to integrate individual functional analyses.
• How to integrate additional patient-speciﬁc problems and co-morbidity.
• Balancing between permissiveness and authoritativeness.
• The therapist’s cognitions regarding the treatment.
• Emotions patients may evoke in the therapist.
• Resistance and motivation of therapist and patient.
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Compliance with the treatment manual
To verify whether the therapists had complied with the guiding principles of the treatment manual, all 
therapy sessions were audio taped and analysed by an independent rater. The independent rater was 
a psychologist who knew the treatment protocol but was not further involved in either the treatment 
or the study. In total 1097 sessions were conducted. A random sample of 61 audiotapes (a good 5%) 
was analysed. In 49 of the cases the tapes comprised a full session. Twelve of the recordings were 
incomplete, mostly because the therapist had forgotten to turn the tape over after half a session, 
when one side of the tape was full. The manual was subdivided and scored for the following treat-
ment aspects: cognitive restructuring, setting limits, activity program, return to work (or resumption 
of other personal goals), and ‘other CBT’. The sessions were analysed by means of the audiotapes, 
their so-called verbatims, and a checklist. For each of the treatment aspects the time dedicated to 
this aspect during a session was noted. In addition, the checklist was used to indicate on a 5-point 
scale (minimal, some, reasonable, considerable, extensive) for each session how much attention the 
therapist had paid to the treatment aspect the manual prescribed for that session. An overall judge-
ment on the session as a whole was given using a 3-point scale (insufﬁcient, sufﬁcient, good). This 
judgement was based on both the amount of time spent as well as the attention paid to the several 
treatment aspects in a session, compared with the prescription by the treatment manual.
Therapists’ ratings of treatment aspects
As regards the questions about the treatment, the manual was subdivided into the same treat-
ment aspects as used for the analyses of audiotapes. In addition, these aspects were further 
subdivided into subcategories (see table 3).
The therapists were asked to evaluate the CBT for CFS manual for these subcategories on a scale 
ranging from 1 (agree) to 6 (disagree) on the basis of the following statements:
• I can adequately apply this myself
• In my view, patients understand the rationale of this aspect well (this item was not 
assessed for the questions relating to 'other CBT')
• I think this is important for a successful treatment
• How this aspect is to be effected, is sufﬁciently described in the manual.
• Can, in my view, not be adequately applied by an untrained psychotherapist, i.e. a (cognitive) 
behaviour therapist working solely on the basis of the manual.
In addition, the following overall statements were included:
• CFS patients are more difﬁcult to treat than other patients with somatic complaints
• CFS patients are more difﬁcult to treat than patients with psychological complaints.
Similarly, these statements were scored on a scale from 1 (agree) to 6 (disagree). Answers were 
dichotomised in agreed (1, 2 or 3) and disagreed (4, 5, 6).
Apart from these last 2 statements, the therapists primarily used score 1 (40% of the answers). 
The scores 2 (26% of the answers) and 3 (17% of the answers) and 4, 5 and 6 (together 17% of 
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the answers) were used far less frequently. This is why, in the representation of the therapists' 
evaluations, we only show the percentages of score 1, reﬂecting the proportion of therapists 
who fully agreed with that speciﬁc statement.
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Results
Did the therapists do what they were expected to do?
During all sessions themes were dealt with as described by the manual. In 25% of the ses-
sions issues that were not related to cognitive behaviour therapy for CFS (other non-cognitive 
behaviour therapy) were raised as well. The proportion of time allotted to these non-relevant 
topics was, on average, 8%. The overall judgement revealed that the rater considered 87% of 
the sessions to be sufﬁcient or good.
A comparison of the proportion of time to be allocated to the various aspects as stipulated in 
the manual with the time actually spent on these themes showed many similarities, particu-
larly with respect to the aspects cognitive restructuring, setting limits and the activity program 
(ﬁgure 1). As regards the percentage of time allocated to return to work and other cognitive 
behaviour therapy the differences were greater. Compared with the manual, less time was dedi-
cated to a return to work and more time was spent on other cognitive behaviour therapy.
Figure 1
PERCENTAGE OF THE TIME SPENT ON THE SEVERAL TOPICS DURING A SESSION AS PRACTISED BY THE THERAPISTS COMPARED WITH 
WHAT WAS PRESCRIBED BY THE MANUAL
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Table 3
THERAPISTS’ RATINGS OF THE COGNITIVE BEHAVIOUR THERAPY FOR CFS TREATMENT ASPECTS
Can I 
adequately 
apply
Is 
understood 
well by the 
patient
Is 
important 
for a 
successful 
treatment
Is 
sufﬁciently 
described 
in the 
manual
Cannot be 
adequately 
applied by 
an untrained 
therapist
Cognitive restructuring
Explanation of rationale 85% 54% 100% 39% 23%
Making an inventory of cognitions 31% 8% 62% 15% 23%
Challenging cognitions 39% 8% 69% 8% 46%
Setting limits
Explanation of limits 69% 62% 92% 46% 23%
Implementing peak-stop exercise 54% 46% 62% 15% 15%
Activity program
Explanation of activity program 69% 62% 85% 31% 15%
Implementing activity program 46% 31% 77% 15% 23%
Return to work/Other personal goals
Deﬁning goals 39% 31% 77% 23% 15%
Action plan return to work 
/personal goals 31% 23% 62% 8% 23%
Implementing plan return to work 
/personal goals
31% 23% 69% 15% 31%
Other CBT
Lack of conﬁdence 31% 85% 8% 54%
Insufﬁcient motivation 23% 92% 8% 46%
Integrating individual problems 31% 77% 8% 39%
Dealing with co morbidity 18% 85% 0% 31%
Which treatment aspects could be applied adequately by the therapists?
For most therapists explaining the treatment’s rationale, the activity program and setting 
limits posed the least problems. At the stage of having the patient implement the peak-stop 
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exercises and activity program fewer therapists stated they could adequately apply. With respect 
to deﬁning and challenging cognitions, formulating the ﬁnal goal, drawing up and realizing a 
plan for a return to work, integrating individual problems and dealing with a lack of conﬁdence, 
a third of the therapists indicated that they could adequately apply. One ﬁfth of the thera-
pists reported that challenging insufﬁcient motivation and dealing with co-morbidity could be 
adequately applied (table 3).
Which treatment aspects were understood adequately by the patients?
The explanation of the rationale, setting limits and the activity program were, according to the 
therapist, best understood by the patient, followed by the implementation of the peak-stop 
exercise and activity program, deﬁning targets and drawing up and executing a plan for a re-
turn to work. A mere 8% (one therapist) had the impression that the patients understood what 
deﬁning and challenging cognitions entailed.
Which aspects did the therapists regard as important for a successful treatment?
For the three elements rated as the least signiﬁcant still 62% of the therapists indicated this 
as important. Deﬁning and challenging cognitions, implementing the peak-stop exercise, and 
making and implementing the plan for a return to work were considered least relevant.
What was described adequately in the manual?
Only with respect to the aspects explaining the treatment rationale, setting limits, and the ac-
tivity program 31-46% of the therapists stated that these were amply described in the manual. 
The aspects implementing the peak-stop exercise and activity program, and also work resump-
tion, cognitive restructuring, and the elements categorized as ‘other CBT’, are hardly indicated 
as having been adequately described in the manual.
Which treatment aspects would not be adequately applied by an untrained therapist?
Table 3 lists for each treatment aspect the percentage of therapists who thought that the par-
ticular aspect could not be adequately applied by an untrained therapist. Lack of conﬁdence, 
insufﬁcient motivation and challenging cognitions were seen by about half of the therapists as 
likely to pose problems for an untrained therapist.
Overall statements
Respectively, the answers of 11 and 12 therapists were available. One therapist just skipped the 
overall statements, one therapist had no prior experience with other patients with somatic com-
plaints. Seven therapists (64%) indicated that they found CFS patients more difﬁcult to treat 
than other patients with somatic complaints. Ten therapists (83%) stated CFS patients were 
more difﬁcult to treat than patients with psychological complaints.
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Discussion
As evidenced by the audiotape analyses, overall the therapists applied the treatment as pre-
scribed by the manual and, as shown by the effect study, successfully3. Still, therapists found 
several aspects of the manual-based CBT for CFS treatment difﬁcult to administer.
Explaining the treatment rationale and having the patients comply with their limits and activity 
program was managed quite well. With respect to bringing about a change in the patient’s cogni-
tions, as well as having the patients draw up and follow up on the action plan aimed at a return to 
work (or reaching other personal goals), already fewer therapists indicated that they could apply 
that adequately. Together with integrating patient-speciﬁc problems and managing a lack of conﬁ-
dence and motivation these aspects posed them the most problems. Particularly for co-morbid-
ity and dealing with lack of conﬁdence and motivation and integrating individual problems the 
therapists expressed the manual was not explicit. These aspects as well as challenging cognitions 
were also the treatment components of which was stated that these could not be easily applied 
without additional training in the use of the manual. Since it is difﬁcult to describe these aspects 
explicitly in a manual, we feel that speciﬁcally these components of the therapy need to be mas-
tered through training and supervision. It needs to be noted that the results as derived from the 
questionnaire are in line with the topics discussed in the plenary supervision sessions. These 
frequently involved cognitive restructuring, tailoring the program to the individual patient, and 
the patient-therapist interaction.
This study had several methodological limitations. For instance, since the questionnaire could 
only be put to the 13 therapists who had participated in the study, our sample was small. In 
addition, only a limited number of scores of the 6-point scale were used. This may possibly be 
due to the respondents’ desire to give socially acceptable answers. However, the scores clearly 
indicated at which aspects the manual was found to be lacking. Furthermore, the responses 
to the various items are consistent in that they show which treatment aspects the therapists 
considered less or more difﬁcult. Despite the limitations, we can say that the responses to the 
questionnaire constitute a useful supplement to the acquired clinical experience in the use of 
the manual and the associated training and supervision.
That deﬁning and challenging cognitions posed serious problems may also be attributed to 
the (lack of) therapists’ prior training and experience. Therapists were selected on the basis 
of their experience with behavioural therapy, but the extent of practical experience with cogni-
tive therapy was not the same for all therapists. Similarly, therapeutic experience with patients 
suffering from somatic complaints was quite diverse and ranged from 0 to 24 years. That the 
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therapists indicated that putting the manual to practice had not always been easy may also 
be related to the version of the manual they were working with, which did not yet differentiate 
between passive and active CFS patients12. The effect study3 had shown that the standardized 
treatment proved speciﬁcally suitable for the treatment of the relatively active CFS patients but 
hardly worked for the passive CFS patients. As passive CFS patients are characterized by a fear 
and avoidance of activity, complying with preset activity limits proved to be of no use to these 
patients. We now know that for this group the stage at which activity levels are raised needs to 
be brought forward.
On the basis of the experiences reported by the participating therapists, their supervisions as 
well as the results of the effect study, the treatment manual has been revised. The manual now 
makes a distinction between the treatment of passive and relatively active CFS patients. Also 
with respect to ﬂexibility the manual has been modiﬁed. It is now stressed that the therapist 
will always need to investigate for each individual patient which the speciﬁc key factors are that 
maintain the complaints of this particular patient. In the course of the treatment a function 
analysis of the patient-speciﬁc perpetuating factors is recommended13, in line with Schulte14 
and Davison15. It is our view that a treatment manual should provide insight into and contain 
detailed information about the function analysis of the patient group as a whole, the speciﬁc 
cognitions and behaviours of the patient or client population, the interventions speciﬁcally tar-
geted at these cognitions and behaviour, likely motivational and interaction problems, as well 
as provide strategies, interventions and additional recommendations illustrating ways to deal 
with such problems. Agreeing with Heimberg16, the difﬁculty is that in order to integrate the 
patient-speciﬁc function analysis with the manual the therapist needs to have full control over 
two different aspects: both the manual and the individualized treatment need to be combined. 
This implies that speciﬁc additional skills may be needed and that the process places high de-
mands on basic technical and interaction skills, as well as on the preparation and evaluation 
of the sessions.
There has been much debate about the desirability of the introduction of research-based treat-
ment manuals in clinical practice. Much of the debate concerned the strengths and weaknesses 
of such evidence-based treatments and the differences between research and practice, which 
have been discussed and refuted frequently16-23. Despite these objections many defend the no-
tion that clinical practice should take advantage of the empirical evidence on the effectiveness 
of treatment procedures or manuals 19,24-28.
Working with the present evidence based treatment manual requires solid cognitive behavioural 
and interaction skills of the therapist, as well as a sound knowledge of the scientiﬁc state of 
affairs concerning CFS. Standardized, empirically validated practice does not necessarily make 
treatment easier, but it may at least enhance quality.
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Abstract
In chronic fatigue syndrome (CFS), facilitating, initiating and perpetuating factors are distin-
guished. Although somatic factors might have initiated symptoms in CFS, they do not explain 
the persistence of fatigue. Perpetuating factors make the symptoms prolong. Cognitive behav-
iour therapy (CBT) for CFS is focused on these perpetuating factors. Recently it has been shown 
that, based on their level of activity, two groups of patients can be distinguished. For so-called 
relatively active CFS patients the main perpetuating factors are non-accepting and demanding 
cognitions leading to bursts of activity. For so-called passive CFS patients the fear that activity 
might worsen their complaints resulting in avoidance of activity, is the most important perpetu-
ating factor. These differences in perpetuating factors result in separate treatment manuals for 
relatively active and for passive CFS patients. Before describing the treatment manuals, basic 
assumptions, considerations before starting CBT for CFS, and ways to determine the activity 
pattern are outlined. 
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Introduction
Chronic fatigue syndrome (CFS) is characterized by a clinically evaluated, unexplained persis-
tent or relapsing chronic fatigue that is of new or deﬁnite onset (i.e. not lifelong), lasts for at 
least 6 months, and that is not the result of ongoing exertion, is not substantially alleviated by 
rest, and results in substantial reduction in previous levels of occupational, educational, social, 
or personal activities1. Several reviews of randomised controlled trials showed that cognitive 
behaviour therapy (CBT) is an effective treatment for CFS2-4. 
In CFS facilitating, initiating and perpetuating factors can be distinguished. Somatic factors 
like viruses are often mentioned to initiate chronic fatigue. Some prospective studies showed 
that 10 to 17 percent of the patients with a viral infection fulﬁlled CFS criteria after 6 months5,6. 
However, patients without a viral infection had the same chance to develop CFS. Although 
there are some indications that psychosocial problems and life events initiate fatigue, convinc-
ing evidence is still lacking7,8. Psychosocial problems are also mentioned as facilitating factors. 
A prospective study showed that psychological problems are a predictor for chronic fatigue8. 
Premorbid action proneness might also facilitate the development of CFS9. Although little is 
known about initiating and facilitating factors in CFS, more evidence is found on the perpetu-
ating factors. According to a model developed by Vercoulen and colleagues10, a strong focus 
on bodily symptoms, low levels of physical activity and a poor sense of control contribute to 
an increase in the severity of fatigue and functional impairment. Strong somatic attributions 
have an indirect inﬂuence on fatigue, via lower levels of physical activity. Most factors in this 
model of perpetuating factors in CFS have been found in other studies as well (for example by 
Heijmans11 and Wessely, Hotopf and Sharpe12). 
The cognitive behavioural treatment for CFS is based on the model of perpetuating factors13. 
CBT for CFS is directed at decreasing somatic attributions and the patients’ focus on bodily 
symptoms, increasing their sense of control over their symptoms, and restoring the balance in 
activity patterns. One of the randomised controlled trials that showed the effectiveness of CBT 
for CFS was the study of Prins and colleagues14. This study showed that the treatment manual 
used was not appropriate for all CFS patients. It seemed that, based on their activity level, three 
types of CFS patients could be distinguished: pervasively active, moderately active and perva-
sively passive CFS patients15. The protocol used in this effect study did not seem to work for the 
so-called passive CFS patients14, which is about 25% of the CFS population15. Based on these 
results, the treatment manual for passive CFS patients was adjusted. The main difference is that 
for pervasively active and moderately active (together so-called relatively active) CFS patients, 
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the treatment starts with a focus on a good alternation between rest and activity. For passive 
CFS patients a gradual increasing activity program is started immediately in the beginning of 
the treatment. 
In this article, ﬁrst basic assumptions of the treatment and considerations before starting CBT 
for CFS are discussed. Thereafter, how to determine the activity pattern and the treatment man-
uals for relatively active and for passive CFS patients are described, followed by suggestions 
for relapse prevention. In conclusion, applying CBT in other than individual ambulatory adult 
patients or CBT for CFS by others than psychotherapists, are discussed. The general treatment 
outline is shown in table 1. 
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Table 1
TREATMENT OUTLINE
Introduction and intake
• Explanation of basic assumptions:
 - distinction between causal and perpetuating factors
 - objective is full recovery, deﬁned in concrete individual treatment goals
• Preconditions: 
 - possible co morbidity can be integrated
 - no ongoing engagement in legal procedures of disability claims
 - no concomitant treatments
• Motivating the patient: discussing attitude and expectancies
• Individualizing treatment:
 - determining and deﬁning fatigue-related cognitions and behaviour 
 - determining and deﬁning the activity level
Treatment
RELATIVELY ACTIVE CFS PATIENTS 
• Explanation of perpetuating factors:
 - non-accepting cognitions 
 - activity peaks
• Challenging complaint-enhancing cognitions 
• Establishing a base level
• Systematic increase of activities
 - physical activity program
 - work-resumption or achieving other personal goals
PASSIVE CFS PATIENTS 
• Explanation of perpetuating factors: 
 - anxious cognitions
 - inactivity
• Challenging activity-impeding cognitions
• Systematic increase of activity
 - physical activity program
 - mental activity program
 - social activity program
 - work-resumption or achieving other personal goals
Relapse prevention
• Encouraging self-activity
• Getting rid of the patient label
• Being aware of pitfalls
• Follow-up and treatment evaluation
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Basic assumptions of CBT for CFS
Discussing basic assumptions of the treatment, the motivation of the patient and exploring fac-
tors that may interfere with CBT for CFS are subject of the ﬁrst sessions with the patient. It is 
recommended to have a spouse or other partner involved in these session at least.
Distinction between causal and perpetuating factors
CBT for CFS is based on the distinction between causal and perpetuating factors. Although 
somatic factors might have initiated the symptoms, they do not explain the persistence of fa-
tigue. Perpetuating factors make the symptoms endure. Therefore, CBT is focused on these 
perpetuating factors.  
Objective of CBT for CFS
Perpetuating factors in CFS are of a cognitive and behavioural nature. Aim of the treatment is to 
restructure these cognitions and behaviours in such a way that the patient’s complaints return 
to healthy proportions and that work or other normal daily activities can be resumed. Recovery 
is the goal aimed for. The patient describes what kind of behaviour he needs to be able to do 
again to consider himself a healthy person. Recovery is deﬁned in concrete behaviour for each 
particular patient, leading to concrete goals for treatment. The objective of being recovered 
poses some extra problems. In case of disease beneﬁts, possible negative ﬁnancial aspects 
of recovery have to be discussed. Becoming healthy will go at the expense of disease beneﬁts, 
which may intervene recovery. To prevent ﬁnancial declination a paid job has to be found. 
Recovery does not mean that the patient will lead the same life as before his complaints. First, 
premorbid activity proneness might have been a facilitating factor. Second, the patient may 
have an unrealistic idea of his premorbid functioning based on incorrect or idealized memo-
ries. Finally, the patient may have an unrealistic idea of what ‘normal’ functioning is, based on 
too high standards.
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Before starting CBT for CFS
Before starting CBT, complaints of the CFS patient should be analysed on a somatic, cognitive, 
behavioural, emotional and social dimension. The somatic dimension involves questioning the 
patient’s symptoms. What are the patient’s complaints? What are the associated functional im-
pairments? How does the patient spend his or her day and how do the complaints manifest them-
selves in the course of the day (description of a normal day)? Is this description exemplary of other 
days? In other words, are there any ﬂuctuations in the occurrence of the complaints? When did the 
complaints mentioned ﬁrst manifest themselves? In what way? Has the patient tried to ﬁnd (pro-
fessional) help? The cognitive dimension involves cognitions concerning fatigue like the patient’s 
sense of control, attributions and his daily cognitive reaction on fatigue. Has the patient in his 
view been sufﬁciently examined physically? What are his views on what caused the complaints? 
Does the patient see other ways of inﬂuencing his complaints? Does the patient have a tendency 
to catastrophise his complaints? What views does the patient have on CFS? What is the patient’s 
attitude regarding his complaints? What is his attitude towards a psychological intervention? The 
behavioural dimension concerns the patients behavioural reaction to his fatigue, including all he 
has done to improve his situation. What medication or diets is the patient on and what other 
treatments is he undergoing at this moment? What does the patient do to prevent his complaints 
from getting worse? What activity pattern is typical for this patient (predominantly passive; both 
active and passive at times, and subsequently passive; still relatively active)? What activities does 
the patient no longer undertake due to his or her complaints? What about the patient’s sleeping 
pattern? Do the complaints affect the patient’s concentration, memory or other mental activities? 
Do the complaints inﬂuence the patient’s social activities? What was the nature of the patient’s 
occupational activities? Since when has he stopped working? What type of beneﬁt does the pa-
tient receive (social, unemployment, disability)? Is the patient involved in any legal procedures 
in relation to beneﬁts? The emotional dimension involves whether the patient is for instance an-
gry, anxious or sad about his situation. Does the patient have any feelings of anxiety that his or 
her complaints will get worse? Is the patient afraid to undertake activities? The social dimension 
involves the patient’s interaction with his social environment, including spouse, family, friends, 
neighbours and physician(s). What effects do the patient’s complaints have on his social environ-
ment? How do the patient’s family members (spouse) react to his complaints? What are their 
ideas about the complaints? How do they react when the patient is affected by his complaints? 
Besides individualization, careful analysis of the patient’s situation has several goals. It may reveal 
factors that can interfere with CBT for CFS.
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Factors that may interfere with CBT for CFS 
Co-morbidity
About half of the CFS patients is known with severe psychological or psychiatric co-morbidity16. 
In most cases they do not offer an explanation for the patients complaints. As in other somatic 
disorders, psychiatric co-morbidity in CFS is found without the existence of a speciﬁc relation-
ship with the disorder. In case of psychological or psychiatric co-morbidity, however, it is impor-
tant to examine whether there is a relationship with the chronic fatigue. If it is a consequent of 
fatigue it might be supposed to dissolve during treatment. If it is an antecedent of the chronic 
fatigue, it will be treated during CBT for CFS. If there is no relationship between the co-morbid-
ity and the chronic fatigue whatsoever, one has to determine the most prominent problem to 
be treated ﬁrst. If chronic fatigue sustains after adequate treatment of the co-morbidity, CBT 
for CFS is still initiated.
Claims for disease-related beneﬁts 
It has been found that engagement in a legal procedure concerning ﬁnancial beneﬁts predict 
a worse outcome of CBT for CFS17,18. Therefore it was stated that CBT should not be offered to 
CFS patients during their engagement in legal procedures of disability claims. In these proce-
dure one has to convince the medical board of the severity of symptoms and disabilities. This is 
incompatible with a treatment aimed at recovery. Involvement in a procedure is carefully ques-
tioned out. Treatment only starts after the procedure is concluded. To the patient it is explained 
that it is hardly possible to work on recovery on the one hand and proving one’s illness severity 
on the other hand. After completion of the procedure the treatment can start after all. 
Concomitant treatments
CFS patients are actively seeking for help. As a consequence, several CFS patients use medica-
tion or have alternative medicine. Mostly without success. For CBT it is necessary not to be in-
volved in other treatments at the same time. During CBT for CFS the patient will start to change 
cognitions and behaviour in order to inﬂuence his symptoms and disabilities. To see whether 
these changes are effective it is necessary to know to what this can be attributed to. This is 
impossible if more than one treatment is followed. Therefore all concomitant treatments are 
inventoried. With understanding for the fact that the patient tries everything to improve, it is 
discussed with the patient whether and, if so, at what time he is prepared to stop concomitant 
treatments. Only thereafter CBT will start. 
Motivation of the patient: attitude and expectancies 
Creating the right treatment conditions is a prerequisite for successful treatment. Establishing 
the patient’s attitude toward CBT is essential. CFS patients often are sceptical and expectantly 
towards a psychotherapeutic treatment. It is therefore important to question this attitude, and 
to make any resistance towards CBT a subject of discussion. Their attitude may originate 
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from several sources. Patient organizations may spread information about CBT for CFS, often 
consisting of summaries of scientiﬁc studies and comments of patients. The patient is stimu-
lated to put any resistance or doubts about the intervention forward. In case of a negative view 
about CBT for CFS, the patient is offered objective information about the intervention, in this 
way giving him the opportunity to form his own opinion. Secondly, the patient may be referred by 
his physician, but feels that he is not yet properly physically examined. If the patient perseveres in 
this opinion after explanation of the CBT treatment model, he can be given the option to go back 
to his physician to discuss the matter once more. To prevent excessive medical consumption, it 
is best ﬁrst to agree about the extent in which physical examinations need to take place. Thirdly, 
the patient’s attitude on CBT may be determined by his previous experience with psychological 
or psychiatric treatments. A study amongst members of the Dutch ME-association showed that 
more than half of them had contacted a psychologist, psychiatrist or social worker19. If these 
treatments concerned the patients fatigue, they were probably focused on better coping and not 
recovery. The patient is asked for his previous treatment experiences, including duration, type, 
content and outcome of the treatment, because they may determine his attitude and expectan-
cies toward the current treatment. Expectancies can be adjusted by explaining the treatment 
model, and how psychological factors, by which thoughts, feelings and behaviours are meant, 
contribute to physical symptoms in general and to CFS in particular. Differences between the 
previous and the current treatment are stressed. To further challenge incorrect expectancies, 
it is emphasized that recovery is the goal of treatment and that self-activity is a prerequisite for 
success. It is not the intention to persuade the patient into CBT, but to give him the opportunity 
to form his own opinion about the treatment and whether or not he wants to go for that. The pa-
tient has to be given the time to make up his mind about the pros and cons of CBT for CFS. 
Although most patients are willing to start CBT after a careful and serious approach of the 
therapist, some need more time to make a ﬁnal decision. In some cases CBT is advised against 
because it is expected that CBT can not get the priority of the patient, for example in case of 
difﬁcult family circumstances. However, in case the patient is not immediately starting, an ar-
rangement is made how the patient can get back to the treatment proposition. In most cases 
CBT can start on a later moment with a motivated patient. 
Individualizing treatment
From scientiﬁc studies perpetuating factors are known for the CFS population as a whole. For 
each particular patient these perpetuating factors have to be deﬁned in individual and concrete 
cognitions and behaviour. Using self-monitoring, the patient examines the speciﬁc cognitions 
and behaviours perpetuating his symptoms and restrictions. Although this self-monitoring 
positively improves the patient’s self-efﬁcacy, it also strengthens the patient’s focus on bodily 
symptoms. Therefore, if the speciﬁc perpetuating cognitions and behaviours of the particular 
patient are known, severity of symptoms is no longer monitored. The focus in self-monitoring 
will be shifted to the registration of the cognitions and behaviours to be changed, in this way 
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also shifting the attention to what the patient himself can do about his situation. So, self-moni-
toring stimulates self-activity of the patient, enables individualization of the treatment, gives 
part of the responsibility for a successful treatment to the patient, and, in this way, improves 
the patient’s sense of control as well as his motivation for treatment.
Determining the activity pattern
In CBT for CFS behavioural change concerning physical activity is essential. The type of CBT 
the patient needs, depends on the type of his activity pattern. The activity pattern is best estab-
lished using an actometer. It allows the activity levels to be determined easily and accurately20,21. 
However, many therapists do not have access to an actometer. Then the activity pattern needs 
to be determined by means of an anamnesis, alternatively supplemented with self-monitoring 
data. 
Because nearly all CFS patients will claim that they hardly do anything anymore, it is important 
to obtain concrete information about the patients activities during a day. Talking through a nor-
mal day will allow the therapist to derive the degree and extent of the patients activities. The 
following questions can help determine whether the patient involved is passive or relatively ac-
tive: “How much time do you spend lying down on your bed or couch each day? How often (per 
day/per week) do you leave the house? For how long? What is the maximum time you spend 
walking at a stretch?” It is clear that the patient with a low activity pattern will spend a great 
deal of time lying down, will not walk for long periods of time and will not go out frequently. 
The answers to the last two queries will also depend on the support the patient receives. Thus, 
a CFS patient who lives alone and does not get any help is compelled to be active to a certain 
extent since he needs to go out for food. 
As stated above, the type of the patient’s activity pattern determines which protocol will be used 
to treat the patient. The self-monitoring records the patient will keep can also be used to test 
this initial pattern and will help determine the deﬁnite pattern.
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The relatively active patient
Challenging complaint-enhancing cognitions
Relatively active CFS patients often have non-accepting, demanding and therefore complaint 
enhancing cognitions. Fluctuations in the activity level of these patients are provoked by these 
cognitions. Figure 1 shows what a circle of perpetuating factors for relatively active CFS patients 
may look like. 
Figure 1
PERPETUATING FACTORS FOR RELATIVELY ACTIVE CFS PATIENTS
Examples of complaint enhancing cognitions leading to bursts of activity are “If I give in to my 
complaints, I will not be able to do anything at all”, “I do not quit my activities, because if I give 
in to my complaints it will only get worse”, “I am a weakling if I do not stay active”, “I have to 
stay active because I don’t want to burden other people”. The moment the principal perpetu-
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ating cognitions and behaviours of the particular patient are clear, cognitions are challenged. 
Hereafter a base level is established and an activity program will start. First the patient will 
however start with practicing more helpful accepting cognitions like “It does not make sense 
to keep opposing to my symptoms, I better accept them for the moment ”, “It is just the way it 
is”, “I don’t have to be able to do everything, I am only a human being too”, “Everyone has his 
limits, so do I”, “ I better learn to increase my activity level in a gradual and systematic way in 
stead of being too active followed by being fagged for a while thereafter”.  
Establishing a base level
For relatively active CFS patients a base level has to be established by alternating rest and activ-
ity in order to prevent bursts of activity and hereby extreme bursts of fatigue. By base level is 
meant: the total of activities a patient can do spread over the day without these causing extreme 
fatigue. The so-called peak-stop exercise can be used to attain the base level. With the peak-stop 
exercise the patient learns to quit his activities the moment his fatigue aggravates. For some 
CFS patients the negative effects only manifest themselves after they have stopped their activi-
ties or even a day thereafter. Here, self-monitoring data are used to determine a base level.
During the peak-stop exercise cognitions like “I will just ﬁnish this and thereafter I will rest” or 
“this has to be done before tomorrow, so I will go on to it’s ﬁnished” or “I know that if I am 
doing to much, my symptoms will be worse tomorrow, but now I have a nice day at least” will 
have to be replaced by cognitions like “I better stop right now, there will be another day tomor-
row and I will ﬁnish my activities then”. The ‘positive’ cognitions the patient may have are often 
satisfying in the short term, but are not conducive to their symptoms and health in the long 
term. During the period the patient applies the peak-stop exercise it is monitored that he does 
not lapse into total inactivity. The exercise is about ﬁnding the right balance between periods of 
rest and periods of activity. It is a temporary aid, which will not be needed later on, because, as 
with non CFS patients, exercise peaks can than be performed without long-lasting negative con-
sequences. Usually, patients are asked to put their base level down on paper. Which activities 
should be included in the base level depends on the patient’s personal circumstances. Some 
may still be able to go out to work a few hours per day, whereas for others the base level will 
have been reached after they have completed taking a shower, got dressed, had breakfast and 
performed some domestic activities. 
The patient’s base level should leave some room for manoeuvre. Unexpected events or unfore-
seen activities – so much part of life – need to ﬁt within the set level. In addition, the base level 
needs to allow room for the activity program, which will be described below.
If, after a number of sessions, a relatively active CFS patient is still seriously fatigued, has im-
proved little since the start of treatment, an evaluation of the base level may reveal that the 
patient still does too much or for too long a period. The fatigue may also be explained by the 
way the patient goes about things, for instance a hurried, tensed or perfectionist manner. Both 
instances warrant special attention and need to be resolved. 
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Setting the base level also implies normalizing the patients sleeping pattern. Most CFS patients 
tend to sleep long hours, sleep and lie down frequently in the course of the day, or cannot get to 
sleep at night even though they are feeling extremely tired. It is essential to try and normalize the 
sleeping pattern of these patients as quickly as possible. This implies going to bed and getting up 
at ﬁxed times and no sleeping during the day. For patients who still work (part-time), it needs to 
be established to what extent the job can be ﬁtted into the base level. Together with the patient 
the compatibility of the (part-time) job with the patient’s base level is judged. If work does not 
involve that the person’s limits are exceeded, it may be useful to have him continue working, 
since this provides an opportunity to evaluate the way the individual goes about his tasks. Is 
the patient always pressed for time, always busy; is there hardly any time for a break? Decide, 
together with the patient, whether his or her work approach is adequate or whether it needs 
to be adjusted. 
It may also be useful to discuss with the patient the possible consequences this base level may 
have on the patient’s environment. The patient may no longer meet (presupposed) require-
ments and no longer lives up to expectations. Generally, the best way to resolve this matter is 
to involve those in the patient’s environment in the treatment and to jointly try and ﬁnd (tempo-
rary) solutions to any emerging problems. Temporarily involving the patient’s spouse or others 
may signiﬁcantly help the patient to comply with his base level. 
Increasing activity 
Activities can be divided into three categories: physical, mental and social. In nearly all cases 
treatment starts with a physical activity program. For relatively active CFS patients this mostly 
sufﬁces to be able to start work-resumption or achieving other personal goals here after. The 
moment the patient has set his base level, the physical activity programs starts. The patient 
selects a simple physical activity that can be performed every day, the duration of which can 
be conveniently recorded. The aim is to have the patient gradually and systematically increase 
the frequency or duration of this particular activity. Walking and cycling are generally good ex-
amples of such an activity. Directive for relatively active CFS patients is to perform an activity 
like walking or cycling twice a day, starting at a level of which is certain that symptoms do not 
aggravate. Mostly this is ﬁve to ten minutes. The activity level is increased with one minute a 
day for each time the activity is performed. A minimal increase of ﬁve minutes a day is agreed 
upon, giving the patient the opportunity to skip the activity once or twice or to refrain from 
raising the walking or cycling time. Although the activities that ﬁt in the base level will expand, 
alternating rest and activity stays important. 
The patient is asked to indicate the actual duration of each activity on a graph. By analysing 
stagnations in the activity program impeding cognitions or difﬁculties the patient might have 
with respecting limitations can be traced. The most common problem with the relatively active 
CFS patients is that they increase their activity level too fast, eventually resulting in an increase 
of symptoms. Another rising problem might be that the activity program is not systematically 
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and consequently or to slowly performed. In these cases the activity program may not have the 
priority of the patient while other daily activities are performed too often or for a too long dura-
tion. By means of the activity program patients also learn to prioritise. This is accompanied by 
a cognitive change essential for a successful treatment outcome. The cognition “quickly doing 
this or that” is replaced by “gradually and systematically increasing activities”. 
In general the activity program will end at a maximum of 60 minutes of walking or cycling. By 
that time most patients will have become aware of the fact that they are capable of doing more 
without experiencing extreme fatigue and that they recover faster than before. The original base 
level has by then already been automatically enhanced. Gradually, walking or cycling is now be-
ing replaced by other activities. One might also choose to systematically expand mental and 
social activities, preparing the patient for a return to work or other personal targets. 
It needs to be noted that the activity program of the relatively active patient is not about im-
proving their physiological condition since, as far as is known at present, these patients are not 
deconditioned in a physiological sense22. The focus of the activity program is a gradual and 
systematic increase in activity. The fact that patients experience that they are capable of achiev-
ing this goal – if approached in the right way – enhances their sense of control and helps bring 
about a positive self-efﬁcacy.
Work-resumption or achieving other personal goals
In accordance with the ultimate objective of the treatment, work-resumption or achieving other 
personal goals is subject to discussion from the start of treatment. In the ﬁrst sessions the 
work situation is analysed. This involves the possibility to return to the old workplace, ﬁnancial 
consequences of recovery, as well as whether the patient wishes to get back to work in case 
of recovery. Thereafter a plan for work resumption or achieving other personal goals is set up. 
Three steps are described. First the ﬁnal goal is determined. Which work activities does the pa-
tient want to be able to perform again, which will also allow him to perceive of him as healthy? 
Secondly, it is formulated which working activities ﬁt in the current base level. What is the pa-
tient capable of at this moment without resultant complaint-enhancing effects? Finally the work 
resumption plan is drawn up. How can the patient build up his activity level from the current 
situation to the ultimate goal without negatively affecting the symptoms? The patient is asked to 
commit the various steps to paper, taking into account any problems that may arise. Compliance 
with the activity plan is evaluated.
The work resumption plan is delineated by a gradual and systematic increase of working hours 
as well as tasks to be performed. Successful work resumption is only possible if it is also pre-
sented to the patient’s employer, company doctor and/or medical adviser of the insurance com-
pany. This is preferably done by the patient himself. 
When a return to work is not an option, an action plan is drawn up stipulating how to achieve other 
personal targets. Principles used are the same as for planning and achieving work resumption. 
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The passive CFS patient 
Challenging activity-impeding cognitions  
For passive CFS patients the fear that activity enhances symptoms is essential. As a result activi-
ties are avoided as much as possible. Because the body gets unused to activity, symptoms will 
emerge at increasingly lower levels of activity. In this way a self-fulﬁlling prophecy is established. 
Figure 2 shows a conceivable perpetuating circle for passive CFS patients. 
Figure 2
PERPETUATING FACTORS FOR  PASSIVE CFS PATIENTS
The aim of restructuring anxious cognitions is decreasing the fear of activity and motivating the 
passive CFS patient to start and sustain the activity program. Essential activity-impeding cogni-
tions may be “As soon as I start feeling tired or start having pain I have to stop everything I’m 
doing ” or “I can’t do anything on my own anymore, others have to help me all the time”. More 
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helpful cognitions are: “If I completely adapt to my symptoms I only make my situation worse”, 
“By raising the level of my activities step-by-step, I will be able to push my physical capabilities 
further”; “If I get complaints by being active it doesn’t necessarily mean that I should stop do-
ing what I’m doing; it’s just a sign that it has been some time since I’ve been active and my 
body simply needs to get used to it again; the only way to break through is by becoming active 
again”. The patient may be requested to keep a record of his cognitions.
Compared to relatively active patients, it is generally more complicated to challenge the cogni-
tions of these passive patients without also involving behavioural change. This is the reason 
why, with these patients, the moment of transfer to the graded exercise program is brought 
forward. 
Increase of activity 
Before starting the activity program, a (gradual) cessation of the use of any aids like a walking 
stick or wheelchair is realized. Such aids tend to obscure the patients symptoms and impair-
ments and may undermine the conﬁdence-building process that allows the patient to believe 
in his own ability to recover. After all, a wheelchair does not allow the patient to independently 
perform the steps of the activity program. Usually, cessation of the use of aids can be accom-
plished by simply explaining the situation and having the patient agree not to use the aids. If 
the patient wants to gradually reduce the use of the walking stick or wheelchair, this requires a 
concrete plan of action, indicating the time-scale, e.g., a maximum of two to three weeks. Even 
though cessation of the use of the aid is likely to result in an even further decrease of activities, 
starting the activity program at this lowered base level offers the better prospect. 
Because passive CFS patients are hardly active anymore, they start their activity program as 
soon as possible. Most of them will choose walking as a building up activity. The directive here 
is to start with a one-minute walk six times a day. Every day the walking time is increased with 
one minute. So, for example, the ﬁrst day the patient has six one-minute walks, the second 
day six two-minute walks, the third day six three-minute walks and so on. A total building up 
of ﬁve minutes a week for each walk a day is aimed at, allowing the patient to skip a day or to 
refrain from raising the duration. Having the activities reﬂected in graphs, the patient can give 
himself positive reinforcement about his progress. Furthermore the graphs are used during 
therapy sessions to detect problems in the activity building. The most common problem for 
passive CFS patients is that the building up process is going to slowly because of the fear that 
activity is harmful. The program will however need to convince the patient that physical com-
plaints should not be taken as a sign to stop the activities. It is explained to the patient that it 
is obvious that, after a long period of inactivity, his body has to get used to activity again. It is 
important to point out that a one-minute raise is absolutely safe and that there is no danger 
whatsoever, nor any over taxation. It is emphasized that by this small but gradual increase, bar-
ring exceptional circumstances, a great deal of progress can be made in only a few weeks time. 
It is common to cut back the frequency of the walks from six times a day to two or three times a 
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day after several weeks. Even before reaching a certain level, for instance a twice-a-day 60-minute 
walk, the patient will already ﬁnd that he is now also able to undertake other activities. By then 
the patient will also have noticed that recovery from an activity is much faster. Because passive 
CFS patients are inactive in every area, a mental activity program is started rather soon as 
well. Mental activities concern reading, watching television, doing puzzles or computer work. 
Usually this kind of activities are started in units of ﬁve minutes three to four times a day. Based 
on the same principles, a social activity program is started shortly thereafter. Here activities 
as making telephone calls, receiving or paying visits, or making other social calls are involved. 
Since the social activity program will also affect the patient’s environment, the patient needs 
to inform others of the program. The patient decides on the content of the information. The 
physical, mental and social activities chosen are geared to the activities needed in the plan for 
work resumption or achieving other personal goals.
Frequently, passive CFS patients have rallied the support of a considerable number of people. 
It is also common for the patient’s environment to be just as concerned and anxious as the 
patient. This may contribute to the complaints being maintained. If this seems to be the case 
the spouse or another key player from the patient’s environment should be invited to attend a 
session to discuss how to cut back the support given.
Work-resumption or achieving personal goals 
As for the relatively active CFS patients, a plan for work resumption or achieving other personal 
goals is made. Here, activities previously performed during the mental and social activity pro-
grams, are used as ﬁrst steps towards work-resumption or achieving other personal goals.
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Relapse prevention
Encouraging self-activity
In order to prevent a relapse it is paramount that the patient’s self-activity is enhanced in each 
phase of the treatment. Will the therapist initially challenge the patient’s cognitions, introduce 
helpful cognitions and moderate behaviour or teach the patient the necessary skills, during the 
course of the treatment this role will increasingly become smaller and the therapist will take 
more of a back seat. After six to ten sessions the therapist’s role will mainly be supportive in ana-
lysing recovery-impeding factors and reinforcing goal-directed steps. By increasingly making it 
the patient’s own responsibility to detect and anticipate difﬁculties and to ﬁnd solutions, the pa-
tient’s sense of control will be enhanced and somatic attributions will be reduced. The patient, 
who by this time no longer is a patient, has learned how he can inﬂuence his complaints. 
Getting rid of the ‘patient label’ 
Many patients ﬁnd it hard to stop seeing themselves as patients. The term chronic fatigue syn-
drome already seems to suggest that having been diagnosed with CFS implies a permanent 
condition. The fact that many CFS patients have been suffering from symptoms for quite some 
time before they are referred for CBT does not contribute to their developing an optimistic out-
look as far as a full recovery is concerned. In addition, patients who are referred to a psycho-
therapist for CFS, generally assume that they will learn to cope with their complaints rather than 
that they will learn to perceive themselves as healthy individuals again. This is why this should 
be one of the ﬁrst points on the treatment agenda. In the ﬁnal phase of the treatment this point 
is raised again when the patient is asked what he thinks still needs to be done before he can 
replace the marker reading ‘patient’ by a label indicating ‘healthy’. The response of healthy in-
dividuals who are suffering from all kinds of ﬂu-like symptoms will be quite different from the 
reactions of CFS patients, who, when they are incidentally experiencing complaints again, will 
usually interpret signals from the body as symptoms of CFS in stead of normal and temporar-
ily ﬂuctuations of the body. 
Being aware of pitfalls
The moment the patient is feeling better, the necessity to apply the newly learned cognitions 
and behaviours seems no longer present. The previously used cognitions and behaviours may 
however be pitfalls for relapse. Within the framework of relapse prevention, conceivable pit-
falls for the particular patient are detected and it is discussed how to anticipate on them. It 
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might be useful to let the patient write down some helpful cognitions and behavioural rules 
he can rely on. 
Furthermore, every patient has his own speciﬁc lifestyle. Some will have difﬁculties 
with communicating their limits to others, others may be perfectionists. There are also 
patients who have such an intense fear of failure that they will be extremely apprehensive about 
achieving the treatment goals and will consequently drop out of treatment at an early stage. 
To prevent relapse, the patient is advised to pay speciﬁc attention to his known weaknesses. 
Different lifestyles may either induce the patient to do too much or too little. Both behaviours 
may elicit that the patient once more ends up in a downward spiral. By helping the patient to 
become conscious of these innate weak spots, he may prevent a relapse or learn to resolve the 
situation in time.
Follow-up and treatment evaluation 
Treatment will usually consist of ten to a maximum of twenty sessions, also depending on the 
therapist’s experience with the treatment. After completion of the actual treatment, follow-up 
sessions are conducted with the single purpose of monitoring whether the treatment effect is 
sustained. The purpose of the follow-up sessions is to discuss with the person involved, the 
‘ex-patient’ now, how he has dealt with fatigue. Has he learned enough to tackle any recurring 
symptoms? Here, the follow-up sessions mainly take the shape of revision lessons or a re-
fresher course. The therapist reinforces the ex-patient’s positive approaches towards fatigue or 
his behaviours that help prevent extreme symptoms. Far better still, the therapist should have 
the ex-patient reinforce himself and thus help to establish a positive sense of control. It is also 
recommended to go through all the positive effects of the treatment once more since most pa-
tients who have been successfully treated will still report feeling tired frequently, although this 
no longer takes extreme forms and recovery occurs more quickly. In other words, the fatigue 
has been normalized. Concomitant complaints like muscle pain or joint-ache will usually already 
have disappeared gradually in the course of the treatment. 
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In conclusion
CBT for CFS as described in this chapter has initially been developed for and tested with adults. 
CBT is also considered suitable for the treatment of young CFS patients, provided that their 
individual circumstances are taken into account. Participation of the parents in their child’s 
treatment is a precondition. In an uncontrolled study Chalder, Tong, and Deary23 examined the 
effectiveness of CBT family therapy for 11-18 year olds. They found 15 of the 23 enrolled patients 
improved at six month follow-up.
CBT for CFS can also take the form of group therapy. In our centre several CFS patients were 
treated in a group setting24. Patients may have a good example from the progress the other mem-
bers of the group are making. Comparing and discussing the participants’ individual actometer 
patterns may help patients to get an idea which direction their activity program should take. 
Although group therapy for CFS has not yet proven to be effective, it seems most suitable for 
patients whose functional impairment is moderate.
A certain number of CFS patients may also be treated with elements of CBT by their family 
physician. It seems wise to select those CFS patients who are most likely to beneﬁt from the 
treatment. This will usually imply CFS patients who are still relatively active and for whom the 
majority of prognostic factors are favourable, that is no co-morbidity, a predominantly posi-
tive self-efﬁcacy regarding the symptoms, moderate somatic attributions, no repetitive use of 
medication, and a social environment that has a positive attitude toward the chances of the 
patient’s recovery. Unfortunately, as yet there is only one study in which general practitioners 
were trained to deliver CBT, but the study suffered from poor recruitment and high drop out, 
and the treatment had no effects on the patients with CFS25. 
In the studies described earlier, therapies provided were always on an outpatient basis. Chalder, 
Butler and Wessely26 reported an uncontrolled study involving six inpatients of a clinic special-
ized in the treatment of CFS. They provide a comprehensive description of the treatment they 
developed for their patients, whose severity of symptoms necessitated inpatient treatment. Five 
of the six patients showed considerable improvement, and this effect was still present three 
months after their release from the clinic. Cox and Findley27 also described CBT and graded 
activity of CFS patients in an inpatient setting. They claimed at 6 months post-discharge a per-
ceived increase in level of ability in 82% compared with prior to their admission to hospital.
It has been shown that behaviour therapists ﬁnd CFS patients hard to treat28. Many problems 
therapists encounter during CBT for CFS involve the interaction with the patient. Especially 
moti-vating the patient for treatment, handling co-morbidity, and realizing work-resumption is 
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found difﬁcult. These problems can best be dealt with by individualizing the treatment, which 
involves making the speciﬁc perpetuating factors of this particular patient concrete and integrat-
ing co-morbidity as it may be part of the perpetuating factors. It is recommended that therapists 
willing to treat CFS patients take knowledge of the current scientiﬁc state of affairs into CFS, and 
are experienced in CBT as well as treating patients with (unexplained) physical symptoms.
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General discussion
In this ﬁnal chapter our results will be summarised and the consequences of our ﬁndings for the 
treatment of CFS patients will be discussed. Ideas for future research will be put forward. 
CFS put on the Dutch map
One aim of this thesis was to examine the prevalence of CFS in the Netherlands. Based on 
GP reports, an estimated prevalence of 112 CFS patients per 100 000 inhabitants was found 
(chapter 2). These results were conﬁrmed in another Dutch study1. Our prevalence study was 
repeated in 19992. This time a prevalence rate of 195 per 100 000 was found. Rather than the 
prevalence of CFS being increased, it is more likely to be an effect of CFS becoming better known. 
The skewed distribution of the reported number of CFS patients in each general practice suggests 
that GP reported prevalence of CFS highly depends on a GP’s attitude towards CFS. Whereas 13% 
of the respondents stated they had no CFS patients in their practice, the mean number of CFS 
patients in each practice was 4.9. In our ﬁrst prevalence study 27% of the GPs stated they had 
no CFS patients in their practice and the mean number of CFS patients in each practice was 2.8. 
In both studies differences between GPs in the number of CFS patients reported were obvious. 
A study by Prins and colleagues on the attitude of Dutch GPs towards CFS showed that half of 
them were reluctant to diagnose CFS, and 20% of these GPs did not accept CFS as a diagnosis3. 
Only 10% of the GPs felt capable of giving sufﬁcient information to CFS patients. These results 
raise questions about the GPs’ adequacy diagnosing CFS. It is not desirable that acknowledge-
ment of the diagnosis CFS depends on the GP a patient is consulting. Especially since a GP can 
play an important role in CFS. If GPs diagnose CFS and acknowledge the patient’s complaints, 
further medicalisation can be prevented and ways for better management can be discussed4. For 
this purpose, recommendations for diagnosing and managing chronic fatigue in general practice 
have been published5-6. Anyhow, based on our prevalence study an estimate of the prevalence of 
CFS in the Netherlands could be made. Furthermore, we seemed to have reached our aim to 
inform GPs about CFS. It surely helped to put CFS on the Dutch map.
Hyperventilation and physical ﬁtness are no perpetuating factors in CFS
After we had examined the GP-reported prevalence of CFS, hyperventilation and physical ﬁtness 
were studied as possible perpetuating factors (chapter 3 and chapter 4). 
Hyperventilation is a respiration that exceeds metabolic demands, immediately resulting 
in a decrease of arterial pCO2 and leading to an increase of pH in the blood (alkalosis). In 
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Hyperventilation Syndrome (HVS), hyperventilation is held responsible for several somatic 
symptoms. Because fatigue seemed to occur in many HVS patients and hyperventilation in 
CFS patients, we hypothesised that hyperventilation could contribute to fatigue in CFS. In our 
study 59% of the CFS patients fulﬁlled symptom criteria for HVS and 59% physiological criteria 
for hyperventilation. However, no signiﬁcant differences between CFS patients with and without 
hyperventilation were found for severity of fatigue, impairment, number of complaints, activity 
level, psychopathology and depression. It seems that hyperventilation is not responsible for the 
symptoms in CFS. We concluded that hyperventilation is not a perpetuating factor in CFS but an 
epiphenomenon. To date, no more studies on CFS and hyperventilation have appeared. 
The assumed role of physical ﬁtness as a perpetuating factor in CFS is complicated. Many treat-
ment manuals are based on the idea - ﬁrst published by Wessely and colleagues in 1989 - that 
a low level of activity, and consequently an assumed physical deconditioning, is the main per-
petuating factor in CFS7. Studies on the effect of graded exercise in CFS, based on this concept 
of physical deconditioning, showed a treatment effect8-9. These study results suggest that CFS 
patients just have to become more active again and improve their physical ﬁtness. This idea, 
however, may be disputed. The ﬁrst argument stems from our own study on physical ﬁtness. It 
was found that CFS patients had the same physical ﬁtness as their healthy controls. The only dif-
ferences found were that CFS patients considered themselves fatigued and quitted the exercise 
test at a lower level of exertion (that is: had a reduced exercise capacity), without a physiologi-
cal reason. The second argument comes from the randomised controlled study of Fulcher and 
White8. They found that a decrease of fatigue and impairment after graded exercise was not cor-
related with physiological improvement. In an additional study, using the patients of this same 
graded exercise trial, the physiological response to exercise in CFS was explored further10. As in 
our study, it was found that although CFS patients were equally unﬁt as sedentary controls, only 
CFS patients had a reduced exercise capacity. They quitted the exercise test earlier than controls 
and perceived greater effort during exercise. It was also found that improved physical ﬁtness 
after graded exercise was associated with increased capacity on the exercise test. A relation with 
fatigue and impairment, however, was not mentioned10. In the randomised controlled study of 
Wearden and colleagues there was a weak but signiﬁcant correlation between improved fatigue 
after graded exercise and improved functional work capacity (the amount of oxygen consumed 
in the ﬁnal minute of exercise)9. According to the authors their results suggest an improve-
ment of the subjects’ tolerance to exercise rather than a substantial increase in cardiorespira-
tory conditioning. It is their view that graded exercise may work by providing the reassurance 
to patients that activity need not cause an exacerbation of fatigue symptoms. Anyhow, it is well 
known that exercising improves physical ﬁtness. There is, however, no evidence that improving 
physical ﬁtness is essential in the treatment CFS and decreases fatigue and impairment in daily 
life. Still, one objection can be made. Van der Werf and colleagues found that, based on their 
activity level, a subgroup of about 25% pervasively passive CFS patients can be distinguished11. 
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These patients have an activity pattern not prevalent in healthy controls, and are characterised 
with more severe disability compared to other CFS patients. The protocol used in our individual 
CBT study did not work for these passive CFS patients (chapter 7). Therefore we decided to im-
mediately start with an activity programme for this subgroup. It is likely that pervasively passive 
CFS patients have a lower physical ﬁtness compared to other CFS patients and healthy controls. 
Although it is thinkable that an assumed decreased physical ﬁtness in this subgroup of patients 
is an epiphnomenon, it might be worthwhile to study the role of ﬁtness as a process variable in 
the treatment of pervasively passive CFS patients. 
Essentials in CBT for CFS
Our individual cognitive behaviour therapy (CBT) for CFS proved to be an effective treatment 
(chapter 7). The effect of individual CBT for CFS has also been shown in several reviews of ran-
domised controlled trials12-14. We could not prove cognitive behaviour group therapy (CBGT) 
to be effective for CFS (chapter 6). Methodological issues have been discussed in the chapters 
concerned. Now what is essential in CBT for CFS will be reﬂected on. First we pay attention 
to ‘What makes CBT for CFS effective?’, discussing, among other things, the role of activity. 
Thereafter the question ‘In what way is CBT for CFS effective?’ will be dealt with, discussing dif-
ferent forms of CBT for CFS, among which CBGT, and the use of the manual. Finally we consider 
’For which patients is CBT for CFS effective?’, discussing the necessity of deﬁning subgroups 
of patients and the applicability of our CBT for CFS manual to the treatment of fatigue in other 
conditions and to the treatment of other unexplained somatic symptoms.
What makes CBT for CFS effective?
An activity programme is an important ingredient in both graded exercise and CBT. But if 
improving physical ﬁtness is not the working mechanism, then what is essential in these 
treatments?
From several controlled studies, comparing CBT with relaxation15 or social support (chapter 7), 
it can be concluded that it is not just the attention received. Deale and colleagues suggest that 
the working element is the behavioural change common to cognitive behaviour and exercise 
therapies that produces a cognitive shift away from fear and avoidance16. Although the rationale 
for cognitive behaviour therapy is a fear avoidance model and exercise therapy is based on a 
physiological model of deconditioning and decreased ﬁtness, both rationales lead to the use of 
an activity programme as an essential factor in treatment. 
Effective treatments have in common that they offer a rationale that makes improvement or 
recovery possible, and set a goal for improvement or recovery. Such a rationale may challenge 
cognitions about the progress that can be made as well as about the chronicity of symptoms. 
Aiming for improvement or for recovery, however, is importantly different. Aiming for improve-
ment suggests that patients will keep on having CFS, and just learn how to cope with their fa-
tigue. Aiming at recovery induces the cognition that cure is possible. This may also partly explain 
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why our group therapy, aiming at coping with CFS, was not effective, where our individual CBT, 
explicitly setting recovery as a goal, was.
A rationale might also challenge the fear that activity is harmful. Using graded activity and 
experiencing that activity is not harmful may challenge the fear that activity is harmful even more. 
Studies showing that activity is safe and that CBT and exercise are effective in CFS may help to pro-
duce important cognitive changes and underline (parts of) the rationale given in these treatments 
(chapter 5). Deale and colleagues show that fear of activity and the belief that activity should 
be avoided are important to be challenged in CBT17. They found that beliefs about avoidance of 
exercise and activity only decreased after CBT, and that this change was associated with improved 
outcome. In line with this, Sharpe and colleagues18 found that avoidance of activity was reported 
less after CBT than before. Also, avoidance of activity decreased more through CBT than through 
medical care. Whether these changes correlated with treatment outcome was not reported. The 
importance of fear of activity, as a cognition producing low levels of activity, is underlined by a 
study of Silver and colleagues19. They found that behavioural persistence to ride an exercise bike 
for as long as one felt able to did not correlate with maximal heart rate or resting heart rate, level 
of tiredness, symptom severity, illness identity or emotional distress, but with a fear of physical 
movement and activity. In contrast to the individual CBT studies, in our CBGT study, beliefs that 
activity should be avoided increased after CBGT (chapter 6). In the wait list condition there were 
no changes. This may, however, be due to the manual used in that study. Establishing a baseline 
- and thus decreasing activities in some ways - was stimulated before an activity programme was 
started. Finally, fear of activity may be most prevalent and important for passive CFS patients. 
Until now, studies on this subject did not differentiate between passive and relatively active CFS 
patients. 
Looking at our model of perpetuating factors, one would expect changes in somatic attributions, 
self-efﬁcacy and focussing on bodily symptoms to be important working elements in CBT as 
well20. Deale and colleagues found that physical illness attributions did not change with treatment, 
and were not associated with poor outcome, neither in CBT nor in the control group17. Sharpe and 
colleagues did ﬁnd a decrease in physical attributions, changing more with CBT than with medical 
care18. Whether these changes correlated with treatment outcome, was not reported. In our CBGT 
study, physical attributions were diminished after CBGT but not in the wait list condition (chapter 6). 
A difﬁculty with measuring physical illness attributions is that physical attributions concerning the 
cause of CFS should be distinguished from physical attributions concerning the perpetuation of 
CFS. Although physical factors may have initiated CFS, there is no reason to believe that they have 
a perpetuating role. In the several studies this distinction has not been made. It will be clear that 
causal somatic attributions do not necessarily have to be changed after CBT.
In our CBGT study, self-efﬁcacy and focussing on bodily symptoms remained unchanged in 
both groups. In other CBT trials these variables were not studied as process variables. In our 
individual CBT trial it was found that a higher sense of control predicted more improvement, 
whereas focussing on bodily symptoms predicted less improvement (chapter 7). These ﬁndings 
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led us to change the manual. Paying more attention to these process variables during treatment 
may lead to even better results of individual CBT for CFS.
The role of physical activity re-examined
Although all effective treatment studies in CFS have a programme to increase activity, none re-
ported an actual increase in the level of physical activity after treatment. In most studies levels of 
activity are measured with questionnaires. As we know from an earlier study, most of these meas- 
ures do not assess actual behaviour but cognitions about behaviour21. In our individual CBT trial, 
the actometer (a behavioural measure of actual activity in daily life) was merely used as a predic-
tor. Only the case study of Prins and Bleijenberg showed an effect on the actometer after CBT22. 
One might wonder whether an increase in the actual level of physical activity can be expected for 
all CFS patients. Surawy and colleagues suggested that complaints of CFS patients were perpetu-
ated by bursts of activity on the one hand and avoidance of activity on the other23. Non-accepting 
cognitions lead to bursts of activity, the idea that activity is harmful leads to avoidance of activity. 
Although there are more explanations possible for the minimal effect of CBGT, our manual, based 
on this idea, did not work very well in CBGT. Based on the ﬁnding that avoidance of activity had 
increased through CBGT, ﬁnding a balance between bursts of activity and avoidance of activity 
remained part of our treatment, but the graded activity programme was more accentuated and 
put forward. Now we know that the manual used in the individual CBT study, was only suitable for 
the relatively active CFS patients, and not for the so-called passive CFS patients. As described in 
chapter 9, we therefore developed a distinct treatment protocol for passive CFS patients. For the 
latter group ﬁnding a balance between rest and activity was left out and the treatment immediately 
starts with an activity programme. It is presumable that for this pervasively passive subgroup of 
CFS patients the level of physical activity needs to be increased after treatment, whereas for the 
other patients an increase of physical activity might not be expected. As Van der Werf and col-
leagues found, 75% of the CFS patients have an activity pattern also present in healthy controls11. 
For these relatively active CFS patients mainly their cognitions about their level of physical activity 
or their regulation of activities may need to be changed. Van der Werf and colleagues also found 
that CFS patients as a group showed longer periods of rest following their activity peaks and pa-
tients were characterised by a larger drop in activity during the hour after the peak, than healthy 
subjects11. This ﬁnding is in agreement with the theory of Surawy and colleagues23 and with the 
basic assumptions of our treatment manual currently being used for the relatively active CFS pa-
tients, underlining the importance of activity regulation. 
In what way is CBT for CFS effective?
Different forms of CBT for CFS
Although individual CBT for CFS has been proven to be effective (chapter 7), that was not the 
case for CBGT (chapter 6). For this various explanations have been given. Cognitions that ac-
tivity should be avoided were increased because of too much emphasis on rest and relaxation, 
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before starting an activity programme. Applying CBGT for CFS might also have been too dif-
ﬁcult for inexperienced therapists. Furthermore, CBGT may only be suitable for a subgroup of 
patients. CFS patients with less severe complaints seemed to proﬁt most from CBGT. Future 
studies will have to reveal whether CBGT for CFS can be effective for subgroups of CFS pa-
tients.
Some uncontrolled studies on the feasibility and effect of forms of CBT for CFS other than am-
bulatory individual therapy show positive results. These reports concern CBT in an inpatient 
setting24-25, CBT as part of a multidisciplinary intervention26 and CBT in a general hospital set-
ting27. Some CFS patients with for example extremely severe complaints, may beneﬁt more 
from an inpatient or a multidisciplinary treatment, while for others a self-help programme may 
be sufﬁcient. Finally, Powell and colleagues proved that even a minimal intervention, consist-
ing of only two individual treatment sessions and two follow-up telephone calls supported by 
a comprehensive educational pack, was effective28. Although only one experienced therapist 
carried out this intervention, this ﬁnding is promising. More research is needed to establish if 
different forms of CBT for CFS will be effective for speciﬁc subgroups of patients. 
How to use the manual?
As stated in chapter 8, standardised, empirically validated practice, written down in a manual, 
does not necessarily make treatment easier to conduct for the therapist, but may enhance its 
quality and effectiveness. For over 25 years there have been manual-based psychotherapy treat-
ments, for both research purposes and training and practice29. The report of the Task Force 
on Promotion and Dissemination of Psychological Procedures of the American Psychological 
Association (APA) in 1995 was the start of a debate on the desirability of research-based treat-
ment manuals in the clinical practice30-43. Much of the debate concerned the strengths and 
weaknesses of such evidence-based treatments and the differences between research and prac-
tice32,41-43. The discussions revealed that the resistance to the use of standardised treatments 
was highest under psychotherapists working in clinical practice. It was objected that the impli-
cations of the differences between client and therapist characteristics, the role of non-speciﬁc 
factors and the necessity to adjust the therapeutic interventions to the client’s (or patient’s) 
speciﬁc complaints were not sufﬁciently taken into account34. More arguments challenging 
standardised treatments included: their failure to take into account co-morbidity and the more 
complex problems of the clinical practice; their lack of ﬂexibility and adjustability preventing 
customisation; the idea that patients or clients are not served adequately by a standardised 
treatment; their failure to do justice to the role of the holistic theory and function analysis; their 
negative effect on the patient-therapist relationship; their negative impact on the competency 
and work satisfaction of the therapist; and their poor practicability32,37,39-41. The debate on the 
pros and cons of standardised treatments in clinical practice has also yielded suggestions as to 
the desired content of such a treatment manual. Many of these suggestions underpin the impor-
tance of a manual that leaves room for customisation and ﬂexible application31,43-47. As a result 
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of our experiences with the manual and the outcome of the therapists’ adherence and percep-
tions study (chapter 8), our manual was adapted (chapter 9). The treatment manual provides 
insight into and contains detailed information about the function analysis of CFS patients, as 
well as the accompanying interventions and difﬁculties. Yet, the manual needs to be individu-
alized. In the course of the treatment making a further speciﬁed function analysis is recom-
mended. Agreeing with Heimberg37 we stated that combining the manual and the individualized 
treatment implies that therapists may need additional speciﬁc skills and that the therapeutic 
process places high demands on the therapist’s basic technical and interaction skills. Hopefully, 
our view on how to use a treatment manual will challenge dismissive cognitions therapists in 
clinical practice have about an evidence-based treatment manual. 
Who can use the manual?
In our studies only behaviour therapists performed CBT for CFS. The therapists involved in our 
individual CBT study reported that in their experience treating CFS patients had been more dif-
ﬁcult than the treatment of patients with a different somatic symptomatology or patients with 
psychosocial or psychiatric problems (chapter 8). Therapists who had little experience in treating 
patients with somatic complaints turned out to have difﬁculties in preventing patients from drop-
ping out2. As we stated in chapter 8 and chapter 9, it is our view that therapists willing to treat 
CFS patients must be knowledgeable about the current scientiﬁc state of affairs of CFS, and be 
experienced in CBT as well as treating patients with (unexplained) physical symptoms. 
One might wonder whether other than behaviour therapists, for instance GPs, can deliver CBT-
like interventions for CFS. Studies on this topic are not yet available. A randomised controlled 
trial on the effect of GP delivered CBT for unexplained fatigue among employees did not show 
any effect48-49. In a study on reattribution for somatisation, conducted by GPs in general prac-
tice, some improvement was found. However, this was a much less complicated intervention 
aimed at increasing subjective health and reducing medical consumption50. Concerning CFS, it 
is conceivable that GPs will be able to treat those patients that are most likely to beneﬁt from 
CBT. This will imply CFS patients for whom the majority of prognostic factors are favourable, 
that means who are still relatively active, have no co-morbidity, a positive self-efﬁcacy regard-
ing the symptoms, moderate somatic attributions, no repetitive use of medication, and a social 
environment that has a positive attitude toward the chances of the patient’s recovery51. It still 
needs to be studied whether GP delivered CBT for this subgroup of CFS patients can be effec-
tive indeed. 
For which patients is CBT for CFS effective?
In trials on individual CBT for CFS it was found that engagement in a claim for a disability-related 
beneﬁt during CBT, a lower sense of control, a passive activity pattern and focussing on bodily 
symptoms predicted less improvement after CBT (chapter 7)52-53. Treatment outcome was not 
inﬂuenced by current or lifetime psychiatric diagnoses53. Bentall and colleagues found that poor 
c
h
a
p
ter 10   |   g
en
er
a
l d
isc
u
ssio
n
160
outcome was predicted by membership of a self-help group, being in receipt of sickness beneﬁt 
at the start of treatment and dysphoria54. Based on these study results, it is recommended that 
CFS patients involved in a claim for a disability-related beneﬁt should not be included in CBT. 
The other factors found to inﬂuence CBT outcome may have consequences for the treatment 
and for the difﬁculty to treat these patients in the ﬁrst place. 
Generalising CBT for CFS to the treatment of fatigue in other conditions
One may wonder whether our treatment manual can be effectively used for the treatment of 
fatigue in other than CFS cases. There are arguments that this is not the case. The manual is 
based on perpetuating factors speciﬁc to CFS. It has been found that the model of perpetuating 
factors in CFS did not ﬁt for fatigue in multiple sclerosis20. A newly developed model revealed 
that in multiple sclerosis emotional instability, neurological impairment, helplessness and de-
pressive mood perpetuate fatigue55. Studies on fatigue after cancer showed that for patients 
still being fatigued years after successful treatment of cancer, other factors seem to determine 
fatigue. Not only a low self-efﬁcacy, lower levels of physical activity, strong causal attributions 
and a high tendency to focus on bodily symptoms seemed to be important, but also elevated 
feelings of anxiety, serious limitations in role functioning, sleep disturbances, low optimism and 
the acceptance of having been confronted with cancer56-61. Based on these perpetuating factors 
a CBT manual for fatigue in disease-free cancer patients has been developed62. A study on the 
effect of this treatment is currently being performed. 
Generalising CBT for CFS to the treatment of other unexplained somatic syndromes
In this thesis the overlap between symptoms in CFS and in other unexplained somatic syn-
dromes has been mentioned several times. Wessely and colleagues63 have stressed similarities 
between syndromes such as chronic fatigue syndrome, premenstrual syndrome, irritable bowel 
syndrome and various pain syndromes. Their arguments mostly concern an overlap on a symp-
tom level. Furthermore, they argue that CBT is superior to minimum care for most of the syn-
dromes in which this approach has been assessed. However, it is important to notice that not 
all CBT treatments are the same. CBT needs to be directed at the perpetuating factors speciﬁc 
to each syndrome. Before treatments can be generalised, studies on similarities and differences 
of the perpetuating factors in these syndromes will have to be accomplished.
Future directions summarised
The distinction between passive and relatively active CFS patients turned out to be very important 
in the treatment of CFS. This has raised several new questions that need to be answered. One 
may assume that passive CFS patients, with an activity level not occurring in healthy controls, 
differ from healthy controls in more aspects than relatively active CFS patients do. This might 
for instance be the case regarding physical ﬁtness, the impact of exercise on symptoms, and the 
accompanying cognitions such as the fear that activity is harmful. It is conceivable, but still to 
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be proved, that physical ﬁtness is a process variable in the treatment of pervasively passive CFS 
patients. Although presumed, it is yet unknown whether a fear of activity is only prevalent and 
important for passive CFS patients, and not for the relatively active CFS patients. Furthermore, 
it might be important to know whether the level of physical activity has to be increased after 
treatment for the pervasively passive CFS patients only. For the other CFS patients successful 
treatment may not have to be accompanied with an increased level of physical activity. Finally, 
although we have developed a separate treatment protocol for pervasively passive CFS patients, 
its effect still has to be demonstrated. 
The effect of different forms of CBT for CFS, such as CBGT, self-help, or inpatient treatments, 
as well as whether these forms of CBT are only effective for subgroups of patients is still un-
known. Furthermore, whether different health professionals, such as a GP, can deliver CBT for 
CFS to subgroups of patients has to be subject of further study. And ﬁnally, before generalising 
the CBT for CFS treatment to other unexplained somatic syndromes or to fatigue in other con-
ditions, studies on similarities and differences in the perpetuating factors in these syndromes 
will have to be accomplished.
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Summary
Chronic fatigue syndrome is deﬁned as ‘an unexplained persistent or relapsing chronic fatigue 
that is not the result of ongoing exertion, is not substantially alleviated by rest, and results 
in a substantial reduction in previous levels of occupational, educational, social, or personal 
activities’. Since 1990, the Nijmegen Fatigue Research Group (NFRG), a collaboration of the 
Departments of General Internal Medicine, Medical Microbiology and Medical Psychology of 
the University Medical Centre St Radboud Nijmegen (UMCN), has been involved in research on 
chronic fatigue syndrome. Studies in the current thesis are all related to the development of the 
treatment manual  ‘Cognitive Behaviour Therapy (CBT) for Chronic Fatigue Syndrome (CFS)’. 
In chapter 1 a general introduction to the studies is given.
In chapter 2 a study on the prevalence of CFS in the Netherlands, as recognized by general 
practitioners (GPs), is presented. Prevalence studies on CFS are rare, and the prevalence of 
CFS in the Netherlands was unknown. Prevalence data are important to assess disease burden 
and give directions for health policy. Furthermore, a GP can play an important role in CFS. If 
GPs diagnose CFS and acknowledge the patients complaints, further medicalisation can be 
prevented and ways for better management can be discussed. Because a cause for CFS has 
not been found and the diagnosis is established by means of exclusion, not all GPs accept 
CFS as a disease. Therefore, studying the prevalence of CFS in general practice was not only 
aimed at gaining insight into the number of CFS patients as recognized by GPs, but it also 
created the opportunity to inform all GPs about the existence of CFS. To prevent patients with 
Primary Fibromyalgia Syndrome (PFS) to be reported as CFS patients, the prevalence of PFS was 
stu-died at the same time. All 6657 GPs in the Netherlands received a mailed questionnaire, of 
which 60% was returned. Through extrapolation we found that in the Netherlands about 112 per 
100 000 inhabitants were recognized by GPs as CFS and 157 per 100 000 as PFS patients. We 
argued that the found prevalence of CFS was a minimal estimate, especially because CFS was 
relatively unknown among GPs. 
In several studies hypotheses on why CFS patients become and remain so tired have been tested. 
Gradually it became clear that in CFS facilitating, initiating and perpetuating factors should be dis-
tinguished. Little is known about facilitating factors. The initiating factors are most likely hetero-
geneous: infection, anaesthesia, operation and psychotrauma might play a role. Most is known 
about the perpetuating factors of symptoms and disabilities. Several studies revealed that cog-
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nitions and behaviour are important perpetuating factors in CFS. Still, the question remained 
whether physiological processes could play a causal or perpetuating role in CFS. In this thesis two 
studies on possible physiological processes underlying CFS are presented. In chapter 3 a study 
on the role of hyperventilation is reported. Because hyperventilation can produce substantial fa-
tigue, and because clinical observations suggested that at least some CFS patients also fulﬁlled 
criteria for Hyperventilation Syndrome (HVS), it seemed worthwhile to investigate their relation-
ship. In our study on CFS and hyperventilation, CFS patients, non-CFS patients known to experi-
ence hyperventilation, and healthy controls were compared on fatigue symptoms and symptoms 
indicative for HVS. Both CFS patients and the non-CFS patients known to experience physiologi-
cal hyperventilation reported extreme fatigue and HVS symptoms, both groups to a similar de-
gree. Physiological evidence of hyperventilation was found in 59% of the CFS patients. This was 
signiﬁcantly more often than in healthy controls, of whom 22% showed physiological evidence 
of hyperventilation. However, no signiﬁcant differences between CFS patients with and without 
physiological hyperventilation were found on severity of fatigue, impairment, number of com-
plaints, activity level, psychopathology and depression. It is therefore concluded that physiologi-
cal hyperventilation in CFS does not play a substantial perpetuating role and should be regarded 
as an epiphenomenon. 
The second study on a possible physiological process in CFS concerns the role of physical de-
conditioning (chapter 4). CFS patients often complain that physical exertion produces an in-
crease of complaints, leading to a greater need of rest and more time spent in bed. It has been 
suggested that this is due to a poor physical ﬁtness and that physical deconditioning is a per-
petuating factor in CFS. Studies on physical deconditioning in CFS so far had shown inconsist-
ent results. In our study 20 CFS patients and 20 matched neighbourhood controls performed 
a maximal exercise test with incremental load. Heart rate, blood pressure, respiratory tidal vol-
ume, oxygen saturation, oxygen consumption, carbon dioxide production, and blood-gas values 
of arterialized capillary blood were measured. Physical ﬁtness was quantiﬁed as the difference 
between the actual and predicted ratios of maximal workload versus increase of heart rate. 
Fatigue, impairment and physical activity were assessed to study their relationship with physical 
ﬁtness. The results showed that CFS patients and their controls did not differ in physical ﬁtness. 
Nine CFS patients even had a better ﬁtness than their control. In both groups a negative rela-
tionship between physical ﬁtness and fatigue was found. For CFS patients a negative correlation 
between ﬁtness and impairment and a positive correlation between ﬁtness and physical activity 
were found as well. Finally, it was found that more CFS patients than controls did not achieve 
a physiological limitation at maximal exercise. To put it brieﬂy, in all subjects a worse physical 
ﬁtness went together with more fatigue. The only difference found was that in CFS patients a 
worse physical ﬁtness was also related to more impairment and less physical activity. Because 
no differences were found in physical ﬁtness between CFS patients and their controls, we con-
cluded that physical deconditioning is not likely to be a perpetuating factor in CFS. Finally, the 
su
m
m
a
r
y
171
fact that CFS patients quitted the exercise at an earlier stage than their controls, while there was 
no physiological reason to stop the exercise, also suggests that other than physiological reasons 
determine a lower level of physical activity in CFS. 
Many CFS patients complain that after physical exercise their symptoms increase and that 
their level of activity decreases, but the actual effect of exercise on symptoms and activity in 
CFS was unclear. The idea that exercise is harmful, however, may produce behaviour, such as 
inactivity, that may contribute to the perpetuation of CFS. Therefore we examined the effects 
of exercise on symptoms and activity in CFS, which study is presented in chapter 5. The 20 
CFS patients and 20 neighbourhood controls used in the former study were the subjects for 
this study as well. They all performed an incremental exercise test until exhaustion. Data on 
symptoms and activity were obtained from three days before the maximal exercise test up to 
ﬁve days thereafter. Data were collected every hour on the day before, the day of and the day 
after the exercise test,. Fatigue, muscle pain, minutes spent resting and the level of physical 
activity were assessed with a self-observation list. Physical activity was also assessed with an 
actometer. Compared with baseline, CFS patients became and remained more fatigued up to 
two days after the exercise test, whereas for controls self-observed fatigue returned to baseline 
after two hours. Concerning physical activity, either self-observed or actometer recorded, ex-
ercise did not induce any changes at all, neither for CFS patients nor for controls. This ﬁnding 
is not congruent with the reported minutes resting. Both CFS patients and controls reported 
that, compared with baseline, they spent more minutes resting on the day before as well as on 
the day after the maximal exercise test. Only CFS patients reported more minutes resting on 
the day of the exercise test. In sum, fatigue in CFS patients increased more after exercise com-
pared both with their own baseline and controls. However, the level of actual physical activity 
remained unchanged for both groups.
No evidence was found that physiological processes were involved in the perpetuation of CFS, 
but more and more studies proved cognitive and behavioural factors to play an important per-
petuating role in CFS. These ﬁndings suggested a promising role for cognitive behaviour therapy 
(CBT) in CFS. Therefore, after successful preliminary individual treatments of CFS patients, con-
trolled studies on the effect of CBT were set up. In this thesis two studies on this subject are 
presented: the ﬁrst concerning cognitive behaviour group therapy (CBGT), the second individual 
CBT (chapter 6 and chapter 7). 
Aim of the ﬁrst CBT study was to investigate the effect of CBGT in an unselected group of CFS 
patients (chapter 6). Pre-treatment characteristics of CFS patients who improved after CBGT 
were compared with those of non-improved CFS patients to explore if CBGT was only effec-
tive for a subgroup of CFS patients. In a wait list controlled design 31 patients were allocated 
to CBGT, and 36 to the wait list condition. Our CBGT consisted of 12 two-hour sessions dur-
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ing six months. Only a moderate effect on fatigue in favour of CBGT was found. For functional 
impairment the effect was opposite to what was expected. Patients improved after CBGT had 
fewer complaints at baseline compared to non-improved patients. Explanations for this moder-
ate effect might be that during CBGT rest and relaxation were too much emphasised, that an 
unselected group of CFS patients was included and that therapists inexperienced with CB(G)T 
for CFS participated. Suggestions to improve CBGT for future research are given.  
In our individual CBT for CFS study (chapter 7) the applicability of this treatment outside spe-
cialised settings is questioned. In this study CBT is compared with guided support groups and 
the natural course in a randomised trial at three centres. 278 patients diagnosed with CFS were 
randomly assigned to CBT (administered by 13 therapists recently trained in this technique for 
CFS), the support group approach or the natural course. Multidimensional assessments were 
done at baseline, 8 months and 14 months. The primary outcome variables were fatigue sever-
ity and functional impairment. Data were analysed by intention to treat. CBT was signiﬁcantly 
more effective than both control conditions for fatigue severity and for functional impairment. 
Support groups were no more effective for CFS patients than the natural course. Prognostic 
factors for outcome after CBT were a higher sense of control predicting more improvement, a 
passive activity pattern and focusing on bodily symptoms predicting less improvement. It was 
concluded that, in a multicentre trial with many therapists, CBT was more effective than guided 
support groups and the natural course. A fundamental ﬁnding was that our treatment manual 
used in this study was effective for the so-called relatively active CFS patients, but not for the 
passive CFS patients.
Now that individual CBT for CFS proved to be effective, we wanted to know to what extent 
therapists complied with the various aspects of the treatment manual during the actual ses-
sions and what their judgment was about the suitability of the treatment for transfer. Our aim 
was not only to have an integrity check for the study, but also to use this information to further 
reﬁne the treatment manual. In our individual CBT for CFS study 13 therapists applied CBT to 
82 CFS patients. In the study presented in chapter 8 therapists’ adherence and perceptions of 
the manual are investigated. Audio taped sessions were conducted to verify the therapists’ ad-
herence. Following completion of the study the therapists were asked to ﬁll in a questionnaire. 
Analyses of the audio tapes showed that in 87% of the sessions the therapists adhered to the 
protocol. The questionnaire revealed that the therapists found it more difﬁcult to treat patients 
with CFS than patients with psychological or other somatic problems. Treatment aspects pos-
ing most difﬁculties were integrating individual problems into the standardized treatment, deal-
ing with the patient’s lack of conﬁdence in the treatment and handling insufﬁcient motivation. 
Based on these study results the treatment manual has been revised. The treatment manual 
gives insight into the function analysis of the CFS patient. Making a further speciﬁed function 
analysis of each individual patient, in which the perpetuating factors of the particular patient 
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are further concretised, is now explicitly part of the manual. Consequently the treatment of each 
patient is individualised.
Following the results of the studies in this thesis, other NFRG studies and the international lit-
erature on CFS, the manual ‘CBT for CFS’ is adapted regularly. In chapter 9 the last version of 
the manual, ‘CBT for relatively active and for passive CFS patients’, is described. Fundamental 
for the treatment of all CFS patients is the distinction between facilitating, initiating and per-
petuating factors. Although somatic factors might have initiated symptoms in CFS, they do not 
explain the persistence of fatigue. Perpetuating factors make the symptoms prolong. Cognitive 
behaviour therapy (CBT) for CFS focuses on these perpetuating factors. It has also been shown 
that the treatment should not be completely the same for all CFS patients. Based on their level of 
activity, two groups of patients can be distinguished. For so-called relatively active CFS patients 
the main perpetuating factors are non-accepting and demanding cognitions leading to bursts of 
activity. For so-called passive CFS patients the fear that activity might worsen their complaints, 
resulting in avoidance of activity, is the most important perpetuating factor. These differences 
in perpetuating factors resulted in partly separate treatment manuals for relatively active and 
passive CFS patients. In this chapter basic assumptions, considerations before starting CBT for 
CFS, and ways to determine the activity pattern are further elaborated upon. To conclude the 
differences in the treatments for relatively active and passive CFS patients are described. 
The general discussion in chapter 10 mainly concerns the consequences of our ﬁndings for the 
treatment of CFS patients. We reﬂect on what is essential in CBT for CFS, the role of physical 
activity, and the use of the manual. The distinction between passive and relatively active CFS pa-
tients turned out to be of major importance in the treatment of CFS. It is plausible that the role 
of physical ﬁtness, a fear of activity and the need to actually increase the level of physical activ-
ity is different for passive and for relatively active CFS patients. However, individual CBT for CFS 
proved to be an effective treatment, especially for relatively active CFS patients. Future studies 
will have to determine whether different forms of CBT for CFS, such as CBGT, self-help, or in-
patient treatments and the manual developed for passive CFS patients are effective as well. 
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Samenvatting
Het chronisch vermoeidheidssyndroom wordt gedeﬁnieerd als een ‘onverklaarde voortdurende 
of terugkerende chronische vermoeidheid die niet het gevolg is van langdurende inspanning, die 
niet substantieel verminderd door rust, en die ernstige beperkingen in het dagelijks leven tot ge-
volg heeft’. Sinds 1990 houdt de ‘Nijmeegse Fatigue Research Group’ (NFRG), een samenwer-
kingsverband tussen de afdelingen Algemeen Interne Geneeskunde, Medische Microbiologie 
en Medische Psychologie van het UMC St Radboud, zich bezig met onderzoek naar het chro-
nisch vermoeidheidssyndroom. De in dit proefschrift gepresenteerde studies zijn steeds op 
een of andere wijze verbonden aan de ontwikkeling van het behandelprotocol ‘Cognitieve 
Gedragstherapie (CGT) voor het Chronisch Vermoeidheidssyndroom (CVS)’. Hoofdstuk 1 be-
helst een algemene introductie op de verschillende studies.
In hoofdstuk 2 wordt een onderzoek naar de prevalentie van CVS, zoals herkend door huis-
artsen, beschreven. De prevalentie van CVS was nog weinig onderzocht, en de prevalentie van 
CVS in Nederland was onbekend. Deze gegevens zijn van belang om de omvang van het pro-
bleem vast te stellen en geven richting aan gezondheidsbeleid. Ook de rol van de huisarts is be-
langrijk bij CVS. Wanneer een huisarts CVS diagnosticeert en de klachten van de patiënt erkent, 
kan verdere medicalisering worden voorkomen en kunnen andere manieren om met de klachten 
om te gaan worden besproken. Omdat een oorzaak voor CVS niet is gevonden, accepteren niet 
alle huisartsen CVS als een aandoening. Naast het onderzoeken van de prevalentie van CVS in 
de huisartsenpraktijk was ons doel om alle huisartsen te informeren over de criteria van CVS. 
Om te voorkomen dat patiënten met het Primaire Fibromyalgie Syndroom (PFS) als CVS pa-
tiënten zouden worden aangemerkt, werd tegelijkertijd de prevalentie van PFS onderzocht. Alle 
praktiserende huisartsen in Nederland kregen een vragenlijst opgestuurd. Hiervan werd 60% 
geretourneerd. Na extrapolatie werd gevonden dat 112 per 100 000 inwoners in Nederland door 
huisartsen werden herkend als CVS patiënten en 157 per 100 000 inwoners als PFS patiënten. 
We beargumenteerden dat de gevonden prevalentie een minimale schatting was, vooral omdat 
CVS nog relatief onbekend was onder huisartsen.
Waarom CVS patiënten zo moe worden alsook waarom ze zo moe blijven was en is onderwerp 
van vele studies. Uit onderzoek werd duidelijk dat bij CVS onderscheid gemaakt moet worden 
tussen faciliterende, initiërende en in stand houdende factoren. Over de faciliterende factoren 
is nog weinig bekend. De initiërende factoren zijn waarschijnlijk heterogeen. Infecties, anes-
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thesie, operaties en psychotrauma’s kunnen een uitlokkende factor zijn. Het meest is bekend 
over factoren die de symptomen en beperkingen van CVS in stand houden. Uit verschillende 
studies bleek dat cognities en gedrag hierbij van belang zijn. Toch bleef het de vraag of fysio-
logische processen niet ook een oorzakelijke of in stand houdende rol spelen. In dit proefschrift 
worden twee studies gepresenteerd die gaan over fysiologische processen en CVS. In hoofdstuk 3 
is een onderzoek naar de relatie tussen CVS en hyperventilatie beschreven. Hyperventilatie 
kan ernstige vermoeidheid tot gevolg hebben. Uit de klinische praktijk bleek dat in ieder geval 
enkele CVS patiënten ook voldeden aan criteria voor het Hyperventilatie Syndroom (HVS). In 
ons onderzoek werden CVS patiënten, niet-CVS patiënten die bekend waren met hyperventi-
latie volgens fysiologische criteria, verder hyperventilatie genoemd, en gezonde controles met 
elkaar vergeleken. Extreme vermoeidheid en symptomen van het HVS werden door CVS pa-
tiënten en niet-CVS patiënten met hyperventilatie in dezelfde mate gerapporteerd. Van de CVS 
patiënten bleek 59% te hyperventileren. Dit was signiﬁcant vaker dan de gezonde controles, 
waarbij voor 22% hyperventilatie werd aangetoond. Voor wat betreft de ernst van vermoeidheid, 
de beperkingen, het aantal klachten, het activiteitenniveau, psychopathologie en depressie wer-
den geen signiﬁcante verschillen gevonden tussen CVS patiënten met en CVS patiënten zonder 
hyperventilatie. Op grond van deze bevindingen werd geconcludeerd dat hyperventilatie geen in 
stand houdende factor is bij CVS, maar beschouwd moet worden als een epifenomeen.
Een tweede fysiologisch proces dat een rol zou kunnen spelen bij CVS betreft de fysieke con-
ditie (hoofdstuk 4). Veel CVS patiënten klagen dat door lichamelijke inspanning hun klachten 
toenemen waardoor ze daarna tot bijna niets meer in staat zijn. Een al lang bestaande hypo-
these was dat dit wordt veroorzaakt door een slechte fysieke conditie en dat een slechte fysieke 
conditie een in stand houdende factor van CVS zou kunnen zijn. Studies die de fysieke conditie 
van CVS patiënten onderzochten lieten inconsistente resultaten zien. In ons onderzoek, weer-
gegeven in hoofdstuk 4, zijn 20 CVS patiënten vergeleken met 20 buurtcontroles. Alle proef-
personen ondergingen een maximale inspanningstest met toenemende belasting. Hierbij wer-
den de hartslag, bloeddruk, ademteugvolume, zuurstofsaturatie, zuurstofconsumptie, koolzuur-
productie, en bloedgaswaarden van gearterialiseerd capillair bloed gemeten. De lichamelijke 
conditie werd geoperationaliseerd als het verschil tussen de actuele en voorspelde ratios van 
de maximale werklast versus de toename in de hartfrequentie. Vermoeidheid, beperkingen en 
lichamelijke activiteit werden gemeten om hun relatie met de fysieke conditie te onderzoeken. 
Uit de resultaten bleek dat er geen verschil was in fysieke conditie tussen CVS patiënten en hun 
controles. Negen CVS patiënten hadden zelfs een betere fysieke conditie dan hun controle. In 
beide groepen werd een negatieve correlatie gevonden tussen fysieke conditie en vermoeidheid. 
Bij CVS patiënten werd tevens een negatief verband gevonden tussen fysieke conditie en beper-
kingen en een positief verband tussen fysieke conditie en lichamelijke activiteit. CVS patiënten 
stopten vaker dan controles met de inspanningstest zonder hun fysiologische grens te heb-
ben bereikt. Omdat CVS patiënten geen slechtere fysieke conditie hadden dan hun controles, 
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concludeerden we dat het niet waarschijnlijk is dat fysieke deconditionering een in stand hou-
dende factor is bij CVS. Het feit dat CVS patiënten eerder stopten met de inspanningstest dan 
hun controles, zonder dat er een fysiologische reden was om te stoppen, suggereert dat andere 
dan fysiologische redenen het lagere activiteitenniveau van CVS patiënten bepalen.
Veel CVS patiënten rapporteren dat na hevige lichamelijke inspanning hun klachten dagenlang 
zijn toegenomen en dat zij tot minder lichamelijke activiteit in staat zijn. Of het niveau van 
lichamelijke activiteit na een grote inspanning inderdaad dagenlang lager is dan daarvoor, was 
nooit aangetoond. Het idee dat inspanning schadelijk is kan gedrag zoals inactiviteit tot gevolg 
hebben, hetgeen CVS in stand kan houden. Daarom onderzochten we het effect van inspan-
ning op de klachten en het lichamelijke activiteitenniveau van CVS patiënten (hoofdstuk 5). Aan 
dit onderzoek namen dezelfde 20 CVS patiënten en hun buurtcontroles deel als in het vorige 
onderzoek. Zij ondergingen allen een maximale inspanningstest tot uitputting. Data betreffende 
symptomen en activiteit werden gemeten drie dagen voor tot en met vijf dagen na de inspan-
ningstest. Op de dag voor, de dag van en de dag na de inspanningstest werden de gegevens 
ieder uur verzameld. Vermoeidheid, spierpijn, het aantal minuten rust en het oordeel over de 
mate van lichamelijke activiteit werden gemeten met een zelfobservatielijst. Lichamelijke acti-
viteit werd tevens gemeten met een actometer. De ervaren vermoeidheid van CVS patiënten 
was tot twee dagen na de inspanningstest verhoogd ten opzicht van de dagen voor de inspan-
ningstest, de vermoeidheid van de controlegroep was twee uur na de inspanningstest weer op 
hetzelfde niveau als voor de inspanningstest. Het niveau van lichamelijke activiteit, zowel geme-
ten met de zelfobservatielijst als met de actometer, bleef na de inspanningstest vrijwel onver-
anderd ten opzichte van het niveau voor de inspanningstest. Dit gold zowel voor CVS patiënten 
als voor de controles. Deze bevinding is niet congruent met het aantal gerapporteerde minuten 
rust. Zowel CVS patiënten als controles rapporteerden dat zij een dag voor de inspanningstest 
en de dag na de inspanningstest meer rustten dan de andere dagen voor de inspanningstest. 
Alleen CVS patiënten rapporteerden ook meer te rusten op de dag van de inspanningstest. De 
belangrijkste conclusie van dit onderzoek was dat ondanks de toename in ervaren vermoeid-
heid deze toegenomen vermoeidheid na de inspanningstest geen gevolgen had voor de mate 
van lichamelijke activiteit.
In de hiervoor genoemde studies vonden wij geen bewijs dat fysiologische processen een rol 
speelden bij het in stand houden van CVS. Steeds meer studies toonden echter aan dat cogni-
ties en gedrag betrokken waren bij het in stand houden van CVS. Deze onderzoeksresultaten 
suggereerden een veelbelovende rol voor cognitieve gedragstherapie (CGT). Daarom is, na 
eerste positieve ervaringen met individuele CGT van CVS, wetenschappelijk onderzoek naar het 
effect van CGT voor CVS gestart. In dit proefschrift zijn hierover twee studies opgenomen. De 
eerste betreft het effect van groeps-CGT voor CVS, de tweede het effect van individuele CGT 
voor CVS (hoofdstuk 6 en hoofdstuk 7).
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Doel van de eerste CGT studie was om het effect te onderzoeken van groeps-CGT in een 
ongeselecteerde groep van CVS patiënten (hoofdstuk 6). In een wachtlijst gecontroleerd 
onderzoek werden 31 patiënten toegewezen aan de groeps-CGT en 36 aan de wachtlijstconditie. 
De groeps-CGT bestond uit 12 sessies van twee uur in een periode van 6 maanden. Er werd 
slechts een matig effect gevonden op vermoeidheid in het voordeel van groeps-CGT. Voor 
wat betreft de beperkingen in het dagelijks leven was het effect tegenovergesteld van hetgeen 
werd verwacht. Voor de patiënten in de wachtlijstconditie waren de beperkingen na 6 maanden 
afgenomen. Voor de patiënten die aan de groeps-CGT hadden deelgenomen niet. Om te achter-
halen of groeps-CGT alleen effectief was voor een subgroep van CVS patiënten werden CVS 
patiënten die verbeterden na de groeps-CGT vergeleken met CVS patiënten die niet verbeterden 
na groeps-CGT op hun kenmerken bij de baseline meting. Uit deze analyses bleek dat patiënten 
die verbeterd waren na groeps-CGT bij baseline minder klachten hadden dan de patiënten die 
niet verbeterd waren. 
Verklaringen voor het geringe effect van de groeps-CGT zouden kunnen zijn dat in de 
behandeling rust en ontspanning teveel werden benadrukt, dat de behandeling aan een on-
geselecteerde groep patiënten werd aangeboden en dat therapeuten die nog onervaren waren met 
(groeps-)CGT de behandeling uitvoerden. Suggesties om de groeps-CGT te verbeteren voor toe-
komstig onderzoek werden besproken.
In de individuele CGT voor CVS studie (hoofdstuk 7) is de mogelijkheid om deze behande-
ling toe te passen in andere dan in CVS gespecialiseerde centra onderzocht. In deze studie 
werd CGT vergeleken met lotgenotencontactgroepen en de gangbare praktijk, in een geran-
domiseerd onderzoek. De behandelingen vonden plaats in drie verschillende centra. In dit 
onderzoek participeerden 278 CVS patiënten. Deze patiënten werden random toegewezen 
aan de CGT conditie, de lotgenotencontactgroepen of de gangbare praktijk conditie. De CGT 
behandelingen werden uitgevoerd door 13 therapeuten, onervaren met de behandeling van 
CVS patiënten. Zij werden van te voren getraind in ‘CGT voor CVS’. Tijdens het uitvoeren van 
de behandeling kregen zij supervisie. Multidimensionele metingen vonden plaats bij baseline, 
bij 8 en bij 14 maanden. De primaire uitkomstmaten waren vermoeidheid en beperkingen in 
het dagelijks leven. De resultaten lieten zien dat CGT signiﬁcant effectiever was dan de beide 
controle condities, zowel voor wat betreft vermoeidheid als voor wat betreft beperkingen. 
Lotgenotencontact was niet effectiever dan de gangbare praktijk. Een positieve self-efﬁcacy 
(het idee dat men zelfs iets aan de klachten kan doen) voorspelde meer verbetering na CGT. 
Een passief activiteitenpatroon en een sterke gerichtheid op lichamelijke symptomen voor-
spelden minder verbetering na CGT. Een belangrijke bevinding was dat het in dit onderzoek 
gebruikte behandelprotocol effectief was voor de zogenaamde relatief actieve CVS patiënten, 
maar niet voor de passieve CVS patiënten. Een belangrijke conclusie was dat CGT voor CVS 
ook effectief uitgevoerd kon worden door therapeuten die tot dan toe geen ervaring hadden 
met deze behandeling. 
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Nu individuele CGT voor CVS effectief was gebleken, wilden we weten in welke mate de the-
rapeuten de behandeling ook daadwerkelijk volgens protocol hadden uitgevoerd. Daarnaast 
wilden we weten in hoeverre de therapeuten van oordeel waren dat de behandeling kon worden 
overgedragen. Doel van dit onderzoek was niet alleen om een integrity check te hebben voor 
de individuele CGT voor CVS studie, maar ook om de verzamelde informatie te gebruiken om 
het behandelprotocol te verbeteren. In hoofdstuk 8 wordt een studie beschreven waarin deze 
vragen worden onderzocht. Aan de individuele CGT voor CVS studie deden 13 therapeuten mee 
die samen de CVS patiënten in de CGT conditie behandelden. Uitgewerkte audio-opnamen van 
de sessies werden gebruikt om de mate waarin de therapeuten zich aan het protocol hadden 
gehouden te onderzoeken. Aan het einde van de studie vulden de therapeuten een vragenlijst 
in. Uit de analyses van de audio-opnamen bleek dat in 87% van de sessies de therapeuten zich 
aan het behandelprotocol hadden gehouden. Dit wordt beschouwd als een goed resultaat. Uit 
de vragenlijst bleek dat therapeuten het moeilijker vonden om CVS patiënten te behandelen dan 
om patiënten met psychische of andere somatische klachten te behandelen. Aspecten van de 
behandeling die de meeste problemen opleverden waren het integreren van individuele proble-
men in een gestandaardiseerde behandeling, het omgaan met een gebrek aan vertrouwen in 
de behandeling van patiënten, en het omgaan met onvoldoende motivatie van de patiënt. Op 
grond van deze onderzoeksresultaten is het behandelprotocol aangepast. Het protocol geeft 
inzicht in de functieanalyse en behandeling van de CVS patiënt. Het maken van een verder 
gespeciﬁceerde functieanalyse voor iedere individuele patiënt, waarin de in stand houdende 
factoren van deze patiënt verder worden geconcretiseerd, is nu expliciet onderdeel van het 
protocol. Hiermee wordt de behandeling verder op het individu toegespitst.
Op grond van de resultaten van de studies in dit proefschrift, van andere studies van de NFRG en 
de internationale literatuur, is het protocol ‘CGT voor CVS’ regelmatig aangepast. In hoofdstuk 9 
wordt de huidige versie van het protocol, ‘CGT voor relatief actieve en voor passieve CVS patiënten’ 
beschreven. Essentieel voor de behandeling van alle CVS patiënten is het onderscheid tussen 
faciliterende, initiërende en in stand houdende factoren. Hoewel somatische factoren een rol 
kunnen hebben gespeeld bij het ontstaan van CVS, bieden zij geen verklaring voor het blijven 
voortbestaan van de vermoeidheid. Het zijn de in stand houdende factoren die maken dat de 
vermoeidheid niet overgaat. CGT voor CVS richt zich op deze in stand houdende factoren. Op 
basis van hun activiteitenniveau kunnen twee groepen patiënten worden onderscheiden. Voor 
de zo genoemde relatief actieve CVS patiënten zijn de belangrijkste in stand houdende factoren 
niet-accepterende en eisende cognities, die leiden tot pieken van activiteit. Voor de zo genoemde 
passieve CVS patiënten is de angst dat activiteit de klachten verergerd, resulterend in het vermij-
den van activiteit, de meest belangrijke in stand houdende factor. Dit verschil in in stand hou-
dende factoren heeft geresulteerd in twee gedeeltelijk verschillende behandelprotocollen. Eén 
voor relatief actieve en één voor passieve CVS patiënten. In hoofdstuk 9 zijn de basis assump-
ties, overwegingen voor het starten van de behandeling ‘CGT voor CVS’ en de wijze waarop het 
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activiteitenpatroon kan worden vastgesteld, beschreven. Daarna worden de verschillen in de 
behandelingen voor relatief actieve en voor passieve CVS patiënten uiteengezet.
De algemene discussie in hoofdstuk 10 gaat vooral over de consequenties van de onderzoeks-
bevindingen voor de behandeling van CVS patiënten. Gereﬂecteerd wordt op wat nu essentieel 
is in de CGT behandeling van CVS, op de rol van lichamelijke activiteit en op het gebruik van 
het behandelprotocol. Het onderscheid tussen passieve en relatief actieve CVS patiënten is van 
groot belang gebleken voor de behandeling. Het is denkbaar dat de rol van lichamelijke activiteit, 
angst voor activiteit en de noodzaak om het daadwerkelijke activiteitenniveau te verhogen ver-
schillend is voor passieve en voor relatief actieve CVS patiënten. Individuele ‘CGT voor CVS’ 
bleek een effectieve behandeling, vooral voor de relatief actieve CVS patiënten. Toekomstig 
onderzoek zal moeten uitwijzen of verschillende vormen van CGT voor CVS, zoals groeps-CGT, 
zelf hulp instructies, of klinische behandeling als ook of het laatste behandelprotocol dat is aan-
gepast voor passieve CVS patiënten, eveneens effectief zijn.
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Dankwoord
Eindelijk. Ook ik heb mijn proefschrift afgerond. Na al die jaren waarin ik als wetenschappe-
lijk onderzoeker mijn taken heb gecombineerd met andere functies binnen wetenschappelijk 
onderzoek, patiëntenzorg, opleiding en de laatste jaren ook onderwijs, zijn er velen aan wie ik 
dank verschuldigd ben. 
Ten eerste zijn er natuurlijk alle patiënten die aan de verschillende onderzoeken hebben mee-
gewerkt. Zonder dat zij wisten wat het effect zou zijn van een inspanningstest of van een cognitief 
gedragstherapeutische (groeps-) behandeling, hebben zij steeds weer aan onderzoek en metingen 
meegedaan. Ik realiseerde me dat het invullen van alle vragenlijsten en het dragen van de actometer 
ook een belasting was. Ik ben hen dankbaar dat zij het onderzoek hebben mogelijk gemaakt. 
Mijn promotoren Gijs Bleijenberg en Jos van der Meer wil ik danken dat ze mij de kans heb-
ben gegeven te promoveren. Jullie vertrouwen in mijn capaciteiten heeft mij veel goed gedaan. 
Jullie creativiteit en kritische houding hebben mij niet alleen hard doen werken, maar ook veel 
geleerd. Zowel over wetenschappelijk onderzoek als over patiëntenzorg. Gijs, je was niet alleen 
mijn promotor en projectleider van de verschillende studies, maar ook opleider en supervisor 
voor mijn patiëntenzorg activiteiten. We hebben zoveel werk samen verricht, en de meeste 
dingen met veel plezier, dat ik er nog lang voor nodig zal hebben om er aan te wennen dat we 
niet meer samenwerken. Jos, hoewel we elkaar vooral de laatste jaren weinig zagen, was ik niet 
alleen altijd blij met je commentaar op mijn werk, maar vooral ook met het feit dat je me het 
gevoel gaf dat je er altijd voor me was als ik je nodig had.
Jan Vercoulen stond aan het begin van mijn onderzoekscarrière. Hij schreef de eerste onder-
zoeksaanvragen voor het prevalentie en het hyperventilatie onderzoek. Jan, je was niet alleen de 
voortrekker van deze onderzoeken, maar je haalde als een van de eerste onderzoekers van het 
Nijmeegse CVS onderzoek voor mij ook vele kastanjes uit het vuur. Hiervoor dank. Jozé Maas 
heeft alle gegevens van het prevalentie onderzoek ingevoerd in een database. Geen geringe 
klus, gezien de hoge respons. 
Hans Folgering dank ik voor zijn betrokkenheid en commentaar bij onze gezamenlijke artikelen. 
Hans, je immer luidende ‘hulde voor je stamina’ heeft mij goed gedaan, en mijn doorzettings-
vermogen nog verder bevorderd. Thijs Bakker, Carolien de Croon en Annemarie Arends hebben 
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als stagiaires veel werk verricht voor het verzamelen van de gegevens rond het inspannings-
onderzoek. Dit was een goede basis voor twee artikelen van dit proefschrift, waarvoor ik jullie 
veel dank verschuldigd ben. 
Judith Prins voerde samen met mij de eerste pilot groepsbehandeling uit. Judith, je bent niet al-
leen vanaf het eerste begin een ﬁjne collega geweest, maar ook door de jaren heen mijn maatje 
gebleken. Behalve bij het samenwerken in wetenschappelijk onderzoek en patiëntenzorg, heb-
ben wij ook op congressen onvergetelijke tijden beleefd, en, last but not least, stond je me bij in 
moeilijke tijden. Chantal Raben heeft samen met Gijs Bleijenberg het eerste behandelprotocol 
voor de groepsbehandelingen op papier gezet. Dit was een begin waarop ik verder kon bou-
wen. Verder dank ik alle therapeuten die de groepsbehandelingen hebben uitgevoerd. Maurice 
Alberts, Rutger Lulofs en Hermien Elgersma deden dit in Maastricht. Maarten Assman en Eeke 
Faber hebben samen en samen met mij de groepsbehandelingen in Nijmegen uitgevoerd. Voor 
het doorlopend verzamelen van de data in Maastricht ben ik Judith Semijn, Carolien Appels en 
Jolanda Couwenberg dankbaar. 
Ria te Winkel heeft, deels samen met Elke Pothof, een grote bijdrage geleverd aan de data ver-
zameling van nagenoeg alle studies. Ria, door jouw gestructureerde manier van werken behield 
ik het overzicht. Verder was je er altijd voor ondersteuning bij computer en powerpoint proble-
men, en heb je een bijdrage geleverd aan het drukklaar maken van mijn proefschrift, waarvoor 
alle woorden van dank te kort zouden schieten. Maar bovenal ben ik je dankbaar voor al je mo-
rele steun. Jaar in, jaar uit. 
De therapeuten die supervisie kregen in de studie naar het effect van individuele CGT voor CVS 
ben ik ook veel dank verschuldigd. Jan-Willem van der Does, Michiel Hengeveld, Monique ter 
Kuile, Jille Merkelbach (†), Yanda van Rood, Hermien Elgersma, Ina Leeuw, Jan van Oosterhout, 
Thea Berends, Eeke Faber, Lieke de Jong, Esther Meijer en Jan Vercoulen: ik ben blij dat jullie 
mijn inbreng accepteerden, want ik realiseerde mij, vooral achteraf, dat het niet altijd makkelijk 
was. Gelukkig bleken onze gezamenlijke inspanningen niet vergeefs. 
Petra Servaes is lange tijd mijn kamergenote geweest. Petra, misschien was samen relativeren 
wel ons grootste goed. Het samen bespreken van al onze dagelijkse beslommeringen maakte het 
kamergenotes zijn van nog meer waarde. Ik ben blij dat we elkaar nog steeds regelmatig zien. 
Nancy van de Steeg en Helma Wouters. Hoeveel dank ben ik jullie wel niet verschuldigd? Jullie 
stonden me niet alleen praktisch bij en zorgden er voor dat ik fatsoenlijk gekleed rondliep, maar 
jullie waren er gewoon altijd, als steun en toeverlaat. Nancy, behalve hiervoor ben ik jou ook 
nog eens vreselijk veel dank verschuldigd voor de bergen werk die je voor de verschillende on-
derzoeksprojecten hebt verzet. 
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Karin Schreurs dank ik voor het kritisch lezen van de laatste Engelstalige teksten voor mijn 
proefschrift. Schrijftaal heeft nooit zo mijn interesse gehad, maar samen jouw op en aanmer-
kingen op mijn taalgebruik bespreken, heeft me ook de leuke kanten van taal doen inzien. Elsa 
Zijlmans, jou wil ik danken dat je er mede voor hebt zorg gedragen dat mijn proefschrift er zo 
mooi uit ziet.
Marieke en Leonie, jullie zijn niet voor niets mijn paranimfen. Jullie weten zelf wel waarom. 
En dan mijn andere vrienden. Wat zijn jullie geduldig met me geweest. Jullie wisten dat je niet 
te vaak moest vragen wanneer ik nu eens mijn proefschrift af zou ronden. Maar nu is het dan 
toch zover. Het lang verwachtte feest. Ik hoop dat jullie nog willen komen...
Tot slot de mensen die het dichtst bij me staan. Anja en Joep, al zien we elkaar niet veel en 
wonen we ver uit elkaar, jullie zijn altijd betrokken gebleven bij mijn doen en laten. Maar het 
meest ben ik jullie dankbaar voor de geweldige neefjes en nichtjes die ik heb gekregen.  
Papa en mama. Ik weet niet wat jullie me allemaal hebben geleerd en gegeven, maar het is veel. 
Misschien wel vooral doorzettingsvermogen en zelfvertrouwen. Jullie gaven en geven me altijd 
het gevoel dat ik alles kan, en dat jullie er altijd voor me zijn. Het eerste heeft er zeker toe bij-
gedragen dat ik deze klus heb geklaard. Het tweede is vooral de afgelopen jaren van bijzonder 
belang gebleken. Voor beide ben ik jullie vreselijk dankbaar.
Yvonne, wat moet ik zeggen? Je bent en blijft mijn ‘allessie’. Soms lijken we wel in alles com-
plementair. Waar ik me bezighield met de binnenkant van mijn proefschrift, zorgde jij voor de 
buitenkant. Ook wij hebben mijn proefschrift afgerond. Eindelijk.
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de onderzoeksaanvraag voor ontwikkelingsgeneeskunde ‘Cognitieve gedragstherapie voor het 
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onderwijstaken, is zij werkzaam voor de patiëntenzorg van verschillende Inwendige Specialismen. 
Van 2000 tot 2002 was zij gedetacheerd op het Universitair Longcentrum Dekkerswald. In 2001 
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In 1999 behaalde zij haar BIG registratie GZ-psycholoog, in 2001 haar BIG registratie psycho-
therapeut en in 2004 haar registratie als supervisor en leertherapeut van de Vereniging voor 
Gedragstherapie en Cognitieve Therapie. 
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